<!DOCTYPE html>
<html lang="en">
<head>
  <title>
    eCFR :: 21 CFR Part 600 -- Biological Products: General
  </title>

  <link rel="canonical" href="https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-600" />

  <link rel="apple-touch-icon" sizes="180x180" href="/assets/favicon/apple-touch-icon-18ac1159c2217e79fb45c21adc630384b65af33c4e6de8eca0ff8527a4fe080e.png">
<link rel="icon" type="image/png" sizes="32x32" href="/assets/favicon/favicon-32x32-601e211398bdd3b5d26f99ae1ddae16e940b6a6223cb83f429419e6709f596f2.png">
<link rel="icon" type="image/png" sizes="16x16" href="/assets/favicon/favicon-16x16-8e7cf46953c8eadd70c27e99d2977556a7ad517c1d809782451b24be80323d14.png">
<link rel="manifest" href="/assets/favicon/site-17bc871d6b501401cd30d1f57e54a581f21f9c964717dd77d28e6f026da4b560.webmanifest">
<link rel="mask-icon" href="/assets/favicon/safari-pinned-tab-42724ccbb4192754e3500f02bee26d07b1c8432d7179433dd34d8d59c4e0882b.svg" color="#fab827">
<link rel="shortcut icon" href="/assets/favicon/favicon-014ef9fe5cc7969da15185d0790dba54c9c41bbcedda5477f9a7214d98263525.ico">
<meta name="msapplication-TileColor" content="#ffc40d">
<meta name="msapplication-config" content="/assets/favicon/browserconfig-d9fe2961ea6e1d05b91dec740f2c7b3b916c646691e7c909c258dea3ad28cd94.xml">
<meta name="theme-color" content="#ffffff">


    <!-- Global site tag (gtag.js) - Google Analytics -->
    <script src="/assets/google_analytics-a2da3bb5c78c39ec6f425a2de69612f49200191a66f6aaac3b373bc53618cf0e.js" async="async" nonce="hlb2uMlbYwq/lYHyClSCCw=="></script>

    <!-- We participate in the US government's analytics program. See the data at analytics.usa.gov. -->
    <script async type="text/javascript" nonce="hlb2uMlbYwq/lYHyClSCCw==" src="https://dap.digitalgov.gov/Universal-Federated-Analytics-Min.js?agency=NARA&subagency=fedreg" id="_fed_an_ua_tag"></script>

  <link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link
href="https://fonts.googleapis.com/css2?family=Roboto:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500;1,700&family=Bitter:ital,wght@0,400;0,500;0,700;1,400;1,500;1,700&display=swap"
rel="preload"
as="style">
<link
href="https://fonts.googleapis.com/css2?family=Roboto:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500;1,700&family=Bitter:ital,wght@0,400;0,500;0,700;1,400;1,500;1,700&display=swap"
rel="stylesheet">


  <link rel="stylesheet" media="all" href="/assets/vendor-ed1f17021e0f5e5ba9861e9a88550a0d17aa9657d0832f953e6156a822fe3a1d.css" data-turbo-track="true" />
  <link rel="stylesheet" media="all" href="/assets/application-cab3fe704abacf30de204627077d84af75f499a7a95a6ebf38ab9f441d80db4b.css" data-turbo-track="true" />
  <link rel="stylesheet" media="print" href="/assets/print-e85ef07360cd8210c510308470ec9745d5d7b31065d9007a9d9b6935c561c232.css" data-turbo-track="true" />

  <script src="/assets/application_pipeline-662bba96b1118fe94244c70ca2c6a5043f8d3e1ea30f8a9d57d521ce1c692105.js" data-turbo-eval="false" async="async" defer="defer" nonce="hlb2uMlbYwq/lYHyClSCCw=="></script>

  <script type="importmap" data-turbo-track="reload" nonce="hlb2uMlbYwq/lYHyClSCCw==">{
  "imports": {
    "application": "/assets/application-335c9d0168c1b2a3960dd56fdf4f6c209d0eec1942adb72b6441483bed14e77f.js",
    "@hotwired/turbo-rails": "/assets/turbo.min-f971c8640d593387ea5afa6f0b3f51d9868c8ab3b4ddf1c811da0ed00d67af2d.js",
    "@hotwired/stimulus": "https://ga.jspm.io/npm:@hotwired/stimulus@3.2.2/dist/stimulus.js",
    "@hotwired/stimulus-loading": "/assets/stimulus-loading-6024ee603e0509bba59098881b54a52936debca30ff797835b5ec6a4ef77ba37.js",
    "@lodash/debounce": "https://ga.jspm.io/npm:lodash.debounce@4.0.8/index.js",
    "stimulus-autocomplete": "/assets/stimulus-autocomplete-0e2d350d1a0100abce1840193618fa0e606c0425d5631eb27dee0fb068cc32df.js",
    "stimulus-use": "https://ga.jspm.io/npm:stimulus-use@0.52.0/dist/index.js",
    "controllers/agencies_controller": "/assets/controllers/agencies_controller-b39755bd0bdc29806a7e88bb2015c8cb873f41228c3332df2a9a0b91e94af87c.js",
    "controllers/application": "/assets/controllers/application-e361dd5f2e228c2fb25a1549ad19f7ab2ee254e8123572f3fb9694ad08711254.js",
    "controllers/changes_controller": "/assets/controllers/changes_controller-7d46a5241e38838956e42fa95fe3b8a38901c1c5c739c623498328449cb8f6d1.js",
    "controllers/compare_controller": "/assets/controllers/compare_controller-d4c7c2f7183e9a0487fb4156d3be50ca77ced0e1881289fbe3b0920b4a88ec95.js",
    "controllers/element_controller": "/assets/controllers/element_controller-124c5e519399db700016351f28875d1aebd96b8966ef7655beb3e8ec42529c3e.js",
    "controllers/form_controller": "/assets/controllers/form_controller-521a8ae5e19bf25bcf358a35c386589c4ae49399968da815af3e5fedb4e66cad.js",
    "controllers": "/assets/controllers/index-075d84f1ecd1595c9ab3e04d66cb668dc9f6fb81d4809c437cbb0a5c0ec6fce2.js",
    "controllers/modal_controller": "/assets/controllers/modal_controller-b9cff36cd77bfb60e03304caa4eecacff19fc3713510141975d9e6f2748ac706.js",
    "controllers/placeholder_controller": "/assets/controllers/placeholder_controller-db5bbdf7df068e036eb77a730c74a68b59d680045962165deb575098d64ea172.js",
    "controllers/recent_changes_controller": "/assets/controllers/recent_changes_controller-b55783709d43d67c169ce404aad187bb8a49f140d816a203405cc382ae31d605.js",
    "controllers/suggestions_controller": "/assets/controllers/suggestions_controller-c86bd514065aba875525a390293adf8e27176ccdd869a92a035c06b027e67771.js",
    "controllers/timeline_controller": "/assets/controllers/timeline_controller-d797067edc737523ee3485893dd7f9f0e658d0e421b93ec3657bd7dcf6d9d1d2.js"
  }
}</script>
<link rel="modulepreload" href="/assets/application-335c9d0168c1b2a3960dd56fdf4f6c209d0eec1942adb72b6441483bed14e77f.js" nonce="hlb2uMlbYwq/lYHyClSCCw==">
<link rel="modulepreload" href="/assets/turbo.min-f971c8640d593387ea5afa6f0b3f51d9868c8ab3b4ddf1c811da0ed00d67af2d.js" nonce="hlb2uMlbYwq/lYHyClSCCw==">
<link rel="modulepreload" href="https://ga.jspm.io/npm:@hotwired/stimulus@3.2.2/dist/stimulus.js" nonce="hlb2uMlbYwq/lYHyClSCCw==">
<link rel="modulepreload" href="/assets/stimulus-loading-6024ee603e0509bba59098881b54a52936debca30ff797835b5ec6a4ef77ba37.js" nonce="hlb2uMlbYwq/lYHyClSCCw==">
<link rel="modulepreload" href="https://ga.jspm.io/npm:lodash.debounce@4.0.8/index.js" nonce="hlb2uMlbYwq/lYHyClSCCw==">
<link rel="modulepreload" href="/assets/stimulus-autocomplete-0e2d350d1a0100abce1840193618fa0e606c0425d5631eb27dee0fb068cc32df.js" nonce="hlb2uMlbYwq/lYHyClSCCw==">
<link rel="modulepreload" href="https://ga.jspm.io/npm:stimulus-use@0.52.0/dist/index.js" nonce="hlb2uMlbYwq/lYHyClSCCw==">
<link rel="modulepreload" href="/assets/controllers/agencies_controller-b39755bd0bdc29806a7e88bb2015c8cb873f41228c3332df2a9a0b91e94af87c.js" nonce="hlb2uMlbYwq/lYHyClSCCw==">
<link rel="modulepreload" href="/assets/controllers/application-e361dd5f2e228c2fb25a1549ad19f7ab2ee254e8123572f3fb9694ad08711254.js" nonce="hlb2uMlbYwq/lYHyClSCCw==">
<link rel="modulepreload" href="/assets/controllers/changes_controller-7d46a5241e38838956e42fa95fe3b8a38901c1c5c739c623498328449cb8f6d1.js" nonce="hlb2uMlbYwq/lYHyClSCCw==">
<link rel="modulepreload" href="/assets/controllers/compare_controller-d4c7c2f7183e9a0487fb4156d3be50ca77ced0e1881289fbe3b0920b4a88ec95.js" nonce="hlb2uMlbYwq/lYHyClSCCw==">
<link rel="modulepreload" href="/assets/controllers/element_controller-124c5e519399db700016351f28875d1aebd96b8966ef7655beb3e8ec42529c3e.js" nonce="hlb2uMlbYwq/lYHyClSCCw==">
<link rel="modulepreload" href="/assets/controllers/form_controller-521a8ae5e19bf25bcf358a35c386589c4ae49399968da815af3e5fedb4e66cad.js" nonce="hlb2uMlbYwq/lYHyClSCCw==">
<link rel="modulepreload" href="/assets/controllers/index-075d84f1ecd1595c9ab3e04d66cb668dc9f6fb81d4809c437cbb0a5c0ec6fce2.js" nonce="hlb2uMlbYwq/lYHyClSCCw==">
<link rel="modulepreload" href="/assets/controllers/modal_controller-b9cff36cd77bfb60e03304caa4eecacff19fc3713510141975d9e6f2748ac706.js" nonce="hlb2uMlbYwq/lYHyClSCCw==">
<link rel="modulepreload" href="/assets/controllers/placeholder_controller-db5bbdf7df068e036eb77a730c74a68b59d680045962165deb575098d64ea172.js" nonce="hlb2uMlbYwq/lYHyClSCCw==">
<link rel="modulepreload" href="/assets/controllers/recent_changes_controller-b55783709d43d67c169ce404aad187bb8a49f140d816a203405cc382ae31d605.js" nonce="hlb2uMlbYwq/lYHyClSCCw==">
<link rel="modulepreload" href="/assets/controllers/suggestions_controller-c86bd514065aba875525a390293adf8e27176ccdd869a92a035c06b027e67771.js" nonce="hlb2uMlbYwq/lYHyClSCCw==">
<link rel="modulepreload" href="/assets/controllers/timeline_controller-d797067edc737523ee3485893dd7f9f0e658d0e421b93ec3657bd7dcf6d9d1d2.js" nonce="hlb2uMlbYwq/lYHyClSCCw==">
<script type="module" nonce="hlb2uMlbYwq/lYHyClSCCw==">import "application"</script>

  

  <meta name="viewport" content="width=970">
  <meta name="format-detection" content="telephone=no">
    <meta name="dcterms.title"
    content="21 CFR Part 600 -- Biological Products: General" />
	<meta name="dcterms.bibliographicCitation"
    content="21 CFR Part 600" />

  <meta property="og:title"
    content="21 CFR Part 600 -- Biological Products: General" />
  <meta property="og:url"
    content="/current/title-21/part-600" />

  <meta property="ecfr:citationDate"
    content="" />


</head>
  <body data-environment="production" data-honeybadger-js-api-key="f722cff2" data-revision="fe90b535b988cdb7ef5a8c4f0a288eb096501233" data-google-ga4-tag="G-K7SMYBYX81" data-service="ecfr-web" data-domain=".ecfr.gov">

    <!-- Zendesk Form -->
      <div class="btn" id="feedbackbutton" type="button"><span class="icon-ecfr-chat"></span>Site Feedback</div>
      <div id="legacy_browser_modal" class="modal fade" role="dialog" aria-labelledby="genericModal" aria-hidden="true" tabindex="-1">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">You are using an unsupported browser
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
        <span aria-hidden="true">&times;</span>
        </h5>
      </div>
      <div class="modal-body">
        <p>
          You are using an unsupported browser. This web site is designed for the current versions of
          Microsoft Edge, Google Chrome, Mozilla Firefox, or Safari.
        </p>
      </div>
    </div>
  </div>
</div>

      <div id="interstitial-feedback-modal" class="modal fade in" aria-hidden="true" tabindex="-1" role="dialog" aria-labelledby="Feedback: Contact Us">
  <div class="modal-dialog" role="document">
    <div class="modal-content">
      <div class="modal-header">
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">×</span>
        </button>
        <h3 class="text-center">Site Feedback</h3>
      </div>
      <div class="modal-body">
        <p>
          The Office of the Federal Register publishes documents on behalf of Federal agencies but does not have any authority over their programs. We recommend you directly contact the agency associated with the content in question.
        </p>
        <hr>
        <div class="row">
          <div id="website-feedback" class="col-xs-6 col-md-6 feedback-section">
            <p>
              If you have comments or suggestions on how to improve the www.ecfr.gov website or have questions about using www.ecfr.gov, please choose the 'Website Feedback' button below.
            </p>
            <div class="text-center">
              <a class="btn btn-primary btn-medium text-center" href="">
                <div><span class="icon-ecfr icon-ecfr-help "></span></div>
                Website Feedback
</a>            </div>
          </div>
          <div id="content-feedback" class="col-xs-6 col-md-6 feedback-section">
            <p>
              If you would like to comment on the current content, please use the 'Content Feedback' button below for instructions on contacting the issuing agency
            </p>
            <div class="text-center">
              <a class="btn btn-primary btn-medium text-center" href="">
                <div><span class="icon-ecfr icon-ecfr-legal "></span></div>
                Content Feedback
</a>            </div>
          </div>
        </div>
        <div class="text-center small-text">If you have questions for the Agency that issued the current document please contact the agency directly.</div>
      </div>
    </div>
  </div>
</div>

      <div id="zendesk-feedback-modal">
  <div class="modal-content zendesk-modal-content">
    <div class="modal-header">
      <button type="button" class="close" data-dismiss="modal" aria-label="Close">
        <span aria-hidden="true">×</span>
      </button>
      <h3>Website Feedback</h3>
    </div>

    <div class="modal-body">
      <form novalidate="novalidate" class="simple_form zendesk_ticket" enctype="multipart/form-data" action="/zendesk_tickets" accept-charset="UTF-8" method="post">
        <div class="form-group string required zendesk_ticket_name"><label class="control-label string required" for="zendesk_ticket_name"><abbr title="required">*</abbr> Your Name</label><input class="form-control string required" required="required" aria-required="true" type="text" name="zendesk_ticket[name]" id="zendesk_ticket_name" /></div>
        <div class="form-group email required zendesk_ticket_email"><label class="control-label email required" for="zendesk_ticket_email"><abbr title="required">*</abbr> Email</label><input class="form-control string email required" required="required" aria-required="true" type="email" name="zendesk_ticket[email]" id="zendesk_ticket_email" /></div>
        <div class="form-group file optional zendesk_ticket_attachment"><label class="control-label file optional" for="zendesk_ticket_attachment">Attachment</label><input class="file optional" type="file" name="zendesk_ticket[attachment]" id="zendesk_ticket_attachment" /></div>
        <div class="form-group text required zendesk_ticket_comment"><label class="control-label text required" for="zendesk_ticket_comment"><abbr title="required">*</abbr> How can we help you?</label><textarea class="form-control text required" name="zendesk_ticket[comment]" id="zendesk_ticket_comment">
</textarea></div>
        <div class="form-group boolean required zendesk_ticket_technical_help"><div class="checkbox"><input value="0" autocomplete="off" type="hidden" name="zendesk_ticket[technical_help]" /><label class="boolean required" for="zendesk_ticket_technical_help"><input class="boolean required" required="required" aria-required="true" type="checkbox" value="1" name="zendesk_ticket[technical_help]" id="zendesk_ticket_technical_help" /><abbr title="required">*</abbr> I am requesting technical help or providing website feedback</label></div></div>
          <div class="modal-text">
            This contact form is only for website help or website suggestions. If you have questions or comments regarding a published document please
            contact the publishing agency. Comments or questions about document content can not be answered by OFR staff. Please do not provide confidential
            information or personal data.
          </div>
        <div class="form-group text-left">
          <input type="submit" name="commit" value="Create Ticket" class="btn btn-primary btn-medium" data-disable-with="Create Ticket" />
        </div>
</form>    </div>
  </div>
</div>


    

    <div class="container">
      <div class='row'>
        <div class="col-xs-12 col-md-12 layout-header">
          <div class="main-navigation" id="main-navigation">
  <ul class="container">
    <li id='nav-home' class="nav-home" tabindex>
      <a class="home" aria-label="Home" href="/">
        <span class="icon-ecfr icon-ecfr-home "></span>
</a>    </li>

    <li id='nav-browse' class="dropdown nav-browse" tabindex=0>
      <a class="top-nav">
        <span class="icon-ecfr icon-ecfr-eye "></span>
        Browse
        <span class="icon-ecfr icon-ecfr-menu-arrow "></span>
      </a>

      <ul class="subnav dropdown-list">
        <li>
          <a href="/titles"><span class="icon-ecfr icon-ecfr-book "></span> Titles</a>
        </li>
        <li>
          <a href="/agencies"><span class="icon-ecfr icon-ecfr-mindmap "></span> Agencies</a>
        </li>
        <li>
          <a href="/incorporation-by-reference"><span class="icon-ecfr icon-ecfr-directions-alt "></span> Incorporation by Reference</a>
        </li>
        <li>
          <a href="/issues"><span class="icon-ecfr icon-ecfr-hourglass "></span> Recent Updates</a>
        </li>
      </ul>
    </li>

    <li id='nav-search' class="nav-search" tabindex>
      <a class="search" aria-label="eCFR Search" href="/search">
        <span class="icon-ecfr icon-ecfr-search "></span> Search
</a>    </li>

    <li id='nav-recent-changes' class="nav-recent-changes" tabindex>
      <a aria-label="eCFR Recent Changes" href="/recent-changes">
        <span class="icon-ecfr icon-ecfr-hourglass "></span> Recent Changes
</a>    </li>

    <li id='nav-ecfr-corrections' class="nav-recent-changes" tabindex>
      <a aria-label="eCFR Corrections" href="/corrections/2025">
        <span class="icon-ecfr icon-ecfr-merge "></span> Corrections
</a>    </li>

    <li id='nav-reader-aids' class="dropdown nav-reader-aids" tabindex=0>
      <a class="top-nav">
        <span class="icon-ecfr icon-ecfr-directions "></span>
        Reader Aids
        <span class="icon-ecfr icon-ecfr-menu-arrow "></span>
      </a>

      <ul class="subnav dropdown-list hierarchical" tabindex=0>
        <li>
          <a tabindex="0" href="/reader-aids">Reader Aids Home</a>
        </li>
          <li>
            <a tabindex="0" href="/reader-aids/using-ecfr">Using the eCFR Point-in-Time System</a>
          </li>
          <li>
            <a tabindex="0" href="/reader-aids/understanding-the-ecfr">Understanding the eCFR</a>
          </li>
          <li>
            <a tabindex="0" href="/reader-aids/government-policy-and-ofr-procedures">Government Policy and OFR Procedures</a>
          </li>
          <li>
            <a tabindex="0" href="/reader-aids/ecfr-developer-resources">Developer Resources</a>
          </li>
      </ul>
    </li>

    <li id='nav-my-ecfr' class="dropdown nav-my-ecfr" tabindex=0>
      <a class="top-nav">
        <span class="icon-ecfr icon-ecfr-male-female-user "></span>
        My eCFR
        <span class="icon-ecfr icon-ecfr-menu-arrow "></span>
      </a>

      <ul class="subnav dropdown-list signed-in hidden" tabindex=0>
        <li>
          <a href="/my/subscriptions">My Subscriptions</a>
        </li>
        <li>
          <a data-turbo="false" href="/sign_out">Sign Out</a>
        </li>
      </ul>

      <ul class="subnav dropdown-list signed-out" tabindex=0>
        <li>
          <a data-turbo="false" href="https://www.ecfr.gov/auth/sign_in?jwt=eyJhbGciOiJIUzI1NiJ9.eyJub3RpZmljYXRpb25zIjp7ImluZm8iOiJZb3Ugd2lsbCBiZSByZWRpcmVjdGVkIGJhY2sgdG8gdGhlIGVDRlIgYWZ0ZXIgeW91IGhhdmUgc2lnbmVkIGluIG9yIGNyZWF0ZWQgYW4gYWNjb3VudC4ifX0.-sYkHWfC02yb0CpuUqmPkxxnF0yzlNHaS5520hYIUy8&amp;redirect_to=https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-600">Sign In / Sign Up</a>
        </li>
      </ul>
    </li>

    <li id='nav-inline-search' class="nav-inline-search" data-controller="placeholder">
      <form class="simple_form nav-search-form" novalidate="novalidate" action="/search" accept-charset="UTF-8" method="get">
        <input value="current" class="hidden" autocomplete="off" type="hidden" name="search[date]" id="search_date" />

          <input value="{&quot;title&quot;:&quot;21&quot;,&quot;chapter&quot;:&quot;I&quot;,&quot;subchapter&quot;:&quot;F&quot;,&quot;part&quot;:&quot;600&quot;}" autocomplete="off" type="hidden" name="search[prior_hierarchy]" id="search_prior_hierarchy" />

        <input autocomplete="off" class="string required nav-search-query" data-action="click-&gt;placeholder#suggestions" placeholder="Search the eCFR" type="text" name="search[query]" id="search_query" />

        <button name="button" type="submit" class="nav-search-btn" title="Search" data-action="click-&gt;placeholder#suggestions">
          <span class="icon-ecfr icon-ecfr-search "></span>
</button>
        <div class='current-hierarchy-dropdown hidden'>
        </div>
</form>    </li>
  </ul>

  <div class='user-utils'>
    <div class='signed-out'>
      <a class="utils-signed-out" tabindex="-1" data-turbo="false" href="https://www.ecfr.gov/auth/sign_in?jwt=eyJhbGciOiJIUzI1NiJ9.eyJub3RpZmljYXRpb25zIjp7ImluZm8iOiJZb3Ugd2lsbCBiZSByZWRpcmVjdGVkIGJhY2sgdG8gdGhlIGVDRlIgYWZ0ZXIgeW91IGhhdmUgc2lnbmVkIGluIG9yIGNyZWF0ZWQgYW4gYWNjb3VudC4ifX0.-sYkHWfC02yb0CpuUqmPkxxnF0yzlNHaS5520hYIUy8&amp;redirect_to=https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-600">Sign In / Sign Up</a>
    </div>

    <div class='signed-in hidden'>
      <p>
        Hi, <span class='user-email'></span>
          <a data-turbo="false" tabindex="-1" href="/sign_out">Sign Out</a>
      </p>
    </div>
  </div>
</div>


<div class="container">
  <div class="row">
    <div class="col-xs-12">
      <div class="logo">
        <div class="hgroup standard">
          <hgroup>
            <h1><a href="/" title="eCFR Home" tabindex=-1>eCFR</a></h1>
            <h2>The Electronic Code of Federal Regulations</h2>
          </hgroup>
        </div>
      </div>
    </div>
  </div>
</div>


        </div>
      </div>
    </div>

    <div class="container">
      <div class='external-url-modal'></div>
      <div class="modal fr-citation-modal" id="frCitationModal" tabindex="-1" role="dialog" aria-labelledby="Federal Register Citation Modal">
        <div class="modal-dialog" role="document">
          <div class="modal-content">
            <span class="icon-ecfr icon-ecfr-badge-x "></span>
            <div class="box box-enhanced "><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content :: FR Reference</h6><div class="row seal-meta"><div class="seal-desc col-md-12 col-xs-12"><p>Enhanced content is provided to the user to provide additional context.</p></div></div></div></div><div class="content-block ">
              <div class="modal-body"></div>
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content :: FR Reference</h6></div></div>          </div>
        </div>
      </div>

      <div class='row'>
        <div class="col-xs-12 col-md-12 title-bar-col">
          <div id="page-top" class="main-title-bar "><div class="bar left"></div><h1 class="">  <span class="icon-ecfr icon-ecfr-books "></span>
  Title 21
</h1><div class="bar right"></div></div>
        </div>
      </div>


          <div class="row " >
  <div class="col-xs-12 col-md-12 content-notification basic print-only print-only-legal-notice"
    id="content-notification-f4223aa6"
  >
    <div class="">

      

      <div class="message">
        <p>This content is from the eCFR and is authoritative but unofficial.<p>
      </div>

    </div>
  </div>
</div>

  <div class="row " >
  <div class="col-xs-12 col-md-12 content-notification info"
    id="content-notification-a4841755"
  >
    <div class="">

      <span class="icon-ecfr icon-ecfr-calendar-alt "></span>

      <div class="message">
        Displaying title 21, up to date as of 4/10/2025. Title 21 was last amended 3/31/2025.<span class="reader-aid"><span data-toggle="tooltip" data-title="Click to learn more about dates in eCFR." class="svg-tooltip clickable" data-url="/reader-aids/understanding-the-ecfr/what-is-the-ecfr#special-rules-and-proceedures-for-future-amendments" data-container="span.reader-aid"><svg class="ecfr-svg-icon ecfr-svg-icon-info-circle "><use xlink:href="/assets/ecfr-icons-c08c495b1eda093da23b5b159c24927a91aa7c13df40f52ca7d30476904de0ea.svg#ecfr-svg-icon-info-circle"></use></svg></span></span>
      </div>

        <div class="message-link">
          <a class="msg-link message-go-to-version" href="#">view historical versions</a>
        </div>
    </div>
  </div>
</div>

  <div class="row hidden" >
  <div class="col-xs-12 col-md-12 content-notification danger"
    id="drafting-site-notification"
  >
    <div class="">
        <div class="dismiss-link">
          <span class="icon-ecfr icon-ecfr-badge-x "></span>
        </div>

      <span class="icon-ecfr icon-ecfr-alert-alt "></span>

      <div class="message">
        A <a data-drafting="true" href="https://drafting.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-600">drafting site is available</a> for use when drafting amendatory language
      </div>

        <div class="message-link">
          <a data-drafting="true" class="msg-link" href="https://drafting.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-600">switch to drafting site</a>
        </div>
    </div>
  </div>
</div>






      <div class='row'>
        <div class="col-xs-12 col-md-12 content-col">
          <div>
  <div id="suggestions" data-controller="suggestions autocomplete"
    data-autocomplete-url-value="/suggestions"
    data-autocomplete-delay-value="300">

    <div class="modal hidden" data-controller="modal"
      data-action="keyup@document->modal#escClose"
      data-suggestions-target="modal">

      <button class="backdrop" type="button" tabindex="-1"
        data-action="modal#close"></button>

      <div class="content">

        <div class="panel panel-default panel-info" data-suggestions-target="help">
          <div class="panel-heading">
            <p>
              <strong>Navigate by entering citations or phrases</strong>
              (eg:
                <span data-action="click->suggestions#fillExample"
                  class="example badge badge-info">1 CFR 1.1</span>
                <span data-action="click->suggestions#fillExample"
                  class="example badge badge-info">49 CFR 172.101</span>
                <span data-action="click->suggestions#fillExample"
                  class="example badge badge-info">Organization and Purpose</span>
                <span data-action="click->suggestions#fillExample"
                  class="example badge badge-info">1/1.1</span>
                <span data-action="click->suggestions#fillExample"
                  class="example badge badge-info">Regulation Y</span>
                <span data-action="click->suggestions#fillExample"
                  class="example badge badge-info">FAR</span>).
            </p>
            <p>
              Choosing an item from
              <span class="suggestion-header-example">citations and headings</span>
              will bring you directly to the content. Choosing an item from
              <span class="suggestion-header-example">full text search results</span>
              will bring you to those results. Pressing enter in the search box
              will also bring you to search results.
            </p>
            <p>
              Background and more details are available in the
              <em>
                <a href="/reader-aids/using-ecfr/navigating-to-content-of-interest#search-navigation">Search &amp; Navigation</a>
              </em>
              guide.
            </p>
          </div>
        </div>

        <div class="cfr-ref-wrapper go-to-cfr-reference">
          <form class="simple_form go-to-cfr-reference" data-suggestions-target="form" data-turbo="false" novalidate="novalidate" action="/cfr-reference" accept-charset="UTF-8" method="get">
            <input value="current" data-param="date" autocomplete="off" type="hidden" name="search[date]" id="search_date" />
            <input value="{&quot;title&quot;:&quot;21&quot;,&quot;chapter&quot;:&quot;I&quot;,&quot;subchapter&quot;:&quot;F&quot;,&quot;part&quot;:&quot;600&quot;}" data-param="hierarchy" autocomplete="off" type="hidden" name="search[hierarchy]" id="search_hierarchy" />
            <input value="{&quot;title&quot;:&quot;21&quot;,&quot;chapter&quot;:&quot;I&quot;,&quot;subchapter&quot;:&quot;F&quot;,&quot;part&quot;:&quot;600&quot;}" data-param="prior_hierarchy" autocomplete="off" type="hidden" name="search[prior_hierarchy]" id="search_prior_hierarchy" />

            <div class="input-group input-group-lg">
              <input type="text" class="form-control"
                placeholder="Enter a search term or CFR reference (eg. fishing or 1 CFR 1.1)"
                aria-describedby="reference-search-icon"
                data-autocomplete-target="input"
                data-suggestions-target="input"
                name="search[query]"
                id="suggestion_query">

              <span class="input-group-btn"
                id="reference-search-icon"
                aria-label="search">
                <button class="btn btn-optional" type="button"
                  data-suggestions-target="searchIcon"
                  data-action="click->suggestions#goDefault">
                    <span class="icon-ecfr icon-ecfr-search "></span>
                </button>
              </span>
            </div>

            <div data-autocomplete-target="results"
              data-suggestions-target="results"></div>
</form>        </div>

      </div>
    </div>

    <form class="simple_form go-to-cfr-reference hidden" data-suggestions-target="nonModalForm" novalidate="novalidate" action="/cfr-reference" accept-charset="UTF-8" method="get">
      <input label="false" value="current" autocomplete="off" type="hidden" name="cfr[date]" id="cfr_date" />
      <input value="{&quot;title&quot;:&quot;21&quot;,&quot;chapter&quot;:&quot;I&quot;,&quot;subchapter&quot;:&quot;F&quot;,&quot;part&quot;:&quot;600&quot;}" autocomplete="off" type="hidden" name="cfr[prior_hierarchy]" id="cfr_prior_hierarchy" />
      <input data-autocomplete-target="hidden" autocomplete="off" type="hidden" name="cfr[suggestion_id]" id="cfr_suggestion_id" />

      <div class="input-group input-group-lg">
        <input type="text" class="form-control string optional"
          data-action="focus->suggestions#modal"
          placeholder="Enter a search term or CFR reference (eg. fishing or 1 CFR 1.1)"
          type="text"
          data-suggestions-target="nonModalInput"
          name="cfr[reference]"
          id="suggestion">
        <span class="input-group-btn"
          data-action="click->suggestions#go">

          <button class="btn btn-optional" type="button"
            data-suggestions-target="nonModalSearchIcon"
            data-action="click->suggestions#go">
              <span class="icon-ecfr icon-ecfr-search "></span>
          </button>
        </span>
      </div>
</form>  </div>
</div>

          



<div class='row'>
  <div class="col-xs-12 col-md-12 no-padding">
    <div class='cfr-ref-wrapper'>
  <div data-controller="placeholder">
    <form class="simple_form go-to-cfr-reference" novalidate="novalidate" action="/cfr-reference" accept-charset="UTF-8" method="get">

      <div class="input-group input-group-lg">
        <input type="text" class="form-control string optional"
          data-action="focus->placeholder#suggestions"
          placeholder="Enter a search term or CFR reference (eg. fishing or 1 CFR 1.1)"
          type="text"
          data-suggestions-target="nonModalInput"
          name="cfr[reference]"
          id="suggestion">
        <span class="input-group-btn"
          data-action="click->placeholder#suggestions">

          <button class="btn btn-optional" type="button"
            data-suggestions-target="nonModalSearchIcon"
            data-action="click->placeholder#suggestions">
              <span class="icon-ecfr icon-ecfr-search "></span>
          </button>
        </span>
      </div>
</form>  </div>
</div>

  </div>
</div>

<div class="row breadcrumbs-wrapper ">
  <div class="col-xs-12 col-md-12 breadcrumb-nav" data-hierarchy="{&quot;title&quot;:&quot;21&quot;,&quot;chapter&quot;:&quot;I&quot;,&quot;subchapter&quot;:&quot;F&quot;,&quot;part&quot;:&quot;600&quot;}" data-filtered-search-enabled="true">
    <div class='row'>
      <div class="col-xs-12 col-md-9">
        <ol>
    <li class="">
        <a class="breadcrumb-link" data-toggle="tooltip" data-placement="top" data-title="View Table of Contents for Title 21—Food and Drugs" href="/current/title-21">Title 21 <span class="print-only breadcrumbs-title" data-hierarchy="{'title':'21'}">—Food and Drugs</span></a>
    </li>
    <li class="">
        <a class="breadcrumb-link" data-toggle="tooltip" data-placement="top" data-title="View Table of Contents for  Chapter I—Food and Drug Administration, Department of Health and Human Services" href="/current/title-21/chapter-I"> Chapter I <span class="print-only breadcrumbs-title" data-hierarchy="{'title':'21','chapter':'I'}">—Food and Drug Administration, Department of Health and Human Services</span></a>
    </li>
    <li class="">
        <a class="breadcrumb-link" data-toggle="tooltip" data-placement="top" data-title="View Table of Contents for Subchapter F—Biologics" href="/current/title-21/chapter-I/subchapter-F">Subchapter F <span class="print-only breadcrumbs-title" data-hierarchy="{'title':'21','chapter':'I','subchapter':'F'}">—Biologics</span></a>
    </li>
    <li class="breadcrumb-current">
        Part 600

    </li>
</ol>

      </div>

      <div class="col-xs-12 col-md-3 text-right">
        <ul class="prev-next-breadcrumb-nav">
  <li>
      <a id="previous-content-link" data-title="Part 589—Substances Prohibited from Use in Animal Food or Feed" data-html="true" href="/current/title-21/chapter-I/subchapter-E/part-589">Previous</a>
  </li>

  <li>
      <a id="next-content-link" data-title="Part 601—Licensing" data-html="true" href="/current/title-21/chapter-I/subchapter-F/part-601">Next</a>
  </li>

  <li id="breadcrumb-back-to-top">
    <a data-title="Back to Top" data-turbo="false" href="#page-top">Top</a>
  </li>
</ul>

      </div>
    </div>
</div></div>


<div class="row ecfr-content-wrapper">
  <div class="col-xs-12 col-md-12 ecfr-content with-utility-bar">
    <div class="row">
      <div class="col-xs-3 col-sm-2 content-nav-wrapper content-nav-wrapper-wide">
        
<ul class="content-nav text-center dropdown drop-enhanced ui sticky">
  <li class="button">
    <span role="button" arial-label="compress content nav" class="icon-ecfr icon-ecfr-previous-media content-nav-compress-toggle"></span>
  </li>

  

<li class="enhanced " id="utility-nav-toc" tabindex="0"><span role="button" aria-label="Table of Contents" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Table of Contents" class="icon-ecfr icon-ecfr-book "></span><span class="content-nav-label " role="button">Table of Contents</span><div class="box box-enhanced box-enhanced-toc box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Table of Contents</h6></div></div><div class="content-block ">      <table class="table-of-contents root">
        <tr class="part  toggler-active"><td class="toc-label " colspan="1"><span data-toggle="{&quot;toggleTargetContext&quot;:&quot;grandparent&quot;}" class="icon-ecfr icon-ecfr-menu-arrow toggle"></span><span class="toc-text-secondary" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;Part 600&lt;/span&gt;">Part 600</span></td><td class="description" colspan="1"><span class="text-toc-secondary" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;Part 600&lt;/span&gt;"><a data-turbo="false" href="#part-600">Biological Products: General</a></span></td><td class="section-identifiers"><span class="toc-range" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;Part 600&lt;/span&gt;"><a data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;600.2 – 600.90&lt;/span&gt;" href="/current/title-21/chapter-I/subchapter-F/part-600?toc=1">600.2 – 600.90</a></span></td></tr><tr class="group"><td colspan="3"><table class="table-of-contents"><tr class="subpart  toggler-active"><td class="toc-label " colspan="1"><span data-toggle="{&quot;toggleTargetContext&quot;:&quot;grandparent&quot;}" class="icon-ecfr icon-ecfr-menu-arrow toggle"></span><span class="toc-text-secondary" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart A&lt;/span&gt;">Subpart A</span></td><td class="description" colspan="1"><span class="text-toc-secondary" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart A&lt;/span&gt;"><a data-turbo="false" href="#subpart-A">General Provisions</a></span></td><td class="section-identifiers"><span class="toc-range" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart A&lt;/span&gt;"><a data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;600.2 – 600.3&lt;/span&gt;" href="/current/title-21/chapter-I/subchapter-F/part-600/subpart-A?toc=1">600.2 – 600.3</a></span></td></tr><tr class="group"><td colspan="3"><table class="table-of-contents"><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.2&lt;/span&gt;">§ 600.2</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.2&lt;/span&gt;"><a data-turbo="false" href="#600.2">Mailing addresses.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.3&lt;/span&gt;">§ 600.3</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.3&lt;/span&gt;"><a data-turbo="false" href="#600.3">Definitions.</a></span></td></tr></table></td></tr><tr class="subpart  toggler-active"><td class="toc-label " colspan="1"><span data-toggle="{&quot;toggleTargetContext&quot;:&quot;grandparent&quot;}" class="icon-ecfr icon-ecfr-menu-arrow toggle"></span><span class="toc-text-secondary" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart B&lt;/span&gt;">Subpart B</span></td><td class="description" colspan="1"><span class="text-toc-secondary" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart B&lt;/span&gt;"><a data-turbo="false" href="#subpart-B">Establishment Standards</a></span></td><td class="section-identifiers"><span class="toc-range" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart B&lt;/span&gt;"><a data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;600.10 – 600.15&lt;/span&gt;" href="/current/title-21/chapter-I/subchapter-F/part-600/subpart-B?toc=1">600.10 – 600.15</a></span></td></tr><tr class="group"><td colspan="3"><table class="table-of-contents"><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.10&lt;/span&gt;">§ 600.10</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.10&lt;/span&gt;"><a data-turbo="false" href="#600.10">Personnel.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.11&lt;/span&gt;">§ 600.11</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.11&lt;/span&gt;"><a data-turbo="false" href="#600.11">Physical establishment, equipment, animals, and care.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.12&lt;/span&gt;">§ 600.12</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.12&lt;/span&gt;"><a data-turbo="false" href="#600.12">Records.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.13&lt;/span&gt;">§ 600.13</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.13&lt;/span&gt;"><a data-turbo="false" href="#600.13">Retention samples.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.14&lt;/span&gt;">§ 600.14</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.14&lt;/span&gt;"><a data-turbo="false" href="#600.14">Reporting of biological product deviations by licensed manufacturers.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.15&lt;/span&gt;">§ 600.15</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.15&lt;/span&gt;"><a data-turbo="false" href="#600.15">Temperatures during shipment.</a></span></td></tr></table></td></tr><tr class="subpart  toggler-active"><td class="toc-label " colspan="1"><span data-toggle="{&quot;toggleTargetContext&quot;:&quot;grandparent&quot;}" class="icon-ecfr icon-ecfr-menu-arrow toggle"></span><span class="toc-text-secondary" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart C&lt;/span&gt;">Subpart C</span></td><td class="description" colspan="1"><span class="text-toc-secondary" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart C&lt;/span&gt;"><a data-turbo="false" href="#subpart-C">Establishment Inspection</a></span></td><td class="section-identifiers"><span class="toc-range" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart C&lt;/span&gt;"><a data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;600.20 – 600.22&lt;/span&gt;" href="/current/title-21/chapter-I/subchapter-F/part-600/subpart-C?toc=1">600.20 – 600.22</a></span></td></tr><tr class="group"><td colspan="3"><table class="table-of-contents"><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.20&lt;/span&gt;">§ 600.20</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.20&lt;/span&gt;"><a data-turbo="false" href="#600.20">Inspectors.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.21&lt;/span&gt;">§ 600.21</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.21&lt;/span&gt;"><a data-turbo="false" href="#600.21">Time of inspection.</a></span></td></tr><tr class="reserved section toc-leaf-node "><td colspan="3"><span class="description">§ 600.22 [Reserved]</span></td></tr></table></td></tr><tr class="subpart  toggler-active"><td class="toc-label " colspan="1"><span data-toggle="{&quot;toggleTargetContext&quot;:&quot;grandparent&quot;}" class="icon-ecfr icon-ecfr-menu-arrow toggle"></span><span class="toc-text-secondary" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart D&lt;/span&gt;">Subpart D</span></td><td class="description" colspan="1"><span class="text-toc-secondary" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart D&lt;/span&gt;"><a data-turbo="false" href="#subpart-D">Reporting of Adverse Experiences</a></span></td><td class="section-identifiers"><span class="toc-range" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;Subpart D&lt;/span&gt;"><a data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;600.80 – 600.90&lt;/span&gt;" href="/current/title-21/chapter-I/subchapter-F/part-600/subpart-D?toc=1">600.80 – 600.90</a></span></td></tr><tr class="group"><td colspan="3"><table class="table-of-contents"><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.80&lt;/span&gt;">§ 600.80</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.80&lt;/span&gt;"><a data-turbo="false" href="#600.80">Postmarketing reporting of adverse experiences.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.81&lt;/span&gt;">§ 600.81</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.81&lt;/span&gt;"><a data-turbo="false" href="#600.81">Distribution reports.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.82&lt;/span&gt;">§ 600.82</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.82&lt;/span&gt;"><a data-turbo="false" href="#600.82">Notification of a permanent discontinuance or an interruption in manufacturing.</a></span></td></tr><tr class="section  toggler-active"><td class="toc-label " colspan="1"><span class="toc-wrapper" data-toggle="tooltip" data-placement="top" data-title="View Text of &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.90&lt;/span&gt;">§ 600.90</span></td><td class="description" colspan="2"><span class="text-wrapper" data-toggle="tooltip" data-placement="left" data-title="View Table of Contents for &lt;span class=&#39;avoid-wrap&#39;&gt;§ 600.90&lt;/span&gt;"><a data-turbo="false" href="#600.90">Waivers.</a></span></td></tr></table></td></tr></table></td></tr>
      </table>
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Table of Contents</h6></div></div></li>

  
<li class="enhanced " id="utility-nav-details" tabindex="0"><span role="button" aria-label="Details" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Details" class="icon-ecfr icon-ecfr-book-alt-2 "></span><span class="content-nav-label " role="button">Details</span><div class="box box-enhanced box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Details</h6></div></div><div class="content-block ">    <dl class="">
      <dt>URL</dt>
      <dd>
        https://www.ecfr.gov/current/title-21/part-600
        <span data-toggle="tooltip" data-title="Copy to Clipboard" class="svg-tooltip copy-to-clipboard" data-title-copied="Copied to Clipboard" data-copy-text="https://www.ecfr.gov/current/title-21/part-600"><svg class="ecfr-svg-icon ecfr-svg-icon-content-copy "><use xlink:href="/assets/ecfr-icons-c08c495b1eda093da23b5b159c24927a91aa7c13df40f52ca7d30476904de0ea.svg#ecfr-svg-icon-content-copy"></use></svg></span>
      </dd>

        <dt>Citation</dt>
        <dd>
          21 CFR Part 600
          <span data-toggle="tooltip" data-title="Copy to Clipboard" class="svg-tooltip copy-to-clipboard" data-title-copied="Copied to Clipboard" data-copy-text="21 CFR Part 600"><svg class="ecfr-svg-icon ecfr-svg-icon-content-copy "><use xlink:href="/assets/ecfr-icons-c08c495b1eda093da23b5b159c24927a91aa7c13df40f52ca7d30476904de0ea.svg#ecfr-svg-icon-content-copy"></use></svg></span>
        </dd>



        <dt>
          Agency
          <span data-toggle="tooltip" data-title="The agency currently associated with this eCFR content. Click for more details." class="svg-tooltip clickable" data-url="/reader-aids/using-ecfr/agency-references#details_sidebar" data-container="dl"><svg class="ecfr-svg-icon ecfr-svg-icon-info-circle "><use xlink:href="/assets/ecfr-icons-c08c495b1eda093da23b5b159c24927a91aa7c13df40f52ca7d30476904de0ea.svg#ecfr-svg-icon-info-circle"></use></svg></span>
        </dt>
          <dd data-issuing-agency=food-and-drug-administration>Food and Drug Administration, Department of Health and Human Services</dd>
    </dl>

    <hr>

    <div id="source-and-authority">
        <div class="additional-source-and-authority">
      <div class="level">
        <a href="/current/title-21/part-600" class="cfr reference">Part 600</a>
        <div class="details" data-hierarchy="{:title=&gt;&quot;21&quot;, :chapter=&gt;&quot;I&quot;, :subchapter=&gt;&quot;F&quot;, :part=&gt;&quot;600&quot;}" data-current="true">
            <div class="authority">
              <h4 class="inline-header">Authority:</h4>
              <p class="inline-paragraph">
                <a href="https://www.govinfo.gov/link/uscode/21/321" class="usc external" target="_blank" rel="noopener noreferrer">21 U.S.C. 321</a>, <a href="https://www.govinfo.gov/link/uscode/21/351" class="usc external" target="_blank" rel="noopener noreferrer">351</a>, <a href="https://www.govinfo.gov/link/uscode/21/352" class="usc external" target="_blank" rel="noopener noreferrer">352</a>, <a href="https://www.govinfo.gov/link/uscode/21/353" class="usc external" target="_blank" rel="noopener noreferrer">353</a>, <a href="https://www.govinfo.gov/link/uscode/21/355" class="usc external" target="_blank" rel="noopener noreferrer">355</a>, <a href="https://www.govinfo.gov/link/uscode/21/356c" class="usc external" target="_blank" rel="noopener noreferrer">356c</a>, <a href="https://www.govinfo.gov/link/uscode/21/356e" class="usc external" target="_blank" rel="noopener noreferrer">356e</a>, <a href="https://www.govinfo.gov/link/uscode/21/360" class="usc external" target="_blank" rel="noopener noreferrer">360</a>, <a href="https://www.govinfo.gov/link/uscode/21/360i" class="usc external" target="_blank" rel="noopener noreferrer">360i</a>, <a href="https://www.govinfo.gov/link/uscode/21/371" class="usc external" target="_blank" rel="noopener noreferrer">371</a>, <a href="https://www.govinfo.gov/link/uscode/21/374" class="usc external" target="_blank" rel="noopener noreferrer">374</a>, <a href="https://www.govinfo.gov/link/uscode/21/379k" class="usc external" target="_blank" rel="noopener noreferrer">379k</a>-l; <a href="https://www.govinfo.gov/link/uscode/42/216" class="usc external" target="_blank" rel="noopener noreferrer">42 U.S.C. 216</a>, <a href="https://www.govinfo.gov/link/uscode/42/262" class="usc external" target="_blank" rel="noopener noreferrer">262</a>, <a href="https://www.govinfo.gov/link/uscode/42/263" class="usc external" target="_blank" rel="noopener noreferrer">263</a>, <a href="https://www.govinfo.gov/link/uscode/42/263a" class="usc external" target="_blank" rel="noopener noreferrer">263a</a>, <a href="https://www.govinfo.gov/link/uscode/42/264" class="usc external" target="_blank" rel="noopener noreferrer">264</a>.


              </p>
            </div>
        </div>
      </div>
  </div>

    </div>
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Details</h6></div></div></li>

  
<li class="enhanced " id="" tabindex="0"><span role="button" aria-label="Print/PDF" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Print/PDF" class="icon-ecfr icon-ecfr-print "></span><span class="content-nav-label " role="button">Print/PDF</span><div class="box box-enhanced box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Print</h6></div></div><div class="content-block ">      <p>
        <a class="generate-pdf" data-original-text="Generate PDF <small class=&quot;text-warning&quot;>(approximately 25+ pages)</small>" href="#">Generate PDF <small class="text-warning">(approximately 25+ pages)</small></a>

        <span class="pdf-spinner" style="display:none;">
          <span class="spinner"></span>
        </span>
      </p>
      <p>
        This content is from the eCFR and may include recent changes applied to the CFR.
        The official, published CFR, is updated annually and available below under
        "Published Edition". You can learn more about the process
        <a href="https://www.govinfo.gov/help/cfr#about">here</a>.
      </p>
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Print</h6></div></div></li>

  
<li class="enhanced " id="" tabindex="0"><span role="button" aria-label="Display Options" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Display Options" class="icon-ecfr icon-ecfr-doc-generic "></span><span class="content-nav-label " role="button">Display Options</span><div class="box box-enhanced box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Display Options</h6></div></div><div class="content-block ">    <turbo-frame id="side_display" src="/display/current/title-21/chapter-I/subchapter-F/part-600" loading="lazy">
      <span class="timeline-spinner">
        <span class="spinner"></span>
      </span>
    </turbo-frame>  
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Display Options</h6></div></div></li>

  
<li class="enhanced utility-nav-subscribe" id="utility-nav-subscribe" tabindex="0"><span role="button" aria-label="Subscribe" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Subscribe" class="icon-ecfr icon-ecfr-message "></span><span class="content-nav-label " role="button">Subscribe</span><div class="box box-enhanced box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Subscribe</h6></div></div><div class="content-block ">    <p><strong>Subscribe to:</strong> 21 CFR Part 600</p>

    <div class="subscription-option">
      <form class="simple_form form-horizontal subscribe" id="new_subscription" data-turbo="false" novalidate="novalidate" action="/my/subscriptions" accept-charset="UTF-8" method="post">
            <div class="form-group hidden subscription_title"><input class="form-control hidden hierarchy-input" value="21" name="search[hierarchy][title]" autocomplete="off" type="hidden" id="subscription_title" /></div>
            <div class="form-group hidden subscription_chapter"><input class="form-control hidden hierarchy-input" value="I" name="search[hierarchy][chapter]" autocomplete="off" type="hidden" id="subscription_chapter" /></div>
            <div class="form-group hidden subscription_subchapter"><input class="form-control hidden hierarchy-input" value="F" name="search[hierarchy][subchapter]" autocomplete="off" type="hidden" id="subscription_subchapter" /></div>
            <div class="form-group hidden subscription_part"><input class="form-control hidden hierarchy-input" value="600" name="search[hierarchy][part]" autocomplete="off" type="hidden" id="subscription_part" /></div>

        <div class="subscription-option">
          <span class="icon-ecfr icon-ecfr-message "></span><label class='email-label'>Via Email:</label>
          <input type="submit" name="commit" value="Subscribe" class="btn-as-link" data-disable-with="Subscribe" />
        </div>

        <!-- <div class="subscription-option"> -->
          <!-- <label class='rss-label'>Via RSS:</label> -->

        <!-- </div> -->
</form>    </div>
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Subscribe</h6></div></div></li>

  <li class="divider"></li>

    
<li class="enhanced " id="utility-nav-timeline" tabindex="0"><span role="button" aria-label="Timeline" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Timeline" class="icon-ecfr icon-ecfr-hourglass "></span><span class="content-nav-label " role="button">Timeline</span><div class="box box-enhanced box-enhanced-timeline box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Timeline</h6></div></div><div class="content-block ">
        <turbo-frame data-controller="timeline" id="side_timeline" target="_top">
      <ol class="timeline list with-bullets enhanced">
          <li>
            <span class='date current-change'>
              3/24/2020
            </span>

            <span class='timeline'>
              <a href="/on/2020-03-24/title-21/chapter-I/subchapter-F/part-600">view on this date</a>
            </span>

            <span class='timeline'>
              <a data-diff-path="/compare/2020-03-24/to/2020-03-23/title-21/chapter-I/subchapter-F/part-600" href="#">view change <span class="hidden-xs hidden-sm">introduced</span></a>
            </span>

              <span class='timeline'>&nbsp;</span>
          </li>
          <li>
            <span class='date'>
              2/21/2020
            </span>

            <span class='timeline'>
              <a href="/on/2020-02-21/title-21/chapter-I/subchapter-F/part-600">view on this date</a>
            </span>

            <span class='timeline'>
              <a data-diff-path="/compare/2020-02-21/to/2020-02-20/title-21/chapter-I/subchapter-F/part-600" href="#">view change <span class="hidden-xs hidden-sm">introduced</span></a>
            </span>

              <span class='timeline'><a data-diff-path="/compare/current/to/2020-02-21/title-21/chapter-I/subchapter-F/part-600" href="#">compare to most recent</a></span>
          </li>
          <li>
            <span class='date'>
              5/02/2019
            </span>

            <span class='timeline'>
              <a href="/on/2019-05-02/title-21/chapter-I/subchapter-F/part-600">view on this date</a>
            </span>

            <span class='timeline'>
              <a data-diff-path="/compare/2019-05-02/to/2019-05-01/title-21/chapter-I/subchapter-F/part-600" href="#">view change <span class="hidden-xs hidden-sm">introduced</span></a>
            </span>

              <span class='timeline'><a data-diff-path="/compare/current/to/2019-05-02/title-21/chapter-I/subchapter-F/part-600" href="#">compare to most recent</a></span>
          </li>
          <li>
            <span class='date'>
              4/02/2019
            </span>

            <span class='timeline'>
              <a href="/on/2019-04-02/title-21/chapter-I/subchapter-F/part-600">view on this date</a>
            </span>

            <span class='timeline'>
              <a data-diff-path="/compare/2019-04-02/to/2019-04-01/title-21/chapter-I/subchapter-F/part-600" href="#">view change <span class="hidden-xs hidden-sm">introduced</span></a>
            </span>

              <span class='timeline'><a data-diff-path="/compare/current/to/2019-04-02/title-21/chapter-I/subchapter-F/part-600" href="#">compare to most recent</a></span>
          </li>
          <li>
            <span class='date'>
              5/07/2018
            </span>

            <span class='timeline'>
              <a href="/on/2018-05-07/title-21/chapter-I/subchapter-F/part-600">view on this date</a>
            </span>

            <span class='timeline'>
              <a data-diff-path="/compare/2018-05-07/to/2018-05-06/title-21/chapter-I/subchapter-F/part-600" href="#">view change <span class="hidden-xs hidden-sm">introduced</span></a>
            </span>

              <span class='timeline'><a data-diff-path="/compare/current/to/2018-05-07/title-21/chapter-I/subchapter-F/part-600" href="#">compare to most recent</a></span>
          </li>
          <li>
            <span class='date'>
              1/26/2018
            </span>

            <span class='timeline'>
              <a href="/on/2018-01-26/title-21/chapter-I/subchapter-F/part-600">view on this date</a>
            </span>

            <span class='timeline'>
              <a data-diff-path="/compare/2018-01-26/to/2018-01-25/title-21/chapter-I/subchapter-F/part-600" href="#">view change <span class="hidden-xs hidden-sm">introduced</span></a>
            </span>

              <span class='timeline'><a data-diff-path="/compare/current/to/2018-01-26/title-21/chapter-I/subchapter-F/part-600" href="#">compare to most recent</a></span>
          </li>
      </ol>
</turbo-frame>
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Timeline</h6></div></div></li>

  
<li class="enhanced " id="utility-nav-go-to-date" tabindex="0"><span role="button" aria-label="Go to Date" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Go to Date" class="icon-ecfr icon-ecfr-calendar-alt "></span><span class="content-nav-label " role="button">Go to Date</span><div class="box box-enhanced box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Go to Date</h6></div></div><div class="content-block ">    <form class="simple_form form-horizontal go-to-date" id="go-to-date-form" autocomplete="off" novalidate="novalidate" action="#" accept-charset="UTF-8" method="get">

      <div class="form-group bootstrap_datepicker optional go_to_date_date"><label class="control-label bootstrap_datepicker optional" for="go_to_date_date">Date</label><div class='input-group'>
<input class="form-control bootstrap_datepicker optional bootstrap-datepicker" data-date-start-date="1/03/2017" data-date-force-parse="false" data-date-assume-nearby-year="true" data-date-format="mm/dd/yyyy" data-date-autoclose="true" data-provide="datepicker" type="text" name="go_to_date[date_box]" id="go_to_date_date_box" />
<span class='input-group-addon calendar-btn'><span class='glyphicon glyphicon-calendar'></span></span>
</div>
<input class="form-control bootstrap_datepicker optional" data-date-start-date="1/03/2017" data-date-force-parse="false" data-date-assume-nearby-year="true" data-date-format="mm/dd/yyyy" data-date-autoclose="true" data-provide="datepicker" id="date_hidden" value="" autocomplete="off" type="hidden" name="go_to_date[date]" />
</div>

      <input type="submit" name="commit" value="Go to date" class="btn btn-default btn btn-primary-alt btn-medium" data-disable-with="Go to date" />
</form>
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Go to Date</h6></div></div></li>

  

<li class="enhanced " id="utility-nav-compare" tabindex="0"><span role="button" aria-label="Compare Dates" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Compare Dates" class="icon-ecfr icon-ecfr-forking "></span><span class="content-nav-label " role="button">Compare Dates</span><div class="box box-enhanced box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Compare Dates</h6></div></div><div class="content-block ">      <form class="simple_form form-horizontal compare-content" id="new_compare" autocomplete="off" novalidate="novalidate" action="/compare" accept-charset="UTF-8" method="post">

        <div class="form-group bootstrap_datepicker optional compare_from"><label class="control-label bootstrap_datepicker optional" for="compare_from">Compare</label><div class='input-group'>
<input class="form-control bootstrap_datepicker optional bootstrap-datepicker" data-date-start-date="1/03/2017" data-date-force-parse="false" data-date-assume-nearby-year="true" data-date-format="mm/dd/yyyy" data-date-autoclose="true" data-provide="datepicker" type="text" name="compare[from_box]" id="compare_from_box" />
<span class='input-group-addon calendar-btn'><span class='glyphicon glyphicon-calendar'></span></span>
</div>
<input class="form-control bootstrap_datepicker optional" data-date-start-date="1/03/2017" data-date-force-parse="false" data-date-assume-nearby-year="true" data-date-format="mm/dd/yyyy" data-date-autoclose="true" data-provide="datepicker" id="from_hidden" value="" autocomplete="off" type="hidden" name="compare[from]" />
</div>

        <div class="form-group bootstrap_datepicker optional compare_to"><label class="control-label bootstrap_datepicker optional" for="compare_to">to</label><div class='input-group'>
<input class="form-control bootstrap_datepicker optional bootstrap-datepicker" data-date-start-date="1/03/2017" data-date-force-parse="false" data-date-assume-nearby-year="true" data-date-format="mm/dd/yyyy" data-date-autoclose="true" data-provide="datepicker" type="text" value="04/09/2025" name="compare[to_box]" id="compare_to_box" />
<span class='input-group-addon calendar-btn'><span class='glyphicon glyphicon-calendar'></span></span>
</div>
<input class="form-control bootstrap_datepicker optional" data-date-start-date="1/03/2017" data-date-force-parse="false" data-date-assume-nearby-year="true" data-date-format="mm/dd/yyyy" data-date-autoclose="true" data-provide="datepicker" id="to_hidden" value="2025-04-09" autocomplete="off" type="hidden" name="compare[to]" />
</div>

        <div class="form-group hidden compare_hierarchy"><input class="form-control hidden" autocomplete="off" type="hidden" value="{&quot;title&quot;:&quot;21&quot;,&quot;chapter&quot;:&quot;I&quot;,&quot;subchapter&quot;:&quot;F&quot;,&quot;part&quot;:&quot;600&quot;,&quot;complete&quot;:true}" name="compare[hierarchy]" id="compare_hierarchy" /></div>
        <div class="form-group hidden compare_view_mode"><input class="form-control hidden" autocomplete="off" type="hidden" name="compare[view_mode]" id="compare_view_mode" /></div>

        <input type="submit" name="commit" value="Compare Dates" class="btn btn-default btn btn-primary-alt btn-medium" data-disable-with="Compare Dates" />
</form>
      <form class="simple_form compare-style-choices" id="new_compare_style_choices" novalidate="novalidate" action="#" accept-charset="UTF-8" method="get">
        <div class="form-group radio_buttons optional compare_style_choices_diff_color"><label class="control-label radio_buttons optional">Show changes as:</label><span class="radio"><label for="compare_style_choices_diff_color_rg-diff"><input class="radio_buttons optional" type="radio" value="rg-diff" checked="checked" name="compare_style_choices[diff_color]" id="compare_style_choices_diff_color_rg-diff" />red/green</label></span><span class="radio"><label for="compare_style_choices_diff_color_po-diff"><input class="radio_buttons optional" type="radio" value="po-diff" name="compare_style_choices[diff_color]" id="compare_style_choices_diff_color_po-diff" />purple/orange</label></span></div>

        <div class="form-group radio_buttons optional compare_style_choices_strikethrough"><label class="control-label radio_buttons optional">Show strike-through for removed content</label><span class="radio"><label for="compare_style_choices_strikethrough_true"><input class="radio_buttons optional" type="radio" value="true" checked="checked" name="compare_style_choices[strikethrough]" id="compare_style_choices_strikethrough_true" />yes</label></span><span class="radio"><label for="compare_style_choices_strikethrough_false"><input class="radio_buttons optional" readonly="readonly" type="radio" value="false" name="compare_style_choices[strikethrough]" id="compare_style_choices_strikethrough_false" />no</label></span></div>
</form></div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Compare Dates</h6></div></div></li>

  <li class="divider"></li>

  
<li class="enhanced published-edition" id="" tabindex="0"><span role="button" aria-label="Published Edition" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Published Edition" class="icon-ecfr icon-ecfr-doc-pdf "></span><span class="content-nav-label " role="button">Published Edition</span><div class="box box-enhanced box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Published Edition</h6></div></div><div class="content-block ">    <p>
      View the most recent official publication:
    </p>

    <ul class="list with-bullets enhanced">
        <li>
          <a data-turbo="false" href="https://www.govinfo.gov/app/collection/cfr/2025">View Title 21 on govinfo.gov</a>
        </li>
        <li>
          <a data-turbo="false" href="https://www.govinfo.gov/link/cfr/21/600?link-type=pdf&amp;year=mostrecent">View the PDF for 21 CFR Part 600</a>
        </li>
    </ul>

    <p>
      These links go to the official, published CFR, which is updated annually. As a
      result, it may not include the most recent changes applied to the CFR.
      <a href="https://www.govinfo.gov/help/cfr#about">Learn more</a>.
    </p>
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Published Edition</h6></div></div></li>

  <li class="divider"></li>

  
<li class="enhanced developer-tools" id="" tabindex="0"><span role="button" aria-label="Developer Tools" data-delay="{&quot;show&quot;:300,&quot;hide&quot;:0}" data-toggle="tooltip" data-placement="top" data-title="Developer Tools" class="icon-ecfr icon-ecfr-console "></span><span class="content-nav-label " role="button">Developer Tools</span><div class="box box-enhanced box-full dropdown-menu dropdown-menu-right" role="menu"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content - Developer Tools</h6></div></div><div class="content-block ">
      <turbo-frame id="side_developer" src="/developer/current/title-21/chapter-I/subchapter-F/part-600" loading="lazy">
        <span class="timeline-spinner">
          <span class="spinner"></span>
        </span>
        <br/><br/>
      </turbo-frame>

    <p>
      Information and documentation can be found in our
      <a href="/reader-aids/ecfr-developer-resources">developer resources</a>.
    </p>
</div><div class="seal-block seal-block-footer"><h6>Enhanced Content - Developer Tools</h6></div></div></li>
</ul>

      </div>

      <div class="col-xs-9 col-sm-10 content-col">
        <div class="box box-published no-print-header compare-settings"><div class="seal-block seal-block-header"><div class="seal-content"><h6>eCFR Content</h6><div class="row seal-meta"><div class="seal-desc col-md-12 col-xs-12"><p><p>The <em>Code of Federal Regulations</em> (CFR) is the official legal print publication containing the codification of the general and permanent rules published in the <em>Federal Register</em> by the departments and agencies of the Federal Government. The Electronic Code of Federal Regulations (eCFR) is a continuously updated online version of the CFR. It is not an official legal edition of the CFR.</p> <p><a href='/reader-aids/understanding-the-ecfr/what-is-the-ecfr'>Learn more</a> about the eCFR, its status, and the editorial process.<p></p></div></div></div></div><div class="content-block ">
            <div class="box box-enhanced slim toc-link no-footer"><div class="seal-block seal-block-header"><div class="seal-content"><h6>Enhanced Content</h6></div></div><div class="content-block ">
              <span class="icon-ecfr icon-ecfr-book "></span> View
              <a id="toc-utility-nav-link" href="">table of contents</a>
              for this page.
</div><div class="seal-block seal-block-footer"></div></div>
          
<div class="part" id="part-600"><h1 data-hierarchy-metadata="{&quot;path&quot;:&quot;/current/title-21/part-600&quot;,&quot;citation&quot;:&quot;21 CFR Part 600&quot;}">PART 600—BIOLOGICAL PRODUCTS: GENERAL
</h1>

<div class="authority"><h4 class="inline-header">Authority:</h4><p class="inline-paragraph"><a href="https://www.govinfo.gov/link/uscode/21/321" class="usc external" target="_blank" rel="noopener noreferrer">21 U.S.C. 321</a>, <a href="https://www.govinfo.gov/link/uscode/21/351" class="usc external" target="_blank" rel="noopener noreferrer">351</a>, <a href="https://www.govinfo.gov/link/uscode/21/352" class="usc external" target="_blank" rel="noopener noreferrer">352</a>, <a href="https://www.govinfo.gov/link/uscode/21/353" class="usc external" target="_blank" rel="noopener noreferrer">353</a>, <a href="https://www.govinfo.gov/link/uscode/21/355" class="usc external" target="_blank" rel="noopener noreferrer">355</a>, <a href="https://www.govinfo.gov/link/uscode/21/356c" class="usc external" target="_blank" rel="noopener noreferrer">356c</a>, <a href="https://www.govinfo.gov/link/uscode/21/356e" class="usc external" target="_blank" rel="noopener noreferrer">356e</a>, <a href="https://www.govinfo.gov/link/uscode/21/360" class="usc external" target="_blank" rel="noopener noreferrer">360</a>, <a href="https://www.govinfo.gov/link/uscode/21/360i" class="usc external" target="_blank" rel="noopener noreferrer">360i</a>, <a href="https://www.govinfo.gov/link/uscode/21/371" class="usc external" target="_blank" rel="noopener noreferrer">371</a>, <a href="https://www.govinfo.gov/link/uscode/21/374" class="usc external" target="_blank" rel="noopener noreferrer">374</a>, <a href="https://www.govinfo.gov/link/uscode/21/379k" class="usc external" target="_blank" rel="noopener noreferrer">379k</a>-l; <a href="https://www.govinfo.gov/link/uscode/42/216" class="usc external" target="_blank" rel="noopener noreferrer">42 U.S.C. 216</a>, <a href="https://www.govinfo.gov/link/uscode/42/262" class="usc external" target="_blank" rel="noopener noreferrer">262</a>, <a href="https://www.govinfo.gov/link/uscode/42/263" class="usc external" target="_blank" rel="noopener noreferrer">263</a>, <a href="https://www.govinfo.gov/link/uscode/42/263a" class="usc external" target="_blank" rel="noopener noreferrer">263a</a>, <a href="https://www.govinfo.gov/link/uscode/42/264" class="usc external" target="_blank" rel="noopener noreferrer">264</a>.
</p></div>

Cross References:
<p>For U.S. Customs Service regulations relating to viruses, serums, and toxins, see <a href="/current/title-19/section-12.21" class="cfr external">19 CFR 12.21-12.23</a>. For U.S. Postal Service regulations relating to the admissibility to the United States mails see parts 124 and 125 of the Domestic Mail Manual, that is incorporated by reference in <a href="/current/title-39/part-111" class="cfr external">39 CFR part 111</a>.</p>

<div class="subpart" id="subpart-A"><h2 data-hierarchy-metadata="{&quot;path&quot;:&quot;/current/title-21/part-600/subpart-A&quot;,&quot;citation&quot;:&quot;21 CFR Part 600 Subpart A&quot;}">Subpart A—General Provisions</h2>
<div class="section" id="600.2">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-600.2","citation":"21 CFR 600.2"}'>§ 600.2 Mailing addresses.</h4>
<div id="p-600.2(a)">
<p class="indent-1" data-title="600.2(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> <em class="paragraph-heading">Licensed biological products regulated by the Center for Biologics Evaluation and Research (CBER).</em>  Unless otherwise stated in <a href="/current/title-21/section-600.2#p-600.2(c)" class="cfr external">paragraph (c)</a> of this section, or as otherwise prescribed by FDA regulation, all submissions to CBER referenced in <a href="/current/title-21/part-600" class="cfr external">parts 600</a> through <a href="/current/title-21/part-680" class="cfr external">680 of this chapter</a>, as applicable, must be sent to: Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002. Examples of such submissions include: Biologics license applications (BLAs) and their amendments and supplements, biological product deviation reports, fatality reports, and other correspondence. Biological products samples must not be sent to this address but must be sent to the address in <a href="/current/title-21/section-600.2#p-600.2(c)" class="cfr external">paragraph (c)</a> of this section.</p>
</div>
<div id="p-600.2(b)">
<p class="indent-1" data-title="600.2(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> <em class="paragraph-heading">Licensed biological products regulated by the Center for Drug Evaluation and Research (CDER).</em>  Unless otherwise stated in <a href="/current/title-21/section-600.2#p-600.2(b)(1)" class="cfr external">paragraphs (b)(1)</a>, <a href="/current/title-21/section-600.2#p-600.2(b)(2)" class="cfr external">(b)(2)</a>, or <a href="/current/title-21/section-600.2#p-600.2(c)" class="cfr external">(c)</a> of this section, or as otherwise prescribed by FDA regulation, all submissions to CDER referenced in <a href="/current/title-21/part-600" class="cfr external">parts 600</a>, <a href="/current/title-21/part-601" class="cfr external">601</a>, and <a href="/current/title-21/part-610" class="cfr external">610 of this chapter</a>, as applicable, must be sent to: CDER Central Document Room, Center for Drug Evaluation and Research, Food and Drug Administration, 5901B Ammendale Rd., Beltsville, MD 20705. Examples of such submissions include: BLAs and their amendments and supplements, and other correspondence.</p>
<div id="p-600.2(b)(1)">
<p class="indent-2" data-title="600.2(b)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> <em class="paragraph-heading">Biological Product Deviation Reporting (CDER).</em>  All biological product deviation reports required under <a href="/current/title-21/section-600.14" class="cfr external">§ 600.14</a> must be sent to: Division of Compliance Risk Management and Surveillance, Office of Compliance, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002.</p>
</div>
<div id="p-600.2(b)(2)">
<p class="indent-2" data-title="600.2(b)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> <em class="paragraph-heading">Advertising and Promotional Labeling (CDER).</em>  All advertising and promotional labeling supplements required under <a href="/current/title-21/section-601.12#p-601.12(f)" class="cfr external">§ 601.12(f) of this chapter</a> must be sent to: Division of Drug Marketing, Advertising and Communication, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266.</p>
</div>
</div>
<div id="p-600.2(c)">
<p class="indent-1" data-title="600.2(c)"><span class="paragraph-hierarchy"><span class="paren">(</span>c<span class="paren">)</span></span> <em class="paragraph-heading">Samples and Protocols for licensed biological products regulated by CBER or CDER.</em> </p>
<div id="p-600.2(c)(1)">
<p class="indent-2" data-title="600.2(c)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> Biological product samples and/or protocols, other than radioactive biological product samples and protocols, required under <a href="/current/title-21/section-600.13" class="cfr external">§§ 600.13</a>, <a href="/current/title-21/section-600.22" class="cfr external">600.22</a>, <a href="/current/title-21/section-601.15" class="cfr external">601.15</a>, <a href="/current/title-21/section-610.2" class="cfr external">610.2</a>, <a href="/current/title-21/section-660.6" class="cfr external">660.6</a>, <a href="/current/title-21/section-660.36" class="cfr external">660.36</a>, or <a href="/current/title-21/section-660.46" class="cfr external">660.46 of this chapter</a> must be sent by courier service to: Food and Drug Administration, Center for Biologics Evaluation and Research, ATTN: Sample Custodian, 10903 New Hampshire Ave., Bldg. 75, Rm. G707, Silver Spring, MD 20993-0002. The protocol(s) may be placed in the box used to ship the samples to CBER. A cover letter should not be included when submitting the protocol with the sample unless it contains pertinent information affecting the release of the lot.</p>
</div>
<div id="p-600.2(c)(2)">
<p class="indent-2" data-title="600.2(c)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> Radioactive biological products required under <a href="/current/title-21/section-610.2" class="cfr external">§ 610.2 of this chapter</a> must be sent by courier service to: Food and Drug Administration, Center for Biologics Evaluation and Research, ATTN: Sample Custodian, c/o White Oak Radiation Safety Program, 10903 New Hampshire Ave., Bldg. 52-72, Rm. G406A, Silver Spring, MD 20993-0002.</p>
</div>
</div>
<div id="p-600.2(d)">
<p class="indent-1" data-title="600.2(d)"><span class="paragraph-hierarchy"><span class="paren">(</span>d<span class="paren">)</span></span> Address information for submissions to CBER and CDER other than those listed in <a href="/current/title-21/part-600" class="cfr external">parts 600</a> through <a href="/current/title-21/part-680" class="cfr external">680 of this chapter</a> are included directly in the applicable regulations.</p>
</div>
<div id="p-600.2(e)"><p class="indent-1" data-title="600.2(e)"><span class="paragraph-hierarchy"><span class="paren">(</span>e<span class="paren">)</span></span> Obtain updated mailing address information for biological products regulated by CBER at <em><a href="http://www.fda.gov/BiologicsBloodVaccines/default.htm" class="external" target="_blank" rel="noopener noreferrer">http://www.fda.gov/BiologicsBloodVaccines/default.htm</a></em>, or for biological products regulated by CDER at <em><a href="http://www.fda.gov/Drugs/default.htm" class="external" target="_blank" rel="noopener noreferrer">http://www.fda.gov/Drugs/default.htm</a>.</em></p></div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/70-FR-14981" class="fr-reference" data-reference="70 FR 14981">70 FR 14981</a>, Mar. 24, 2005, as amended at <a href="https://www.federalregister.gov/citation/74-FR-13114" class="fr-reference" data-reference="74 FR 13114">74 FR 13114</a>, Mar. 26, 2009; <a href="https://www.federalregister.gov/citation/78-FR-19585" class="fr-reference" data-reference="78 FR 19585">78 FR 19585</a>, Apr. 2, 2013; <a href="https://www.federalregister.gov/citation/80-FR-18091" class="fr-reference" data-reference="80 FR 18091">80 FR 18091</a>, Apr. 3, 2015; <a href="https://www.federalregister.gov/citation/79-FR-33090" class="fr-reference" data-reference="79 FR 33090">79 FR 33090</a>, June 10, 2014]
</p>
</div>

<div class="section" id="600.3">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-600.3","citation":"21 CFR 600.3"}'>§ 600.3 Definitions.</h4>
<p>As used in this subchapter:</p>
<div id="p-600.3(a)">
<p class="indent-1" data-title="600.3(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> <em class="paragraph-heading">Act</em>  means the Public Health Service Act (58 Stat. 682), approved July 1, 1944.</p>
</div>
<div id="p-600.3(b)">
<p class="indent-1" data-title="600.3(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> <em class="paragraph-heading">Secretary</em>  means the Secretary of Health and Human Services and any other officer or employee of the Department of Health and Human Services to whom the authority involved has been delegated.</p>
</div>
<div id="p-600.3(c)">
<p class="indent-1" data-title="600.3(c)"><span class="paragraph-hierarchy"><span class="paren">(</span>c<span class="paren">)</span></span> <em class="paragraph-heading">Commissioner of Food and Drugs</em>  means the Commissioner of the Food and Drug Administration.</p>
</div>
<div id="p-600.3(d)">
<p class="indent-1" data-title="600.3(d)"><span class="paragraph-hierarchy"><span class="paren">(</span>d<span class="paren">)</span></span> <em class="paragraph-heading">Center for Biologics Evaluation and Research</em>  means Center for Biologics Evaluation and Research of the Food and Drug Administration.</p>
</div>
<div id="p-600.3(e)">
<p class="indent-1" data-title="600.3(e)"><span class="paragraph-hierarchy"><span class="paren">(</span>e<span class="paren">)</span></span> <em class="paragraph-heading">State</em>  means a State or the District of Columbia, Puerto Rico, or the Virgin Islands.</p>
</div>
<div id="p-600.3(f)">
<p class="indent-1" data-title="600.3(f)"><span class="paragraph-hierarchy"><span class="paren">(</span>f<span class="paren">)</span></span> <em class="paragraph-heading">Possession</em>  includes among other possessions, Puerto Rico and the Virgin Islands.</p>
</div>
<div id="p-600.3(g)">
<p class="indent-1" data-title="600.3(g)"><span class="paragraph-hierarchy"><span class="paren">(</span>g<span class="paren">)</span></span> <em class="paragraph-heading">Products</em>  includes biological products and trivalent organic arsenicals.</p>
</div>
<div id="p-600.3(h)">
<p class="indent-1" data-title="600.3(h)"><span class="paragraph-hierarchy"><span class="paren">(</span>h<span class="paren">)</span></span> <em class="paragraph-heading">Biological product</em>  means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein, or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.</p>
<div id="p-600.3(h)(1)">
<p class="indent-2" data-title="600.3(h)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> A virus is interpreted to be a product containing the minute living cause of an infectious disease and includes but is not limited to filterable viruses, bacteria, rickettsia, fungi, and protozoa.</p>
</div>
<div id="p-600.3(h)(2)">
<p class="indent-2" data-title="600.3(h)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> A therapeutic serum is a product obtained from blood by removing the clot or clot components and the blood cells.</p>
</div>
<div id="p-600.3(h)(3)">
<p class="indent-2" data-title="600.3(h)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> A toxin is a product containing a soluble substance poisonous to laboratory animals or to man in doses of 1 milliliter or less (or equivalent in weight) of the product, and having the property, following the injection of non-fatal doses into an animal, of causing to be produced therein another soluble substance which specifically neutralizes the poisonous substance and which is demonstrable in the serum of the animal thus immunized.</p>
</div>
<div id="p-600.3(h)(4)">
<p class="indent-2" data-title="600.3(h)(4)"><span class="paragraph-hierarchy"><span class="paren">(</span>4<span class="paren">)</span></span> An antitoxin is a product containing the soluble substance in serum or other body fluid of an immunized animal which specifically neutralizes the toxin against which the animal is immune.</p>
</div>
<div id="p-600.3(h)(5)">
<p class="indent-2" data-title="600.3(h)(5)"><span class="paragraph-hierarchy"><span class="paren">(</span>5<span class="paren">)</span></span> A product is analogous:</p>
<div id="p-600.3(h)(5)(i)">
<p class="indent-3" data-title="600.3(h)(5)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> To a virus if prepared from or with a virus or agent actually or potentially infectious, without regard to the degree of virulence or toxicogenicity of the specific strain used.</p>
</div>
<div id="p-600.3(h)(5)(ii)">
<p class="indent-3" data-title="600.3(h)(5)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> To a therapeutic serum, if composed of whole blood or plasma or containing some organic constituent or product other than a hormone or an amino acid, derived from whole blood, plasma, or serum.</p>
</div>
<div id="p-600.3(h)(5)(iii)">
<p class="indent-3" data-title="600.3(h)(5)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> To a toxin or antitoxin, if intended, irrespective of its source of origin, to be applicable to the prevention, treatment, or cure of disease or injuries of man through a specific immune process.</p>
</div>
</div>
<div id="p-600.3(h)(6)">
<p class="indent-2" data-title="600.3(h)(6)"><span class="paragraph-hierarchy"><span class="paren">(</span>6<span class="paren">)</span></span> A protein is any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size. When two or more amino acid chains in an amino acid polymer are associated with each other in a manner that occurs in nature, the size of the amino acid polymer for purposes of this <a href="/current/title-21/section-600.3#p-600.3(h)(6)" class="cfr external">paragraph (h)(6)</a> will be based on the total number of amino acids in those chains, and will not be limited to the number of amino acids in a contiguous sequence.</p>
</div>
</div>
<div id="p-600.3(i)">
<p class="indent-1" data-title="600.3(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> <em class="paragraph-heading">Trivalent organic arsenicals</em>  means arsphenamine and its derivatives (or any other trivalent organic arsenic compound) applicable to the prevention, treatment, or cure of diseases or injuries of man.</p>
</div>
<div id="p-600.3(j)">
<p class="indent-1" data-title="600.3(j)"><span class="paragraph-hierarchy"><span class="paren">(</span>j<span class="paren">)</span></span> A product is deemed <em>applicable to the prevention, treatment, or cure of diseases or injuries of man</em> irrespective of the mode of administration or application recommended, including use when intended through administration or application to a person as an aid in diagnosis, or in evaluating the degree of susceptibility or immunity possessed by a person, and including also any other use for purposes of diagnosis if the diagnostic substance so used is prepared from or with the aid of a biological product.</p>
</div>
<div id="p-600.3(k)">
<p class="indent-1" data-title="600.3(k)"><span class="paragraph-hierarchy"><span class="paren">(</span>k<span class="paren">)</span></span> <em class="paragraph-heading">Proper name,</em>  as applied to a product, means the name designated in the license for use upon each package of the product.</p>
</div>
<div id="p-600.3(l)">
<p class="indent-1" data-title="600.3(l)"><span class="paragraph-hierarchy"><span class="paren">(</span>l<span class="paren">)</span></span> <em class="paragraph-heading">Dating period</em>  means the period beyond which the product cannot be expected beyond reasonable doubt to yield its specific results.</p>
</div>
<div id="p-600.3(m)">
<p class="indent-1" data-title="600.3(m)"><span class="paragraph-hierarchy"><span class="paren">(</span>m<span class="paren">)</span></span> <em class="paragraph-heading">Expiration date</em>  means the calendar month and year, and where applicable, the day and hour, that the dating period ends.</p>
</div>
<div id="p-600.3(n)">
<p class="indent-1" data-title="600.3(n)"><span class="paragraph-hierarchy"><span class="paren">(</span>n<span class="paren">)</span></span> The word <em>standards</em> means specifications and procedures applicable to an establishment or to the manufacture or release of products, which are prescribed in this subchapter or established in the biologics license application designed to insure the continued safety, purity, and potency of such products.</p>
</div>
<div id="p-600.3(o)">
<p class="indent-1" data-title="600.3(o)"><span class="paragraph-hierarchy"><span class="paren">(</span>o<span class="paren">)</span></span> The word <em>continued</em> as applied to the safety, purity and potency of products is interpreted to apply to the dating period.</p>
</div>
<div id="p-600.3(p)">
<p class="indent-1" data-title="600.3(p)"><span class="paragraph-hierarchy"><span class="paren">(</span>p<span class="paren">)</span></span> The word <em>safety</em> means the relative freedom from harmful effect to persons affected, directly or indirectly, by a product when prudently administered, taking into consideration the character of the product in relation to the condition of the recipient at the time.</p>
</div>
<div id="p-600.3(q)">
<p class="indent-1" data-title="600.3(q)"><span class="paragraph-hierarchy"><span class="paren">(</span>q<span class="paren">)</span></span> The word <em>sterility</em> is interpreted to mean freedom from viable contaminating microorganisms, as determined by the tests conducted under <a href="/current/title-21/section-610.12" class="cfr external">§ 610.12 of this chapter</a>.</p>
</div>
<div id="p-600.3(r)">
<p class="indent-1" data-title="600.3(r)"><span class="paragraph-hierarchy"><span class="paren">(</span>r<span class="paren">)</span></span> <em class="paragraph-heading">Purity</em>  means relative freedom from extraneous matter in the finished product, whether or not harmful to the recipient or deleterious to the product. <em>Purity</em> includes but is not limited to relative freedom from residual moisture or other volatile substances and pyrogenic substances.</p>
</div>
<div id="p-600.3(s)">
<p class="indent-1" data-title="600.3(s)"><span class="paragraph-hierarchy"><span class="paren">(</span>s<span class="paren">)</span></span> The word <em>potency</em> is interpreted to mean the specific ability or capacity of the product, as indicated by appropriate laboratory tests or by adequately controlled clinical data obtained through the administration of the product in the manner intended, to effect a given result.</p>
</div>
<div id="p-600.3(t)">
<p class="indent-1" data-title="600.3(t)"><span class="paragraph-hierarchy"><span class="paren">(</span>t<span class="paren">)</span></span> <em class="paragraph-heading">Manufacturer</em>  means any legal person or entity engaged in the manufacture of a product subject to license under the act; “Manufacturer” also includes any legal person or entity who is an applicant for a license where the applicant assumes responsibility for compliance with the applicable product and establishment standards.</p>
</div>
<div id="p-600.3(u)">
<p class="indent-1" data-title="600.3(u)"><span class="paragraph-hierarchy"><span class="paren">(</span>u<span class="paren">)</span></span> <em class="paragraph-heading">Manufacture</em>  means all steps in propagation or manufacture and preparation of products and includes but is not limited to filling, testing, labeling, packaging, and storage by the manufacturer.</p>
</div>
<div id="p-600.3(v)">
<p class="indent-1" data-title="600.3(v)"><span class="paragraph-hierarchy"><span class="paren">(</span>v<span class="paren">)</span></span> <em class="paragraph-heading">Location</em>  includes all buildings, appurtenances, equipment and animals used, and personnel engaged by a manufacturer within a particular area designated by an address adequate for identification.</p>
</div>
<div id="p-600.3(w)">
<p class="indent-1" data-title="600.3(w)"><span class="paragraph-hierarchy"><span class="paren">(</span>w<span class="paren">)</span></span> <em class="paragraph-heading">Establishment</em>  has the same meaning as “facility” in section 351 of the Public Health Service Act and includes all locations.</p>
</div>
<div id="p-600.3(x)">
<p class="indent-1" data-title="600.3(x)"><span class="paragraph-hierarchy"><span class="paren">(</span>x<span class="paren">)</span></span> <em class="paragraph-heading">Lot</em>  means that quantity of uniform material identified by the manufacturer as having been thoroughly mixed in a single vessel.</p>
</div>
<div id="p-600.3(y)">
<p class="indent-1" data-title="600.3(y)"><span class="paragraph-hierarchy"><span class="paren">(</span>y<span class="paren">)</span></span> A <em>filling</em> refers to a group of final containers identical in all respects, which have been filled with the same product from the same bulk lot without any change that will affect the integrity of the filling assembly.</p>
</div>
<div id="p-600.3(z)">
<p class="indent-1" data-title="600.3(z)"><span class="paragraph-hierarchy"><span class="paren">(</span>z<span class="paren">)</span></span> <em class="paragraph-heading">Process</em>  refers to a manufacturing step that is performed on the product itself which may affect its safety, purity or potency, in contrast to such manufacturing steps which do not affect intrinsically the safety, purity or potency of the product.</p>
</div>
<div id="p-600.3(aa)">
<p class="indent-1" data-title="600.3(aa)"><span class="paragraph-hierarchy"><span class="paren">(</span>aa<span class="paren">)</span></span> <span class="paragraph-heading"><em>Selling agent</em> or <em>distributor</em></span>  means any person engaged in the unrestricted distribution, other than by sale at retail, of products subject to license.</p>
</div>
<div id="p-600.3(bb)">
<p class="indent-1" data-title="600.3(bb)"><span class="paragraph-hierarchy"><span class="paren">(</span>bb<span class="paren">)</span></span> <em class="paragraph-heading">Container</em>  (referred to also as “final container”) is the immediate unit, bottle, vial, ampule, tube, or other receptacle containing the product as distributed for sale, barter, or exchange.</p>
</div>
<div id="p-600.3(cc)">
<p class="indent-1" data-title="600.3(cc)"><span class="paragraph-hierarchy"><span class="paren">(</span>cc<span class="paren">)</span></span> <em class="paragraph-heading">Package</em>  means the immediate carton, receptacle, or wrapper, including all labeling matter therein and thereon, and the contents of the one or more enclosed containers. If no package, as defined in the preceding sentence, is used, the container shall be deemed to be the package.</p>
</div>
<div id="p-600.3(dd)">
<p class="indent-1" data-title="600.3(dd)"><span class="paragraph-hierarchy"><span class="paren">(</span>dd<span class="paren">)</span></span> <em class="paragraph-heading">Label</em>  means any written, printed, or graphic matter on the container or package or any such matter clearly visible through the immediate carton, receptacle, or wrapper.</p>
</div>
<div id="p-600.3(ee)">
<p class="indent-1" data-title="600.3(ee)"><span class="paragraph-hierarchy"><span class="paren">(</span>ee<span class="paren">)</span></span> <em class="paragraph-heading">Radioactive biological product</em>  means a biological product which is labeled with a radionuclide or intended solely to be labeled with a radionuclide.</p>
</div>
<div id="p-600.3(ff)">
<p class="indent-1" data-title="600.3(ff)"><span class="paragraph-hierarchy"><span class="paren">(</span>ff<span class="paren">)</span></span> <em class="paragraph-heading">Amendment</em>  is the submission of information to a pending license application or supplement, to revise or modify the application as originally submitted.</p>
</div>
<div id="p-600.3(gg)">
<p class="indent-1" data-title="600.3(gg)"><span class="paragraph-hierarchy"><span class="paren">(</span>gg<span class="paren">)</span></span> <em class="paragraph-heading">Supplement</em>  is a request to approve a change in an approved license application.</p>
</div>
<div id="p-600.3(hh)">
<p class="indent-1" data-title="600.3(hh)"><span class="paragraph-hierarchy"><span class="paren">(</span>hh<span class="paren">)</span></span> <em class="paragraph-heading">Distributed</em>  means the biological product has left the control of the licensed manufacturer.</p>
</div>
<div id="p-600.3(ii)">
<p class="indent-1" data-title="600.3(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> <em class="paragraph-heading">Control</em>  means having responsibility for maintaining the continued safety, purity, and potency of the product and for compliance with applicable product and establishment standards, and for compliance with current good manufacturing practices.</p>
</div>
<div id="p-600.3(jj)">
<p class="indent-1" data-title="600.3(jj)"><span class="paragraph-hierarchy"><span class="paren">(</span>jj<span class="paren">)</span></span> <em class="paragraph-heading">Assess the effects of the change</em> , as used in <a href="/current/title-21/section-601.12" class="cfr external">§ 601.12 of this chapter</a>, means to evaluate the effects of a manufacturing change on the identity, strength, quality, purity, and potency of a product as these factors may relate to the safety or effectiveness of the product.</p>
</div>
<div id="p-600.3(kk)">
<p class="indent-1" data-title="600.3(kk)"><span class="paragraph-hierarchy"><span class="paren">(</span>kk<span class="paren">)</span></span> <em class="paragraph-heading">Specification</em> , as used in <a href="/current/title-21/section-601.12" class="cfr external">§ 601.12 of this chapter</a>, means the quality standard (i.e., tests, analytical procedures, and acceptance criteria) provided in an approved application to confirm the quality of products, intermediates, raw materials, reagents, components, in-process materials, container closure systems, and other materials used in the production of a product. For the purpose of this definition, <em>acceptance criteria</em> means numerical limits, ranges, or other criteria for the tests described.</p>
</div>
<div id="p-600.3(ll)">
<p class="indent-1" data-title="600.3(ll)"><span class="paragraph-hierarchy"><span class="paren">(</span>ll<span class="paren">)</span></span> <em class="paragraph-heading">Complete response letter</em>  means a written communication to an applicant from FDA usually describing all of the deficiencies that the agency has identified in a biologics license application or supplement that must be satisfactorily addressed before it can be approved.</p>
</div>
<div id="p-600.3(mm)"><p class="indent-1" data-title="600.3(mm)"><span class="paragraph-hierarchy"><span class="paren">(</span>mm<span class="paren">)</span></span> <em class="paragraph-heading">Resubmission</em>  means a submission by the biologics license applicant or supplement applicant of all materials needed to fully address all deficiencies identified in the complete response letter. A biologics license application or supplement for which FDA issued a complete response letter, but which was withdrawn before approval and later submitted again, is not a resubmission.</p></div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/38-FR-32048" class="fr-reference" data-reference="38 FR 32048">38 FR 32048</a>, Nov. 20, 1973, as amended at <a href="https://www.federalregister.gov/citation/40-FR-31313" class="fr-reference" data-reference="40 FR 31313">40 FR 31313</a>, July 25, 1975; <a href="https://www.federalregister.gov/citation/55-FR-11014" class="fr-reference" data-reference="55 FR 11014">55 FR 11014</a>, Mar. 26, 1990; <a href="https://www.federalregister.gov/citation/61-FR-24232" class="fr-reference" data-reference="61 FR 24232">61 FR 24232</a>, May 14, 1996; <a href="https://www.federalregister.gov/citation/62-FR-39901" class="fr-reference" data-reference="62 FR 39901">62 FR 39901</a>, July 24, 1997; <a href="https://www.federalregister.gov/citation/64-FR-56449" class="fr-reference" data-reference="64 FR 56449">64 FR 56449</a>, Oct. 20, 1999; <a href="https://www.federalregister.gov/citation/65-FR-66634" class="fr-reference" data-reference="65 FR 66634">65 FR 66634</a>, Nov. 7, 2000; <a href="https://www.federalregister.gov/citation/69-FR-18766" class="fr-reference" data-reference="69 FR 18766">69 FR 18766</a>, Apr. 8, 2004; <a href="https://www.federalregister.gov/citation/70-FR-14982" class="fr-reference" data-reference="70 FR 14982">70 FR 14982</a>, Mar. 24, 2005; <a href="https://www.federalregister.gov/citation/73-FR-39610" class="fr-reference" data-reference="73 FR 39610">73 FR 39610</a>, July 10, 2008; <a href="https://www.federalregister.gov/citation/77-FR-26174" class="fr-reference" data-reference="77 FR 26174">77 FR 26174</a>, May 3, 2012; <a href="https://www.federalregister.gov/citation/85-FR-10063" class="fr-reference" data-reference="85 FR 10063">85 FR 10063</a>, Feb. 21, 2020]
</p>
</div>

</div>

<div class="subpart" id="subpart-B"><h2 data-hierarchy-metadata="{&quot;path&quot;:&quot;/current/title-21/part-600/subpart-B&quot;,&quot;citation&quot;:&quot;21 CFR Part 600 Subpart B&quot;}">Subpart B—Establishment Standards</h2>
<div class="section" id="600.10">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-600.10","citation":"21 CFR 600.10"}'>§ 600.10 Personnel.</h4>
<div id="p-600.10(a)">
<p class="indent-1" data-title="600.10(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> [Reserved]</p>
</div>
<div id="p-600.10(b)">
<p class="indent-1" data-title="600.10(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> <em class="paragraph-heading">Personnel.</em>  Personnel shall have capabilities commensurate with their assigned functions, a thorough understanding of the manufacturing operations which they perform, the necessary training and experience relating to individual products, and adequate information concerning the application of the pertinent provisions of this subchapter to their respective functions. Personnel shall include such professionally trained persons as are necessary to insure the competent performance of all manufacturing processes.</p>
</div>
<div id="p-600.10(c)">
<p class="indent-1" data-title="600.10(c)"><span class="paragraph-hierarchy"><span class="paren">(</span>c<span class="paren">)</span></span> <em class="paragraph-heading">Restrictions on personnel</em> —</p>
<div id="p-600.10(c)(1)">
<p class="indent-2" data-title="600.10(c)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> <em class="paragraph-heading">Specific duties.</em>  Persons whose presence can affect adversely the safety and purity of a product shall be excluded from the room where the manufacture of a product is in progress.</p>
</div>
<div id="p-600.10(c)(2)">
<p class="indent-2" data-title="600.10(c)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> <em class="paragraph-heading">Sterile operations.</em>  Personnel performing sterile operations shall wear clean or sterilized protective clothing and devices to the extent necessary to protect the product from contamination.</p>
</div>
<div id="p-600.10(c)(3)">
<p class="indent-2" data-title="600.10(c)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> <em class="paragraph-heading">Pathogenic viruses and spore-forming organisms.</em>  Persons working with viruses pathogenic for man or with spore-forming microorganisms, and persons engaged in the care of animals or animal quarters, shall be excluded from areas where other products are manufactured, or such persons shall change outer clothing, including shoes, or wear protective covering prior to entering such areas.</p>
</div>
<div id="p-600.10(c)(4)"><p class="indent-2" data-title="600.10(c)(4)"><span class="paragraph-hierarchy"><span class="paren">(</span>4<span class="paren">)</span></span> <em class="paragraph-heading">Live vaccine work areas.</em>  Persons may not enter a live vaccine processing area after having worked with other infectious agents in any other laboratory during the same working day. Only persons actually concerned with propagation of the culture, production of the vaccine, and unit maintenance, shall be allowed in live vaccine processing areas when active work is in progress. Casual visitors shall be excluded from such units at all times and all others having business in such areas shall be admitted only under supervision. Street clothing, including shoes, shall be replaced or covered by suitable laboratory clothing before entering a live vaccine processing unit. Persons caring for animals used in the manufacture of live vaccines shall be excluded from other animal quarters and from contact with other animals during the same working day.</p></div>
</div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/38-FR-32048" class="fr-reference" data-reference="38 FR 32048">38 FR 32048</a>, Nov. 20, 1973, as amended at <a href="https://www.federalregister.gov/citation/49-FR-23833" class="fr-reference" data-reference="49 FR 23833">49 FR 23833</a>, June 8, 1984; <a href="https://www.federalregister.gov/citation/55-FR-11014" class="fr-reference" data-reference="55 FR 11014">55 FR 11014</a>, Mar. 26, 1990; <a href="https://www.federalregister.gov/citation/62-FR-53538" class="fr-reference" data-reference="62 FR 53538">62 FR 53538</a>, Oct. 15, 1997; <a href="https://www.federalregister.gov/citation/68-FR-75119" class="fr-reference" data-reference="68 FR 75119">68 FR 75119</a>, Dec. 30, 2003]
</p>
</div>

<div class="section" id="600.11">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-600.11","citation":"21 CFR 600.11"}'>§ 600.11 Physical establishment, equipment, animals, and care.</h4>
<div id="p-600.11(a)">
<p class="indent-1" data-title="600.11(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> <em class="paragraph-heading">Work areas.</em>  All rooms and work areas where products are manufactured or stored shall be kept orderly, clean, and free of dirt, dust, vermin and objects not required for manufacturing. Precautions shall be taken to avoid clogging and back-siphonage of drainage systems. Precautions shall be taken to exclude extraneous infectious agents from manufacturing areas. Work rooms shall be well lighted and ventilated. The ventilation system shall be arranged so as to prevent the dissemination of microorganisms from one manufacturing area to another and to avoid other conditions unfavorable to the safety of the product. Filling rooms, and other rooms where open, sterile operations are conducted, shall be adequate to meet manufacturing needs and such rooms shall be constructed and equipped to permit thorough cleaning and to keep air-borne contaminants at a minimum. If such rooms are used for other purposes, they shall be cleaned and prepared prior to use for sterile operations. Refrigerators, incubators and warm rooms shall be maintained at temperatures within applicable ranges and shall be free of extraneous material which might affect the safety of the product.</p>
</div>
<div id="p-600.11(b)">
<p class="indent-1" data-title="600.11(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> <em class="paragraph-heading">Equipment.</em>  Apparatus for sterilizing equipment and the method of operation shall be such as to insure the destruction of contaminating microorganisms. The effectiveness of the sterilization procedure shall be no less than that achieved by an attained temperature of 121.5 °C maintained for 20 minutes by saturated steam or by an attained temperature of 170 °C maintained for 2 hours with dry heat. Processing and storage containers, filters, filling apparatus, and other pieces of apparatus and accessory equipment, including pipes and tubing, shall be designed and constructed to permit thorough cleaning and, where possible, inspection for cleanliness. All surfaces that come in contact with products shall be clean and free of surface solids, leachable contaminants, and other materials that will hasten the deterioration of the product or otherwise render it less suitable for the intended use. For products for which sterility is a factor, equipment shall be sterile, unless sterility of the product is assured by subsequent procedures.</p>
</div>
<div id="p-600.11(c)">
<p class="indent-1" data-title="600.11(c)"><span class="paragraph-hierarchy"><span class="paren">(</span>c<span class="paren">)</span></span> <em class="paragraph-heading">Laboratory and bleeding rooms.</em>  Rooms used for the processing of products, including bleeding rooms, shall be effectively fly-proofed and kept free of flies and vermin. Such rooms shall be so constructed as to insure freedom from dust, smoke and other deleterious substances and to permit thorough cleaning and disinfection. Rooms for animal injection and bleeding, and rooms for smallpox vaccine animals, shall be disinfected and be provided with the necessary water, electrical and other services.</p>
</div>
<div id="p-600.11(d)">
<p class="indent-1" data-title="600.11(d)"><span class="paragraph-hierarchy"><span class="paren">(</span>d<span class="paren">)</span></span> <em class="paragraph-heading">Animal quarters and stables.</em>  Animal quarters, stables and food storage areas shall be of appropriate construction, fly-proofed, adequately lighted and ventilated, and maintained in a clean, vermin-free and sanitary condition. No manure or refuse shall be stored as to permit the breeding of flies on the premises, nor shall the establishment be located in close proximity to off-property manure or refuse storage capable of engendering fly breeding.</p>
</div>
<div id="p-600.11(e)">
<p class="indent-1" data-title="600.11(e)"><span class="paragraph-hierarchy"><span class="paren">(</span>e<span class="paren">)</span></span> <em class="paragraph-heading">Restrictions on building and equipment use</em> —</p>
<div id="p-600.11(e)(1)">
<p class="indent-2" data-title="600.11(e)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> <em class="paragraph-heading">Work of a diagnostic nature.</em>  Laboratory procedures of a clinical diagnostic nature involving materials that may be contaminated, shall not be performed in space used for the manufacture of products except that manufacturing space which is used only occasionally may be used for diagnostic work provided spore-forming pathogenic microorganisms are not involved and provided the space is thoroughly cleaned and disinfected before the manufacture of products is resumed.</p>
</div>
<div id="p-600.11(e)(2)">
<p class="indent-2" data-title="600.11(e)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> <em class="paragraph-heading">Spore-forming organisms for supplemental sterilization procedure control test.</em>  Spore-forming organisms used as an additional control in sterilization procedures may be introduced into areas used for the manufacture of products, only for the purposes of the test and only immediately before use for such purposes: <em>Provided,</em> That </p>
<div id="p-600.11(e)(2)(i)"><p class="indent-3" data-title="600.11(e)(2)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> the organism is not pathogenic for man or animals and does not produce pyrogens or toxins, </p></div>
<div id="p-600.11(e)(2)(ii)"><p class="indent-3" data-title="600.11(e)(2)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> the culture is demonstrated to be pure, </p></div>
<div id="p-600.11(e)(2)(iii)"><p class="indent-3" data-title="600.11(e)(2)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> transfer of test cultures to culture media shall be limited to the sterility test area or areas designated for work with spore-forming organisms, </p></div>
<div id="p-600.11(e)(2)(iv)"><p class="indent-3" data-title="600.11(e)(2)(iv)"><span class="paragraph-hierarchy"><span class="paren">(</span>iv<span class="paren">)</span></span> each culture be labeled with the name of the microorganism and the statement “Caution: microbial spores. See directions for storage, use and disposition.”, and </p></div>
<div id="p-600.11(e)(2)(v)">
<p class="indent-3" data-title="600.11(e)(2)(v)"><span class="paragraph-hierarchy"><span class="paren">(</span>v<span class="paren">)</span></span> the container of each culture is designed to withstand handling without breaking.</p>
</div>
</div>
<div id="p-600.11(e)(3)">
<p class="indent-2" data-title="600.11(e)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> <em class="paragraph-heading">Work with spore-forming microorganisms.</em> </p>
<div id="p-600.11(e)(3)(i)">
<p class="indent-3" data-title="600.11(e)(3)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> Manufacturing processes using spore-forming microorganisms conducted in a multiproduct manufacturing site must be performed under appropriate controls to prevent contamination of other products and areas within the site. Prevention of spore contamination can be achieved by using a separate dedicated building or by using process containment if manufacturing is conducted in a multiproduct manufacturing building. All product and personnel movement between the area where the spore-forming microorganisms are manufactured and other manufacturing areas must be conducted under conditions that will prevent the introduction of spores into other areas of the facility.</p>
</div>
<div id="p-600.11(e)(3)(ii)">
<p class="indent-3" data-title="600.11(e)(3)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> If process containment is employed in a multiproduct manufacturing area, procedures must be in place to demonstrate adequate removal of the spore-forming microorganism(s) from the manufacturing area for subsequent manufacture of other products. These procedures must provide for adequate removal or decontamination of the spore-forming microorganisms on and within manufacturing equipment, facilities, and ancillary room items as well as the removal of disposable or product dedicated items from the manufacturing area. Environmental monitoring specific for the spore-forming microorganism(s) must be conducted in adjacent areas during manufacturing operations and in the manufacturing area after completion of cleaning and decontamination.</p>
</div>
</div>
<div id="p-600.11(e)(4)">
<p class="indent-2" data-title="600.11(e)(4)"><span class="paragraph-hierarchy"><span class="paren">(</span>4<span class="paren">)</span></span> <em class="paragraph-heading">Live vaccine processing.</em>  Live vaccine processing must be performed under appropriate controls to prevent cross contamination of other products and other manufacturing areas within the building. Appropriate controls must include, at a minimum:</p>
<div id="p-600.11(e)(4)(i)">
<p class="indent-3" data-title="600.11(e)(4)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> </p>
<div id="p-600.11(e)(4)(i)(A)">
<p class="indent-4" data-title="600.11(e)(4)(i)(A)"><span class="paragraph-hierarchy"><span class="paren">(</span>A<span class="paren">)</span></span> Using a dedicated manufacturing area that is either in a separate building, in a separate wing of a building, or in quarters at the blind end of a corridor and includes adequate space and equipment for all processing steps up to, but not including, filling into final containers; and</p>
</div>
<div id="p-600.11(e)(4)(i)(B)">
<p class="indent-4" data-title="600.11(e)(4)(i)(B)"><span class="paragraph-hierarchy"><span class="paren">(</span>B<span class="paren">)</span></span> Not conducting test procedures that potentially involve the presence of microorganisms other than the vaccine strains or the use of tissue culture cell lines other than primary cultures in space used for processing live vaccine; or</p>
</div>
</div>
<div id="p-600.11(e)(4)(ii)">
<p class="indent-3" data-title="600.11(e)(4)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> If manufacturing is conducted in a multiproduct manufacturing building or area, using procedural controls, and where necessary, process containment. Process containment is deemed to be necessary unless procedural controls are sufficient to prevent cross contamination of other products and other manufacturing areas within the building. Process containment is a system designed to mechanically isolate equipment or an area that involves manufacturing using live vaccine organisms. All product, equipment, and personnel movement between distinct live vaccine processing areas and between live vaccine processing areas and other manufacturing areas, up to, but not including, filling in final containers, must be conducted under conditions that will prevent cross contamination of other products and manufacturing areas within the building, including the introduction of live vaccine organisms into other areas. In addition, written procedures and effective processes must be in place to adequately remove or decontaminate live vaccine organisms from the manufacturing area and equipment for subsequent manufacture of other products. Written procedures must be in place for verification that processes to remove or decontaminate live vaccine organisms have been followed.</p>
</div>
</div>
<div id="p-600.11(e)(5)">
<p class="indent-2" data-title="600.11(e)(5)"><span class="paragraph-hierarchy"><span class="paren">(</span>5<span class="paren">)</span></span> <em class="paragraph-heading">Equipment and supplies—contamination.</em>  Equipment and supplies used in work on or otherwise exposed to any pathogenic or potentially pathogenic agent shall be kept separated from equipment and supplies used in the manufacture of products to the extent necessary to prevent cross-contamination.</p>
</div>
</div>
<div id="p-600.11(f)">
<p class="indent-1" data-title="600.11(f)"><span class="paragraph-hierarchy"><span class="paren">(</span>f<span class="paren">)</span></span> <em class="paragraph-heading">Animals used in manufacture</em> —</p>
<div id="p-600.11(f)(1)">
<p class="indent-2" data-title="600.11(f)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> <em class="paragraph-heading">Care of animals used in manufacturing.</em>  Caretakers and attendants for animals used for the manufacture of products shall be sufficient in number and have adequate experience to insure adequate care. Animal quarters and cages shall be kept in sanitary condition. Animals on production shall be inspected daily to observe response to production procedures. Animals that become ill for reasons not related to production shall be isolated from other animals and shall not be used for production until recovery is complete. Competent veterinary care shall be provided as needed.</p>
</div>
<div id="p-600.11(f)(2)">
<p class="indent-2" data-title="600.11(f)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> <em class="paragraph-heading">Quarantine of animals</em> —</p>
<div id="p-600.11(f)(2)(i)">
<p class="indent-3" data-title="600.11(f)(2)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> <em class="paragraph-heading">General.</em>  No animal shall be used in processing unless kept under competent daily inspection and preliminary quarantine for a period of at least 7 days before use, or as otherwise provided in this subchapter. Only healthy animals free from detectable communicable diseases shall be used. Animals must remain in overt good health throughout the quarantine periods and particular care shall be taken during the quarantine periods to reject animals of the equine genus which may be infected with glanders and animals which may be infected with tuberculosis.</p>
</div>
<div id="p-600.11(f)(2)(ii)">
<p class="indent-3" data-title="600.11(f)(2)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> <em class="paragraph-heading">Quarantine of monkeys.</em>  In addition to observing the pertinent general quarantine requirements, monkeys used as a source of tissue in the manufacture of vaccine shall be maintained in quarantine for at least 6 weeks prior to use, except when otherwise provided in this part. Only monkeys that have reacted negatively to tuberculin at the start of the quarantine period and again within 2 weeks prior to use shall be used in the manufacture of vaccine. Due precaution shall be taken to prevent cross-infection from any infected or potentially infected monkeys on the premises. Monkeys to be used in the manufacture of a live vaccine shall be maintained throughout the quarantine period in cages closed on all sides with solid materials except the front which shall be screened, with no more than two monkeys housed in one cage. Cage mates shall not be interchanged.</p>
</div>
</div>
<div id="p-600.11(f)(3)">
<p class="indent-2" data-title="600.11(f)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> <em class="paragraph-heading">Immunization against tetanus.</em>  Horses and other animals susceptible to tetanus, that are used in the processing steps of the manufacture of biological products, shall be treated adequately to maintain immunity to tetanus.</p>
</div>
<div id="p-600.11(f)(4)">
<p class="indent-2" data-title="600.11(f)(4)"><span class="paragraph-hierarchy"><span class="paren">(</span>4<span class="paren">)</span></span> <em class="paragraph-heading">Immunization and bleeding of animals used as a source of products.</em>  Toxins or other nonviable antigens administered in the immunization of animals used in the manufacture of products shall be sterile. Viable antigens, when so used, shall be free of contaminants, as determined by appropriate tests prior to use. Injections shall not be made into horses within 6 inches of bleeding site. Horses shall not be bled for manufacturing purposes while showing persistent general reaction or local reaction near the site of bleeding. Blood shall not be used if it was drawn within 5 days of injecting the animals with viable microorganisms. Animals shall not be bled for manufacturing purposes when they have an intercurrent disease. Blood intended for use as a source of a biological product shall be collected in clean, sterile vessels. When the product is intended for use by injection, such vessels shall also be pyrogen-free.</p>
</div>
<div id="p-600.11(f)(5)">
<p class="indent-2" data-title="600.11(f)(5)"><span class="paragraph-hierarchy"><span class="paren">(</span>5<span class="paren">)</span></span> [Reserved]</p>
</div>
<div id="p-600.11(f)(6)">
<p class="indent-2" data-title="600.11(f)(6)"><span class="paragraph-hierarchy"><span class="paren">(</span>6<span class="paren">)</span></span> <em class="paragraph-heading">Reporting of certain diseases.</em>  In cases of actual or suspected infection with foot and mouth disease, glanders, tetanus, anthrax, gas gangrene, equine infectious anemia; equine encephalomyelitis, or any of the pock diseases among animals intended for use or used in the manufacture of products, the manufacturer shall immediately notify the Director, Center for Biologics Evaluation and Research or the Director, Center for Drug Evaluation and Research (see mailing addresses in <a href="/current/title-21/section-600.2#p-600.2(a)" class="cfr external">§ 600.2(a)</a> or <a href="/current/title-21/section-600.2#p-600.2(b)" class="cfr external">(b)</a>).</p>
</div>
<div id="p-600.11(f)(7)">
<p class="indent-2" data-title="600.11(f)(7)"><span class="paragraph-hierarchy"><span class="paren">(</span>7<span class="paren">)</span></span> <em class="paragraph-heading">Monkeys used previously for experimental or test purposes.</em>  Monkeys that have been used previously for experimental or test purposes with live microbiological agents shall not be used as a source of kidney tissue for the manufacture of vaccine. Except as provided otherwise in this subchapter, monkeys that have been used previously for other experimental or test purposes may be used as a source of kidney tissue upon their return to a normal condition, provided all quarantine requirements have been met.</p>
</div>
<div id="p-600.11(f)(8)">
<p class="indent-2" data-title="600.11(f)(8)"><span class="paragraph-hierarchy"><span class="paren">(</span>8<span class="paren">)</span></span> <em class="paragraph-heading">Necropsy examination of monkeys.</em>  Each monkey used in the manufacture of vaccine shall be examined at necropsy under the direction of a qualified pathologist, physician, or veterinarian having experience with diseases of monkeys, for evidence of ill health, particularly for </p>
<div id="p-600.11(f)(8)(i)"><p class="indent-3" data-title="600.11(f)(8)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> evidence of tuberculosis, </p></div>
<div id="p-600.11(f)(8)(ii)"><p class="indent-3" data-title="600.11(f)(8)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> presence of herpes-like lesions, including eruptions or plaques on or around the lips, in the buccal cavity or on the gums, and </p></div>
<div id="p-600.11(f)(8)(iii)">
<p class="indent-3" data-title="600.11(f)(8)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> signs of conjunctivitis. If there are any such signs or other significant gross pathological lesions, the tissue shall not be used in the manufacture of vaccine.</p>
</div>
</div>
</div>
<div id="p-600.11(g)">
<p class="indent-1" data-title="600.11(g)"><span class="paragraph-hierarchy"><span class="paren">(</span>g<span class="paren">)</span></span> <em class="paragraph-heading">Filling procedures.</em>  Filling procedures shall be such as will not affect adversely the safety, purity or potency of the product.</p>
</div>
<div id="p-600.11(h)"><p class="indent-1" data-title="600.11(h)"><span class="paragraph-hierarchy"><span class="paren">(</span>h<span class="paren">)</span></span> <em class="paragraph-heading">Containers and closures.</em>  All final containers and closures shall be made of material that will not hasten the deterioration of the product or otherwise render it less suitable for the intended use. All final containers and closures shall be clean and free of surface solids, leachable contaminants and other materials that will hasten the deterioration of the product or otherwise render it less suitable for the intended use. After filling, sealing shall be performed in a manner that will maintain the integrity of the product during the dating period. In addition, final containers and closures for products intended for use by injection shall be sterile and free from pyrogens. Except as otherwise provided in the regulations of this subchapter, final containers for products intended for use by injection shall be colorless and sufficiently transparent to permit visual examination of the contents under normal light. As soon as possible after filling final containers shall be labeled as prescribed in <a href="/current/title-21/section-610.60" class="cfr external">§ 610.60</a> <em>et seq.</em> of this chapter, except that final containers may be stored without such prescribed labeling provided they are stored in a sealed receptacle labeled both inside and outside with at least the name of the product, the lot number, and the filling identification.</p></div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/38-FR-32048" class="fr-reference" data-reference="38 FR 32048">38 FR 32048</a>, Nov. 20, 1973, as amended at <a href="https://www.federalregister.gov/citation/41-FR-10428" class="fr-reference" data-reference="41 FR 10428">41 FR 10428</a>, Mar. 11, 1976; <a href="https://www.federalregister.gov/citation/49-FR-23833" class="fr-reference" data-reference="49 FR 23833">49 FR 23833</a>, June 8, 1984; <a href="https://www.federalregister.gov/citation/55-FR-11013" class="fr-reference" data-reference="55 FR 11013">55 FR 11013</a>, Mar. 26, 1990; <a href="https://www.federalregister.gov/citation/68-FR-75119" class="fr-reference" data-reference="68 FR 75119">68 FR 75119</a>, Dec. 30, 2003; <a href="https://www.federalregister.gov/citation/70-FR-14982" class="fr-reference" data-reference="70 FR 14982">70 FR 14982</a>, Mar. 24, 2005; <a href="https://www.federalregister.gov/citation/72-FR-59003" class="fr-reference" data-reference="72 FR 59003">72 FR 59003</a>, Oct. 18, 2007; <a href="https://www.federalregister.gov/citation/80-FR-18092" class="fr-reference" data-reference="80 FR 18092">80 FR 18092</a>, Apr. 3, 2015]
</p>
</div>

<div class="section" id="600.12">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-600.12","citation":"21 CFR 600.12"}'>§ 600.12 Records.</h4>
<div id="p-600.12(a)">
<p class="indent-1" data-title="600.12(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> <em class="paragraph-heading">Maintenance of records.</em>  Records shall be made, concurrently with the performance, of each step in the manufacture and distribution of products, in such a manner that at any time successive steps in the manufacture and distribution of any lot may be traced by an inspector. Such records shall be legible and indelible, shall identify the person immediately responsible, shall include dates of the various steps, and be as detailed as necessary for clear understanding of each step by one experienced in the manufacture of products.</p>
</div>
<div id="p-600.12(b)">
<p class="indent-1" data-title="600.12(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> <em class="paragraph-heading">Records retention</em> —</p>
<div id="p-600.12(b)(1)">
<p class="indent-2" data-title="600.12(b)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> <em class="paragraph-heading">General.</em>  Records shall be retained for such interval beyond the expiration date as is necessary for the individual product, to permit the return of any clinical report of unfavorable reactions. The retention period shall be no less than five years after the records of manufacture have been completed or six months after the latest expiration date for the individual product, whichever represents a later date.</p>
</div>
<div id="p-600.12(b)(2)">
<p class="indent-2" data-title="600.12(b)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> <em class="paragraph-heading">Records of recall.</em>  Complete records shall be maintained pertaining to the recall from distribution of any product upon notification by the Director, Center for Biologics Evaluation and Research or the Director, Center for Drug Evaluation and Research, to recall for failure to conform with the standards prescribed in the regulations of this subchapter, because of deterioration of the product or for any other factor by reason of which the distribution of the product would constitute a danger to health.</p>
</div>
<div id="p-600.12(b)(3)">
<p class="indent-2" data-title="600.12(b)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> <em class="paragraph-heading">Suspension of requirement for retention.</em>  The Director, Center for Biologics Evaluation and Research or the Director, Center for Drug Evaluation and Research, may authorize the suspension of the requirement to retain records of a specific manufacturing step upon a showing that such records no longer have significance for the purposes for which they were made: <em>Provided,</em> That a summary of such records shall be retained.</p>
</div>
</div>
<div id="p-600.12(c)">
<p class="indent-1" data-title="600.12(c)"><span class="paragraph-hierarchy"><span class="paren">(</span>c<span class="paren">)</span></span> <em class="paragraph-heading">Records of sterilization of equipment and supplies.</em>  Records relating to the mode of sterilization, date, duration, temperature and other conditions relating to each sterilization of equipment and supplies used in the processing of products shall be made by means of automatic recording devices or by means of a system of recording which gives equivalent assurance of the accuracy and reliability of the record. Such records shall be maintained in a manner that permits an identification of the product with the particular manufacturing process to which the sterilization relates.</p>
</div>
<div id="p-600.12(d)">
<p class="indent-1" data-title="600.12(d)"><span class="paragraph-hierarchy"><span class="paren">(</span>d<span class="paren">)</span></span> <em class="paragraph-heading">Animal necropsy records.</em>  A necropsy record shall be kept on each animal from which a biological product has been obtained and which dies or is sacrificed while being so used.</p>
</div>
<div id="p-600.12(e)"><p class="indent-1" data-title="600.12(e)"><span class="paragraph-hierarchy"><span class="paren">(</span>e<span class="paren">)</span></span> <em class="paragraph-heading">Records in case of divided manufacturing responsibility.</em>  If two or more establishments participate in the manufacture of a product, the records of each such establishment must show plainly the degree of its responsibility. In addition, each participating manufacturer shall furnish to the manufacturer who prepares the product in final form for sale, barter or exchange, a copy of all records relating to the manufacturing operations performed by such participating manufacturer insofar as they concern the safety, purity and potency of the lots of the product involved, and the manufacturer who prepares the product in final form shall retain a complete record of all the manufacturing operations relating to the product.</p></div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/38-FR-32048" class="fr-reference" data-reference="38 FR 32048">38 FR 32048</a>, Nov. 20, 1973, as amended at <a href="https://www.federalregister.gov/citation/49-FR-23833" class="fr-reference" data-reference="49 FR 23833">49 FR 23833</a>, June 8, 1984; <a href="https://www.federalregister.gov/citation/55-FR-11013" class="fr-reference" data-reference="55 FR 11013">55 FR 11013</a>, Mar. 26, 1990; <a href="https://www.federalregister.gov/citation/70-FR-14982" class="fr-reference" data-reference="70 FR 14982">70 FR 14982</a>, Mar. 24, 2005]
</p>
</div>

<div class="section" id="600.13">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-600.13","citation":"21 CFR 600.13"}'>§ 600.13 Retention samples.</h4>
<p>Manufacturers shall retain for a period of at least 6 months after the expiration date, unless a different time period is specified in additional standards, a quantity of representative material of each lot of each product, sufficient for examination and testing for safety and potency, except Whole Blood, Cryoprecipitated AHF, Platelets, Red Blood Cells, Plasma, and Source Plasma and Allergenic Products prepared to a physician's prescription. Samples so retained shall be selected at random from either final container material, or from bulk and final containers, provided they include at least one final container as a final package, or package-equivalent of such filling of each lot of the product as intended for distribution. Such sample material shall be stored at temperatures and under conditions which will maintain the identity and integrity of the product. Samples retained as required in this section shall be in addition to samples of specific products required to be submitted to the Center for Biologics Evaluation and Research or the Center for Drug Evaluation and Research (see mailing addresses in <a href="/current/title-21/section-600.2" class="cfr external">§ 600.2</a>). Exceptions may be authorized by the Director, Center for Biologics Evaluation and Research or the Director, Center for Drug Evaluation and Research, when the lot yields relatively few final containers and when such lots are prepared by the same method in large number and in close succession.</p>
<p class="citation">[<a href="https://www.federalregister.gov/citation/41-FR-10428" class="fr-reference" data-reference="41 FR 10428">41 FR 10428</a>, Mar. 11, 1976, as amended at <a href="https://www.federalregister.gov/citation/49-FR-23833" class="fr-reference" data-reference="49 FR 23833">49 FR 23833</a>, June 8, 1984; <a href="https://www.federalregister.gov/citation/50-FR-4133" class="fr-reference" data-reference="50 FR 4133">50 FR 4133</a>, Jan. 29, 1985; <a href="https://www.federalregister.gov/citation/55-FR-11013" class="fr-reference" data-reference="55 FR 11013">55 FR 11013</a>, Mar. 26, 1990; <a href="https://www.federalregister.gov/citation/70-FR-14982" class="fr-reference" data-reference="70 FR 14982">70 FR 14982</a>, Mar. 24, 2005]
</p>
</div>

<div class="section" id="600.14">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-600.14","citation":"21 CFR 600.14"}'>§ 600.14 Reporting of biological product deviations by licensed manufacturers.</h4>
<div id="p-600.14(a)">
<p class="indent-1" data-title="600.14(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> <em class="paragraph-heading">Who must report under this section?</em> </p>
<div id="p-600.14(a)(1)">
<p class="indent-2" data-title="600.14(a)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> You, the manufacturer who holds the biological product license and who had control over the product when the deviation occurred, must report under this section. If you arrange for another person to perform a manufacturing, holding, or distribution step, while the product is in your control, that step is performed under your control. You must establish, maintain, and follow a procedure for receiving information from that person on all deviations, complaints, and adverse events concerning the affected product.</p>
</div>
<div id="p-600.14(a)(2)">
<p class="indent-2" data-title="600.14(a)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> Exceptions:</p>
<div id="p-600.14(a)(2)(i)">
<p class="indent-3" data-title="600.14(a)(2)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> Persons who manufacture only in vitro diagnostic products that are not subject to licensing under section 351 of the Public Health Service Act do not report biological product deviations for those products under this section but must report in accordance with <a href="/current/title-21/part-803" class="cfr external">part 803 of this chapter</a>;</p>
</div>
<div id="p-600.14(a)(2)(ii)">
<p class="indent-3" data-title="600.14(a)(2)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> Persons who manufacture blood and blood components, including licensed manufacturers, unlicensed registered blood establishments, and transfusion services, do not report biological product deviations for those products under this section but must report under <a href="/current/title-21/section-606.171" class="cfr external">§ 606.171 of this chapter</a>;</p>
</div>
<div id="p-600.14(a)(2)(iii)">
<p class="indent-3" data-title="600.14(a)(2)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> Persons who manufacture Source Plasma or any other blood component and use that Source Plasma or any other blood component in the further manufacture of another licensed biological product must report:</p>
<div id="p-600.14(a)(2)(iii)(A)">
<p class="indent-4" data-title="600.14(a)(2)(iii)(A)"><span class="paragraph-hierarchy"><span class="paren">(</span>A<span class="paren">)</span></span> Under <a href="/current/title-21/section-606.171" class="cfr external">§ 606.171 of this chapter</a>, if a biological product deviation occurs during the manufacture of that Source Plasma or any other blood component; or</p>
</div>
<div id="p-600.14(a)(2)(iii)(B)">
<p class="indent-4" data-title="600.14(a)(2)(iii)(B)"><span class="paragraph-hierarchy"><span class="paren">(</span>B<span class="paren">)</span></span> Under this section, if a biological product deviation occurs after the manufacture of that Source Plasma or any other blood component, and during manufacture of the licensed biological product.</p>
</div>
</div>
</div>
</div>
<div id="p-600.14(b)">
<p class="indent-1" data-title="600.14(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> <em class="paragraph-heading">What do I report under this section?</em>  You must report any event, and information relevant to the event, associated with the manufacturing, to include testing, processing, packing, labeling, or storage, or with the holding or distribution, of a licensed biological product, if that event meets all the following criteria:</p>
<div id="p-600.14(b)(1)">
<p class="indent-2" data-title="600.14(b)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> Either:</p>
<div id="p-600.14(b)(1)(i)">
<p class="indent-3" data-title="600.14(b)(1)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> Represents a deviation from current good manufacturing practice, applicable regulations, applicable standards, or established specifications that may affect the safety, purity, or potency of that product; or</p>
</div>
<div id="p-600.14(b)(1)(ii)">
<p class="indent-3" data-title="600.14(b)(1)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> Represents an unexpected or unforeseeable event that may affect the safety, purity, or potency of that product; and</p>
</div>
</div>
<div id="p-600.14(b)(2)">
<p class="indent-2" data-title="600.14(b)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> Occurs in your facility or another facility under contract with you; and</p>
</div>
<div id="p-600.14(b)(3)">
<p class="indent-2" data-title="600.14(b)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> Involves a distributed biological product.</p>
</div>
</div>
<div id="p-600.14(c)">
<p class="indent-1" data-title="600.14(c)"><span class="paragraph-hierarchy"><span class="paren">(</span>c<span class="paren">)</span></span> <em class="paragraph-heading">When do I report under this section?</em>  You should report a biological product deviation as soon as possible but you must report at a date not to exceed 45-calendar days from the date you, your agent, or another person who performs a manufacturing, holding, or distribution step under your control, acquire information reasonably suggesting that a reportable event has occurred.</p>
</div>
<div id="p-600.14(d)">
<p class="indent-1" data-title="600.14(d)"><span class="paragraph-hierarchy"><span class="paren">(</span>d<span class="paren">)</span></span> <em class="paragraph-heading">How do I report under this section</em>  You must report on Form FDA-3486.</p>
</div>
<div id="p-600.14(e)">
<p class="indent-1" data-title="600.14(e)"><span class="paragraph-hierarchy"><span class="paren">(</span>e<span class="paren">)</span></span> <em class="paragraph-heading">Where do I report under this section?</em> </p>
<div id="p-600.14(e)(1)">
<p class="indent-2" data-title="600.14(e)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> For biological products regulated by the Center for Biologics Evaluation and Research (CBER), send the completed Form FDA 3486 to the CBER Document Control Center (see mailing address in <a href="/current/title-21/section-600.2#p-600.2(a)" class="cfr external">§ 600.2(a)</a>), or submit electronically using CBER's electronic Web-based application.</p>
</div>
<div id="p-600.14(e)(2)">
<p class="indent-2" data-title="600.14(e)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> For biological products regulated by the Center for Drug Evaluation and Research (CDER), send the completed Form FDA-3486 to the Division of Compliance Risk Management and Surveillance (HFD-330) (see mailing addresses in <a href="/current/title-21/section-600.2" class="cfr external">§ 600.2</a>). CDER does not currently accept electronic filings.</p>
</div>
<div id="p-600.14(e)(3)">
<p class="indent-2" data-title="600.14(e)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> If you make a paper filing, you should identify on the envelope that a biological product deviation report (BPDR) is enclosed.</p>
</div>
</div>
<div id="p-600.14(f)"><p class="indent-1" data-title="600.14(f)"><span class="paragraph-hierarchy"><span class="paren">(</span>f<span class="paren">)</span></span> <em class="paragraph-heading">How does this regulation affect other FDA regulations?</em>  This part supplements and does not supersede other provisions of the regulations in this chapter. All biological product deviations, whether or not they are required to be reported under this section, should be investigated in accordance with the applicable provisions of <a href="/current/title-21/part-211" class="cfr external">parts 211</a> and <a href="/current/title-21/part-820" class="cfr external">820 of this chapter</a>.</p></div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/65-FR-66634" class="fr-reference" data-reference="65 FR 66634">65 FR 66634</a>, Nov. 7, 2000, as amended at <a href="https://www.federalregister.gov/citation/70-FR-14982" class="fr-reference" data-reference="70 FR 14982">70 FR 14982</a>, Mar. 24, 2005; <a href="https://www.federalregister.gov/citation/80-FR-18092" class="fr-reference" data-reference="80 FR 18092">80 FR 18092</a>, Apr. 3, 2015]
</p>
</div>

<div class="section" id="600.15">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-600.15","citation":"21 CFR 600.15"}'>§ 600.15 Temperatures during shipment.</h4>
<p>The following products shall be maintained during shipment at the specified temperatures:</p>
<div id="p-600.15(a)">
<p class="indent-1" data-title="600.15(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> <em class="paragraph-heading">Products.</em> </p>
<div class="table-wrapper">
<div class="gpotbl_div"><table border="1" cellpadding="1" cellspacing="1" class="gpo_table" frame="void" width="100%">
<thead>
<tr>
<th class="center border-top-single border-bottom-single border-right-single">Product</th>
<th class="center border-top-single border-bottom-single">Temperature</th>
</tr>
</thead>
<tbody>
<tr>
<td class="left border-right-single">Cryoprecipitated AHF</td>
<td class="left">−18 °C or colder.</td>
</tr>
<tr>
<td class="left border-right-single">Measles and Rubella Virus Vaccine Live</td>
<td class="left">10 °C or colder.</td>
</tr>
<tr>
<td class="left border-right-single">Measles Live and Smallpox Vaccine</td>
<td class="left"> Do.</td>
</tr>
<tr>
<td class="left border-right-single">Measles, Mumps, and Rubella Virus Vaccine Live</td>
<td class="left"> Do.</td>
</tr>
<tr>
<td class="left border-right-single">Measles and Mumps Virus Vaccine Live</td>
<td class="left"> Do.</td>
</tr>
<tr>
<td class="left border-right-single">Measles Virus Vaccine Live</td>
<td class="left"> Do.</td>
</tr>
<tr>
<td class="left border-right-single">Mumps Virus Vaccine Live</td>
<td class="left"> Do.</td>
</tr>
<tr>
<td class="left border-right-single">Fresh Frozen Plasma</td>
<td class="left">−18 °C or colder.</td>
</tr>
<tr>
<td class="left border-right-single">Liquid Plasma</td>
<td class="left">1 to 10 °C.</td>
</tr>
<tr>
<td class="left border-right-single">Plasma</td>
<td class="left">−18 °C or colder.</td>
</tr>
<tr>
<td class="left border-right-single">Platelet Rich Plasma</td>
<td class="left">Between 1 and 10 °C if the label indicates storage between 1 and 6 °C, or all reasonable methods to maintain the temperature as close as possible to a range between 20 and 24 °C, if the label indicates storage between 20 and 24 °C.</td>
</tr>
<tr>
<td class="left border-right-single">Platelets</td>
<td class="left">Between 1 and 10 °C if the label indicates storage between 1 and 6 °C, or all reasonable methods to maintain the temperature as close as possible to a range between 20 to 24 °C, if the label indicates storage between 20 and 24 °C.</td>
</tr>
<tr>
<td class="left border-right-single">Poliovirus Vaccine Live Oral Trivalent</td>
<td class="left">0 °C or colder.</td>
</tr>
<tr>
<td class="left border-right-single">Poliovirus Vaccine Live Oral Type I</td>
<td class="left"> Do.</td>
</tr>
<tr>
<td class="left border-right-single">Poliovirus Vaccine Live Oral Type II</td>
<td class="left"> Do.</td>
</tr>
<tr>
<td class="left border-right-single">Poliovirus Vaccine Live Oral Type III</td>
<td class="left"> Do.</td>
</tr>
<tr>
<td class="left border-right-single">Red Blood Cells (liquid product)</td>
<td class="left">Between 1 and 10 °C.</td>
</tr>
<tr>
<td class="left border-right-single">Red Blood Cells Frozen</td>
<td class="left">−65 °C or colder.</td>
</tr>
<tr>
<td class="left border-right-single">Rubella and Mumps Virus Vaccine Live</td>
<td class="left">10 °C or colder.</td>
</tr>
<tr>
<td class="left border-right-single">Rubella Virus Vaccine Live</td>
<td class="left"> Do.</td>
</tr>
<tr>
<td class="left border-right-single">Smallpox Vaccine (Liquid Product)</td>
<td class="left">0 °C or colder.</td>
</tr>
<tr>
<td class="left border-right-single">Source Plasma</td>
<td class="left">−5 °C or colder.</td>
</tr>
<tr>
<td class="left border-right-single">Source Plasma Liquid</td>
<td class="left">10 °C or colder.</td>
</tr>
<tr>
<td class="left border-right-single">Whole Blood</td>
<td class="left">Blood that is transported from the collecting facility to the processing facility shall be transported in an environment capable of continuously cooling the blood toward a temperature range of 1 to 10 °C, or at a temperature as close as possible to 20 to 24 °C for a period not to exceed 6 hours. Blood transported from the storage facility shall be placed in an appropriate environment to maintain a temperature range between 1 to 10 °C during shipment.</td>
</tr>
<tr>
<td class="left border-bottom-single border-right-single">Yellow Fever Vaccine</td>
<td class="left border-bottom-single">0 °C or colder.</td>
</tr>
</tbody>
</table></div>
</div>
</div>
<div id="p-600.15(b)"><p class="indent-1" data-title="600.15(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> <em class="paragraph-heading">Exemptions.</em>  Exemptions or modifications shall be made only upon written approval, in the form of a supplement to the biologics license application, approved by the Director, Center for Biologics Evaluation and Research.</p></div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/39-FR-39872" class="fr-reference" data-reference="39 FR 39872">39 FR 39872</a>, Nov. 12, 1974, as amended at <a href="https://www.federalregister.gov/citation/49-FR-23833" class="fr-reference" data-reference="49 FR 23833">49 FR 23833</a>, June 8, 1984; <a href="https://www.federalregister.gov/citation/50-FR-4133" class="fr-reference" data-reference="50 FR 4133">50 FR 4133</a>, Jan. 29, 1985; <a href="https://www.federalregister.gov/citation/50-FR-9000" class="fr-reference" data-reference="50 FR 9000">50 FR 9000</a>, Mar. 6, 1985; <a href="https://www.federalregister.gov/citation/55-FR-11013" class="fr-reference" data-reference="55 FR 11013">55 FR 11013</a>, Mar. 26, 1990; <a href="https://www.federalregister.gov/citation/59-FR-49351" class="fr-reference" data-reference="59 FR 49351">59 FR 49351</a>, Sept. 28, 1994; <a href="https://www.federalregister.gov/citation/64-FR-56449" class="fr-reference" data-reference="64 FR 56449">64 FR 56449</a>, Oct. 20, 1999]
</p>
</div>

</div>

<div class="subpart" id="subpart-C"><h2 data-hierarchy-metadata="{&quot;path&quot;:&quot;/current/title-21/part-600/subpart-C&quot;,&quot;citation&quot;:&quot;21 CFR Part 600 Subpart C&quot;}">Subpart C—Establishment Inspection</h2>
<div class="section" id="600.20">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-600.20","citation":"21 CFR 600.20"}'>§ 600.20 Inspectors.</h4>
<p>Inspections shall be made by an officer of the Food and Drug Administration having special knowledge of the methods used in the manufacture and control of products and designated for such purposes by the Commissioner of Food and Drugs, or by any officer, agent, or employee of the Department of Health and Human Services specifically designated for such purpose by the Secretary.</p>
<p class="citation">[<a href="https://www.federalregister.gov/citation/38-FR-32048" class="fr-reference" data-reference="38 FR 32048">38 FR 32048</a>, Nov. 20, 1973]
</p>
</div>

<div class="section" id="600.21">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-600.21","citation":"21 CFR 600.21"}'>§ 600.21 Time of inspection.</h4>
<p>The inspection of an establishment for which a biologics license application is pending need not be made until the establishment is in operation and is manufacturing the complete product for which a biologics license is desired.</p>
<p class="citation">[<a href="https://www.federalregister.gov/citation/38-FR-32048" class="fr-reference" data-reference="38 FR 32048">38 FR 32048</a>, Nov. 20, 1973, as amended at <a href="https://www.federalregister.gov/citation/48-FR-26314" class="fr-reference" data-reference="48 FR 26314">48 FR 26314</a>, June 7, 1983; <a href="https://www.federalregister.gov/citation/64-FR-56449" class="fr-reference" data-reference="64 FR 56449">64 FR 56449</a>, Oct. 20, 1999; <a href="https://www.federalregister.gov/citation/84-FR-12508" class="fr-reference" data-reference="84 FR 12508">84 FR 12508</a>, Apr. 2, 2019]
</p>
</div>

<div class="section" id="600.22">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-600.22","citation":"21 CFR 600.22"}'>§ 600.22 [Reserved]</h4>
</div>

</div>

<div class="subpart" id="subpart-D"><h2 data-hierarchy-metadata="{&quot;path&quot;:&quot;/current/title-21/part-600/subpart-D&quot;,&quot;citation&quot;:&quot;21 CFR Part 600 Subpart D&quot;}">Subpart D—Reporting of Adverse Experiences</h2>

<div class="source"><h4 class="inline-header">Source:</h4><p class="inline-paragraph"><a href="https://www.federalregister.gov/citation/59-FR-54042" class="fr-reference" data-reference="59 FR 54042">59 FR 54042</a>, Oct. 27, 1994, unless otherwise noted.
</p></div>
<div class="section" id="600.80">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-600.80","citation":"21 CFR 600.80"}'>§ 600.80 Postmarketing reporting of adverse experiences.</h4>
<div id="p-600.80(a)">
<p class="indent-1" data-title="600.80(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> <em class="paragraph-heading">Definitions.</em>  The following definitions of terms apply to this section:</p>
<div id="p-600.80(a)(Adverse%20experience)">
<p class="indent-2" data-title="600.80(a) “Adverse experience”" data-term="true"><em class="paragraph-hierarchy">Adverse experience.</em>   Any adverse event associated with the use of a biological product in humans, whether or not considered product related, including the following: An adverse event occurring in the course of the use of a biological product in professional practice; an adverse event occurring from overdose of the product whether accidental or intentional; an adverse event occurring from abuse of the product; an adverse event occurring from withdrawal of the product; and any failure of expected pharmacological action.</p>
</div>
<div id="p-600.80(a)(Blood%20Component)">
<p class="indent-2" data-title="600.80(a) “Blood Component”" data-term="true"><em class="paragraph-hierarchy">Blood Component.</em>   As defined in <a href="/current/title-21/section-606.3#p-606.3(c)" class="cfr external">§ 606.3(c) of this chapter</a>.</p>
</div>
<div id="p-600.80(a)(Disability)">
<p class="indent-2" data-title="600.80(a) “Disability”" data-term="true"><em class="paragraph-hierarchy">Disability.</em>   A substantial disruption of a person's ability to conduct normal life functions.</p>
</div>
<div id="p-600.80(a)(Individual%20case%20safety%20report%20(ICSR))">
<p class="indent-2" data-title="600.80(a) “Individual case safety report (ICSR)”" data-term="true"><em class="paragraph-hierarchy">Individual case safety report (ICSR).</em>   A description of an adverse experience related to an individual patient or subject.</p>
</div>
<div id="p-600.80(a)(ICSR%20attachments)">
<p class="indent-2" data-title="600.80(a) “ICSR attachments”" data-term="true"><em class="paragraph-hierarchy">ICSR attachments.</em>   Documents related to the adverse experience described in an ICSR, such as medical records, hospital discharge summaries, or other documentation.</p>
</div>
<div id="p-600.80(a)(Life-threatening%20adverse%20experience)">
<p class="indent-2" data-title="600.80(a) “Life-threatening adverse experience”" data-term="true"><em class="paragraph-hierarchy">Life-threatening adverse experience.</em>   Any adverse experience that places the patient, in the view of the initial reporter, at immediate risk of death from the adverse experience as it occurred, i.e., it does not include an adverse experience that, had it occurred in a more severe form, might have caused death.</p>
</div>
<div id="p-600.80(a)(Serious%20adverse%20experience)">
<p class="indent-2" data-title="600.80(a) “Serious adverse experience”" data-term="true"><em class="paragraph-hierarchy">Serious adverse experience.</em>   Any adverse experience occurring at any dose that results in any of the following outcomes: Death, a life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered a serious adverse experience when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.</p>
</div>
<div id="p-600.80(a)(Unexpected%20adverse%20experience)">
<p class="indent-2" data-title="600.80(a) “Unexpected adverse experience”" data-term="true"><em class="paragraph-hierarchy">Unexpected adverse experience</em>  : Any adverse experience that is not listed in the current labeling for the biological product. This includes events that may be symptomatically and pathophysiologically related to an event listed in the labeling, but differ from the event because of greater severity or specificity. For example, under this definition, hepatic necrosis would be unexpected (by virtue of greater severity) if the labeling only referred to elevated hepatic enzymes or hepatitis. Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected (by virtue of greater specificity) if the labeling only listed cerebral vascular accidents. “Unexpected,” as used in this definition, refers to an adverse experience that has not been previously observed (i.e., included in the labeling) rather than from the perspective of such experience not being anticipated from the pharmacological properties of the pharmaceutical product.</p>
</div>
</div>
<div id="p-600.80(b)">
<p class="indent-1" data-title="600.80(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> <em class="paragraph-heading">Review of adverse experiences.</em>  Any person having a biologics license under <a href="/current/title-21/section-601.20" class="cfr external">§ 601.20 of this chapter</a> must promptly review all adverse experience information pertaining to its product obtained or otherwise received by the applicant from any source, foreign or domestic, including information derived from commercial marketing experience, postmarketing clinical investigations, postmarketing epidemiological/surveillance studies, reports in the scientific literature, and unpublished scientific papers. Applicants are not required to resubmit to FDA adverse product experience reports forwarded to the applicant by FDA; applicants, however, must submit all followup information on such reports to FDA. Any person subject to the reporting requirements under <a href="/current/title-21/section-600.80#p-600.80(c)" class="cfr external">paragraph (c)</a> of this section must also develop written procedures for the surveillance, receipt, evaluation, and reporting of postmarketing adverse experiences to FDA.</p>
</div>
<div id="p-600.80(c)">
<p class="indent-1" data-title="600.80(c)"><span class="paragraph-hierarchy"><span class="paren">(</span>c<span class="paren">)</span></span> <em class="paragraph-heading">Reporting requirements.</em>  The applicant must submit to FDA postmarketing 15-day Alert reports and periodic safety reports pertaining to its biological product as described in this section. These reports must be submitted to the Agency in electronic format as described in <a href="/current/title-21/section-600.80#p-600.80(h)(1)" class="cfr external">paragraph (h)(1)</a> of this section, except as provided in <a href="/current/title-21/section-600.80#p-600.80(h)(2)" class="cfr external">paragraph (h)(2)</a> of this section.</p>
<div id="p-600.80(c)(1)">
<p class="indent-2" data-title="600.80(c)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> </p>
<div id="p-600.80(c)(1)(i)">
<p class="indent-3" data-title="600.80(c)(1)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> <em class="paragraph-heading">Postmarketing 15-day “Alert reports”.</em>  The applicant must report each adverse experience that is both serious and unexpected, whether foreign or domestic, as soon as possible but no later than 15 calendar days from initial receipt of the information by the applicant.</p>
</div>
<div id="p-600.80(c)(1)(ii)">
<p class="indent-3" data-title="600.80(c)(1)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> <em class="paragraph-heading">Postmarketing 15-day “Alert reports”—followup.</em>  The applicant must promptly investigate all adverse experiences that are the subject of these postmarketing 15-day Alert reports and must submit followup reports within 15 calendar days of receipt of new information or as requested by FDA. If additional information is not obtainable, records should be maintained of the unsuccessful steps taken to seek additional information.</p>
</div>
<div id="p-600.80(c)(1)(iii)">
<p class="indent-3" data-title="600.80(c)(1)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> <em class="paragraph-heading">Submission of reports.</em>  The requirements of <a href="/current/title-21/section-600.80#p-600.80(c)(1)(i)" class="cfr external">paragraphs (c)(1)(i)</a> and <a href="/current/title-21/section-600.80#p-600.80(c)(1)(ii)" class="cfr external">(c)(1)(ii)</a> of this section, concerning the submission of postmarketing 15-day Alert reports, also apply to any person whose name appears on the label of a licensed biological product as a manufacturer, packer, distributor, shared manufacturer, joint manufacturer, or any other participant involved in divided manufacturing. To avoid unnecessary duplication in the submission to FDA of reports required by <a href="/current/title-21/section-600.80#p-600.80(c)(1)(i)" class="cfr external">paragraphs (c)(1)(i)</a> and <a href="/current/title-21/section-600.80#p-600.80(c)(1)(ii)" class="cfr external">(c)(1)(ii)</a> of this section, obligations of persons other than the applicant of the final biological product may be met by submission of all reports of serious adverse experiences to the applicant of the final product. If a person elects to submit adverse experience reports to the applicant rather than to FDA, the person must submit, by any appropriate means, each report to the applicant within 5 calendar days of initial receipt of the information by the person, and the applicant must then comply with the requirements of this section. Under this circumstance, a person who elects to submit reports to the applicant of the final product shall maintain a record of this action which must include:</p>
<div id="p-600.80(c)(1)(iii)(A)">
<p class="indent-4" data-title="600.80(c)(1)(iii)(A)"><span class="paragraph-hierarchy"><span class="paren">(</span>A<span class="paren">)</span></span> A copy of all adverse biological product experience reports submitted to the applicant of the final product;</p>
</div>
<div id="p-600.80(c)(1)(iii)(B)">
<p class="indent-4" data-title="600.80(c)(1)(iii)(B)"><span class="paragraph-hierarchy"><span class="paren">(</span>B<span class="paren">)</span></span> The date the report was received by the person;</p>
</div>
<div id="p-600.80(c)(1)(iii)(C)">
<p class="indent-4" data-title="600.80(c)(1)(iii)(C)"><span class="paragraph-hierarchy"><span class="paren">(</span>C<span class="paren">)</span></span> The date the report was submitted to the applicant of the final product; and—</p>
</div>
<div id="p-600.80(c)(1)(iii)(D)">
<p class="indent-4" data-title="600.80(c)(1)(iii)(D)"><span class="paragraph-hierarchy"><span class="paren">(</span>D<span class="paren">)</span></span> The name and address of the applicant of the final product.</p>
</div>
</div>
</div>
<div id="p-600.80(c)(2)">
<p class="indent-2" data-title="600.80(c)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> <em class="paragraph-heading">Periodic adverse experience reports.</em> </p>
<div id="p-600.80(c)(2)(i)">
<p class="indent-3" data-title="600.80(c)(2)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> The applicant must report each adverse experience not reported under <a href="/current/title-21/section-600.80#p-600.80(c)(1)(i)" class="cfr external">paragraph (c)(1)(i)</a> of this section at quarterly intervals, for 3 years from the date of issuance of the biologics license, and then at annual intervals. The applicant must submit each quarterly report within 30 days of the close of the quarter (the first quarter beginning on the date of issuance of the biologics license) and each annual report within 60 days of the anniversary date of the issuance of the biologics license. Upon written notice, FDA may extend or reestablish the requirement that an applicant submit quarterly reports, or require that the applicant submit reports under this section at different times than those stated. Followup information to adverse experiences submitted in a periodic report may be submitted in the next periodic report.</p>
</div>
<div id="p-600.80(c)(2)(ii)">
<p class="indent-3" data-title="600.80(c)(2)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> Each periodic report is required to contain:</p>
<div id="p-600.80(c)(2)(ii)(A)">
<p class="indent-4" data-title="600.80(c)(2)(ii)(A)"><span class="paragraph-hierarchy"><span class="paren">(</span>A<span class="paren">)</span></span> <em class="paragraph-heading">Descriptive information.</em> </p>
<div id="p-600.80(c)(2)(ii)(A)(1)">
<p class="indent-5" data-title="600.80(c)(2)(ii)(A)(&lt;em&gt;1&lt;/em&gt;)"><span class="paragraph-hierarchy"><span class="paren">(</span><em>1</em><span class="paren">)</span></span> A narrative summary and analysis of the information in the report;</p>
</div>
<div id="p-600.80(c)(2)(ii)(A)(2)">
<p class="indent-5" data-title="600.80(c)(2)(ii)(A)(&lt;em&gt;2&lt;/em&gt;)"><span class="paragraph-hierarchy"><span class="paren">(</span><em>2</em><span class="paren">)</span></span> An analysis of the 15-day Alert reports submitted during the reporting interval (all 15-day Alert reports being appropriately referenced by the applicant's patient identification code for nonvaccine biological product reports or by the unique case identification number for vaccine reports, adverse reaction term(s), and date of submission to FDA);</p>
</div>
<div id="p-600.80(c)(2)(ii)(A)(3)">
<p class="indent-5" data-title="600.80(c)(2)(ii)(A)(&lt;em&gt;3&lt;/em&gt;)"><span class="paragraph-hierarchy"><span class="paren">(</span><em>3</em><span class="paren">)</span></span> A history of actions taken since the last report because of adverse experiences (for example, labeling changes or studies initiated);</p>
</div>
<div id="p-600.80(c)(2)(ii)(A)(4)">
<p class="indent-5" data-title="600.80(c)(2)(ii)(A)(&lt;em&gt;4&lt;/em&gt;)"><span class="paragraph-hierarchy"><span class="paren">(</span><em>4</em><span class="paren">)</span></span> An index consisting of a line listing of the applicant's patient identification code for nonvaccine biological product reports or by the unique case identification number for vaccine reports and adverse reaction term(s) for ICSRs submitted under <a href="/current/title-21/section-600.80#p-600.80(c)(2)(ii)(B)" class="cfr external">paragraph (c)(2)(ii)(B)</a> of this section; and</p>
</div>
</div>
<div id="p-600.80(c)(2)(ii)(B)">
<p class="indent-4" data-title="600.80(c)(2)(ii)(B)"><span class="paragraph-hierarchy"><span class="paren">(</span>B<span class="paren">)</span></span> <em class="paragraph-heading">ICSRs for serious, expected and, nonserious adverse experiences.</em>  An ICSR for each adverse experience not reported under <a href="/current/title-21/section-600.80#p-600.80(c)(1)(i)" class="cfr external">paragraph (c)(1)(i)</a> of this section (all serious, expected and nonserious adverse experiences). All such ICSRs must be submitted to FDA (either individually or in one or more batches) within the timeframe specified in <a href="/current/title-21/section-600.80#p-600.80(c)(2)(i)" class="cfr external">paragraph (c)(2)(i)</a> of this section. ICSRs must only be submitted to FDA once.</p>
</div>
</div>
<div id="p-600.80(c)(2)(iii)">
<p class="indent-3" data-title="600.80(c)(2)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> Periodic reporting, except for information regarding 15-day Alert reports, does not apply to adverse experience information obtained from postmarketing studies (whether or not conducted under an investigational new drug application), from reports in the scientific literature, and from foreign marketing experience.</p>
</div>
</div>
</div>
<div id="p-600.80(d)">
<p class="indent-1" data-title="600.80(d)"><span class="paragraph-hierarchy"><span class="paren">(</span>d<span class="paren">)</span></span> <em class="paragraph-heading">Scientific literature.</em>  A 15-day Alert report based on information in the scientific literature must be accompanied by a copy of the published article. The 15-day Alert reporting requirements in <a href="/current/title-21/section-600.80#p-600.80(c)(1)(i)" class="cfr external">paragraph (c)(1)(i)</a> of this section (i.e., serious, unexpected adverse experiences) apply only to reports found in scientific and medical journals either as case reports or as the result of a formal clinical trial.</p>
</div>
<div id="p-600.80(e)">
<p class="indent-1" data-title="600.80(e)"><span class="paragraph-hierarchy"><span class="paren">(</span>e<span class="paren">)</span></span> <em class="paragraph-heading">Postmarketing studies.</em>  Applicants are not required to submit a 15-day Alert report under <a href="/current/title-21/section-600.80#p-600.80(c)" class="cfr external">paragraph (c)</a> of this section for an adverse experience obtained from a postmarketing clinical study (whether or not conducted under a biological investigational new drug application) unless the applicant concludes that there is a reasonable possibility that the product caused the adverse experience.</p>
</div>
<div id="p-600.80(f)">
<p class="indent-1" data-title="600.80(f)"><span class="paragraph-hierarchy"><span class="paren">(</span>f<span class="paren">)</span></span> <em class="paragraph-heading">Information reported on ICSRs for nonvaccine biological products.</em>  ICSRs for nonvaccine biological products include the following information:</p>
<div id="p-600.80(f)(1)">
<p class="indent-2" data-title="600.80(f)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> <em class="paragraph-heading">Patient information.</em> </p>
<div id="p-600.80(f)(1)(i)">
<p class="indent-3" data-title="600.80(f)(1)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> Patient identification code;</p>
</div>
<div id="p-600.80(f)(1)(ii)">
<p class="indent-3" data-title="600.80(f)(1)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> Patient age at the time of adverse experience, or date of birth;</p>
</div>
<div id="p-600.80(f)(1)(iii)">
<p class="indent-3" data-title="600.80(f)(1)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> Patient gender; and</p>
</div>
<div id="p-600.80(f)(1)(iv)">
<p class="indent-3" data-title="600.80(f)(1)(iv)"><span class="paragraph-hierarchy"><span class="paren">(</span>iv<span class="paren">)</span></span> Patient weight.</p>
</div>
</div>
<div id="p-600.80(f)(2)">
<p class="indent-2" data-title="600.80(f)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> <em class="paragraph-heading">Adverse experience.</em> </p>
<div id="p-600.80(f)(2)(i)">
<p class="indent-3" data-title="600.80(f)(2)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> Outcome attributed to adverse experience;</p>
</div>
<div id="p-600.80(f)(2)(ii)">
<p class="indent-3" data-title="600.80(f)(2)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> Date of adverse experience;</p>
</div>
<div id="p-600.80(f)(2)(iii)">
<p class="indent-3" data-title="600.80(f)(2)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> Date of report;</p>
</div>
<div id="p-600.80(f)(2)(iv)">
<p class="indent-3" data-title="600.80(f)(2)(iv)"><span class="paragraph-hierarchy"><span class="paren">(</span>iv<span class="paren">)</span></span> Description of adverse experience (including a concise medical narrative);</p>
</div>
<div id="p-600.80(f)(2)(v)">
<p class="indent-3" data-title="600.80(f)(2)(v)"><span class="paragraph-hierarchy"><span class="paren">(</span>v<span class="paren">)</span></span> Adverse experience term(s);</p>
</div>
<div id="p-600.80(f)(2)(vi)">
<p class="indent-3" data-title="600.80(f)(2)(vi)"><span class="paragraph-hierarchy"><span class="paren">(</span>vi<span class="paren">)</span></span> Description of relevant tests, including dates and laboratory data; and</p>
</div>
<div id="p-600.80(f)(2)(vii)">
<p class="indent-3" data-title="600.80(f)(2)(vii)"><span class="paragraph-hierarchy"><span class="paren">(</span>vii<span class="paren">)</span></span> Other relevant patient history, including preexisting medical conditions.</p>
</div>
</div>
<div id="p-600.80(f)(3)">
<p class="indent-2" data-title="600.80(f)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> <em class="paragraph-heading">Suspect medical product(s).</em> </p>
<div id="p-600.80(f)(3)(i)">
<p class="indent-3" data-title="600.80(f)(3)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> Name;</p>
</div>
<div id="p-600.80(f)(3)(ii)">
<p class="indent-3" data-title="600.80(f)(3)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> Dose, frequency, and route of administration used;</p>
</div>
<div id="p-600.80(f)(3)(iii)">
<p class="indent-3" data-title="600.80(f)(3)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> Therapy dates;</p>
</div>
<div id="p-600.80(f)(3)(iv)">
<p class="indent-3" data-title="600.80(f)(3)(iv)"><span class="paragraph-hierarchy"><span class="paren">(</span>iv<span class="paren">)</span></span> Diagnosis for use (indication);</p>
</div>
<div id="p-600.80(f)(3)(v)">
<p class="indent-3" data-title="600.80(f)(3)(v)"><span class="paragraph-hierarchy"><span class="paren">(</span>v<span class="paren">)</span></span> Whether the product is a combination product as defined in <a href="/current/title-21/section-3.2#p-3.2(e)" class="cfr external">§ 3.2(e) of this chapter</a>;</p>
</div>
<div id="p-600.80(f)(3)(vi)">
<p class="indent-3" data-title="600.80(f)(3)(vi)"><span class="paragraph-hierarchy"><span class="paren">(</span>vi<span class="paren">)</span></span> Whether the product is a prescription or nonprescription product;</p>
</div>
<div id="p-600.80(f)(3)(vii)">
<p class="indent-3" data-title="600.80(f)(3)(vii)"><span class="paragraph-hierarchy"><span class="paren">(</span>vii<span class="paren">)</span></span> Whether adverse experience abated after product use stopped or dose reduced;</p>
</div>
<div id="p-600.80(f)(3)(viii)">
<p class="indent-3" data-title="600.80(f)(3)(viii)"><span class="paragraph-hierarchy"><span class="paren">(</span>viii<span class="paren">)</span></span> Whether adverse experience reappeared after reintroduction of the product;</p>
</div>
<div id="p-600.80(f)(3)(ix)">
<p class="indent-3" data-title="600.80(f)(3)(ix)"><span class="paragraph-hierarchy"><span class="paren">(</span>ix<span class="paren">)</span></span> Lot number;</p>
</div>
<div id="p-600.80(f)(3)(x)">
<p class="indent-3" data-title="600.80(f)(3)(x)"><span class="paragraph-hierarchy"><span class="paren">(</span>x<span class="paren">)</span></span> Expiration date;</p>
</div>
<div id="p-600.80(f)(3)(xi)">
<p class="indent-3" data-title="600.80(f)(3)(xi)"><span class="paragraph-hierarchy"><span class="paren">(</span>xi<span class="paren">)</span></span> National Drug Code (NDC) number, or other unique identifier; and</p>
</div>
<div id="p-600.80(f)(3)(xii)">
<p class="indent-3" data-title="600.80(f)(3)(xii)"><span class="paragraph-hierarchy"><span class="paren">(</span>xii<span class="paren">)</span></span> Concomitant medical products and therapy dates.</p>
</div>
</div>
<div id="p-600.80(f)(4)">
<p class="indent-2" data-title="600.80(f)(4)"><span class="paragraph-hierarchy"><span class="paren">(</span>4<span class="paren">)</span></span> <em class="paragraph-heading">Initial reporter information.</em> </p>
<div id="p-600.80(f)(4)(i)">
<p class="indent-3" data-title="600.80(f)(4)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> Name, address, and telephone number;</p>
</div>
<div id="p-600.80(f)(4)(ii)">
<p class="indent-3" data-title="600.80(f)(4)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> Whether the initial reporter is a health care professional; and</p>
</div>
<div id="p-600.80(f)(4)(iii)">
<p class="indent-3" data-title="600.80(f)(4)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> Occupation, if a health care professional.</p>
</div>
</div>
<div id="p-600.80(f)(5)">
<p class="indent-2" data-title="600.80(f)(5)"><span class="paragraph-hierarchy"><span class="paren">(</span>5<span class="paren">)</span></span> <em class="paragraph-heading">Applicant information.</em> </p>
<div id="p-600.80(f)(5)(i)">
<p class="indent-3" data-title="600.80(f)(5)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> Applicant name and contact office address;</p>
</div>
<div id="p-600.80(f)(5)(ii)">
<p class="indent-3" data-title="600.80(f)(5)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> Telephone number;</p>
</div>
<div id="p-600.80(f)(5)(iii)">
<p class="indent-3" data-title="600.80(f)(5)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> Report source, such as spontaneous, literature, or study;</p>
</div>
<div id="p-600.80(f)(5)(iv)">
<p class="indent-3" data-title="600.80(f)(5)(iv)"><span class="paragraph-hierarchy"><span class="paren">(</span>iv<span class="paren">)</span></span> Date the report was received by applicant;</p>
</div>
<div id="p-600.80(f)(5)(v)">
<p class="indent-3" data-title="600.80(f)(5)(v)"><span class="paragraph-hierarchy"><span class="paren">(</span>v<span class="paren">)</span></span> Application number and type;</p>
</div>
<div id="p-600.80(f)(5)(vi)">
<p class="indent-3" data-title="600.80(f)(5)(vi)"><span class="paragraph-hierarchy"><span class="paren">(</span>vi<span class="paren">)</span></span> Whether the ICSR is a 15-day “Alert report”;</p>
</div>
<div id="p-600.80(f)(5)(vii)">
<p class="indent-3" data-title="600.80(f)(5)(vii)"><span class="paragraph-hierarchy"><span class="paren">(</span>vii<span class="paren">)</span></span> Whether the ICSR is an initial report or followup report; and</p>
</div>
<div id="p-600.80(f)(5)(viii)">
<p class="indent-3" data-title="600.80(f)(5)(viii)"><span class="paragraph-hierarchy"><span class="paren">(</span>viii<span class="paren">)</span></span> Unique case identification number, which must be the same in the initial report and any subsequent followup report(s).</p>
</div>
</div>
</div>
<div id="p-600.80(g)">
<p class="indent-1" data-title="600.80(g)"><span class="paragraph-hierarchy"><span class="paren">(</span>g<span class="paren">)</span></span> <em class="paragraph-heading">Information reported on ICSRs for vaccine products.</em>  ICSRs for vaccine products include the following information:</p>
<div id="p-600.80(g)(1)">
<p class="indent-2" data-title="600.80(g)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> <em class="paragraph-heading">Patient information.</em> </p>
<div id="p-600.80(g)(1)(i)">
<p class="indent-3" data-title="600.80(g)(1)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> Patient name, address, telephone number;</p>
</div>
<div id="p-600.80(g)(1)(ii)">
<p class="indent-3" data-title="600.80(g)(1)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> Patient age at the time of vaccination, or date of birth;</p>
</div>
<div id="p-600.80(g)(1)(iii)">
<p class="indent-3" data-title="600.80(g)(1)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> Patient gender; and</p>
</div>
<div id="p-600.80(g)(1)(iv)">
<p class="indent-3" data-title="600.80(g)(1)(iv)"><span class="paragraph-hierarchy"><span class="paren">(</span>iv<span class="paren">)</span></span> Patient birth weight for children under age 5.</p>
</div>
</div>
<div id="p-600.80(g)(2)">
<p class="indent-2" data-title="600.80(g)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> <em class="paragraph-heading">Adverse experience.</em> </p>
<div id="p-600.80(g)(2)(i)">
<p class="indent-3" data-title="600.80(g)(2)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> Outcome attributed to adverse experience;</p>
</div>
<div id="p-600.80(g)(2)(ii)">
<p class="indent-3" data-title="600.80(g)(2)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> Date and time of adverse experience;</p>
</div>
<div id="p-600.80(g)(2)(iii)">
<p class="indent-3" data-title="600.80(g)(2)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> Date of report;</p>
</div>
<div id="p-600.80(g)(2)(iv)">
<p class="indent-3" data-title="600.80(g)(2)(iv)"><span class="paragraph-hierarchy"><span class="paren">(</span>iv<span class="paren">)</span></span> Description of adverse experience (including a concise medical narrative);</p>
</div>
<div id="p-600.80(g)(2)(v)">
<p class="indent-3" data-title="600.80(g)(2)(v)"><span class="paragraph-hierarchy"><span class="paren">(</span>v<span class="paren">)</span></span> Adverse experience term(s);</p>
</div>
<div id="p-600.80(g)(2)(vi)">
<p class="indent-3" data-title="600.80(g)(2)(vi)"><span class="paragraph-hierarchy"><span class="paren">(</span>vi<span class="paren">)</span></span> Illness at the time of vaccination;</p>
</div>
<div id="p-600.80(g)(2)(vii)">
<p class="indent-3" data-title="600.80(g)(2)(vii)"><span class="paragraph-hierarchy"><span class="paren">(</span>vii<span class="paren">)</span></span> Description of relevant tests, including dates and laboratory data; and</p>
</div>
<div id="p-600.80(g)(2)(viii)">
<p class="indent-3" data-title="600.80(g)(2)(viii)"><span class="paragraph-hierarchy"><span class="paren">(</span>viii<span class="paren">)</span></span> Other relevant patient history, including preexisting medical conditions.</p>
</div>
</div>
<div id="p-600.80(g)(3)">
<p class="indent-2" data-title="600.80(g)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> <em class="paragraph-heading">Suspect medical product(s), including vaccines administered on the same date.</em> </p>
<div id="p-600.80(g)(3)(i)">
<p class="indent-3" data-title="600.80(g)(3)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> Name;</p>
</div>
<div id="p-600.80(g)(3)(ii)">
<p class="indent-3" data-title="600.80(g)(3)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> Dose, frequency, and route or site of administration used;</p>
</div>
<div id="p-600.80(g)(3)(iii)">
<p class="indent-3" data-title="600.80(g)(3)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> Number of previous vaccine doses;</p>
</div>
<div id="p-600.80(g)(3)(iv)">
<p class="indent-3" data-title="600.80(g)(3)(iv)"><span class="paragraph-hierarchy"><span class="paren">(</span>iv<span class="paren">)</span></span> Vaccination date(s) and time(s);</p>
</div>
<div id="p-600.80(g)(3)(v)">
<p class="indent-3" data-title="600.80(g)(3)(v)"><span class="paragraph-hierarchy"><span class="paren">(</span>v<span class="paren">)</span></span> Diagnosis for use (indication);</p>
</div>
<div id="p-600.80(g)(3)(vi)">
<p class="indent-3" data-title="600.80(g)(3)(vi)"><span class="paragraph-hierarchy"><span class="paren">(</span>vi<span class="paren">)</span></span> Whether the product is a combination product (as defined in <a href="/current/title-21/section-3.2#p-3.2(e)" class="cfr external">§ 3.2(e) of this chapter</a>);</p>
</div>
<div id="p-600.80(g)(3)(vii)">
<p class="indent-3" data-title="600.80(g)(3)(vii)"><span class="paragraph-hierarchy"><span class="paren">(</span>vii<span class="paren">)</span></span> Whether the adverse experience abated after product use stopped or dose reduced;</p>
</div>
<div id="p-600.80(g)(3)(viii)">
<p class="indent-3" data-title="600.80(g)(3)(viii)"><span class="paragraph-hierarchy"><span class="paren">(</span>viii<span class="paren">)</span></span> Whether the adverse experience reappeared after reintroduction of the product;</p>
</div>
<div id="p-600.80(g)(3)(ix)">
<p class="indent-3" data-title="600.80(g)(3)(ix)"><span class="paragraph-hierarchy"><span class="paren">(</span>ix<span class="paren">)</span></span> Lot number;</p>
</div>
<div id="p-600.80(g)(3)(x)">
<p class="indent-3" data-title="600.80(g)(3)(x)"><span class="paragraph-hierarchy"><span class="paren">(</span>x<span class="paren">)</span></span> Expiration date;</p>
</div>
<div id="p-600.80(g)(3)(xi)">
<p class="indent-3" data-title="600.80(g)(3)(xi)"><span class="paragraph-hierarchy"><span class="paren">(</span>xi<span class="paren">)</span></span> National Drug Code (NDC) number, or other unique identifier; and</p>
</div>
<div id="p-600.80(g)(3)(xii)">
<p class="indent-3" data-title="600.80(g)(3)(xii)"><span class="paragraph-hierarchy"><span class="paren">(</span>xii<span class="paren">)</span></span> Concomitant medical products and therapy dates.</p>
</div>
</div>
<div id="p-600.80(g)(4)">
<p class="indent-2" data-title="600.80(g)(4)"><span class="paragraph-hierarchy"><span class="paren">(</span>4<span class="paren">)</span></span> <em class="paragraph-heading">Vaccine(s) administered in the 4 weeks prior to the vaccination date.</em> </p>
<div id="p-600.80(g)(4)(i)">
<p class="indent-3" data-title="600.80(g)(4)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> Name of vaccine;</p>
</div>
<div id="p-600.80(g)(4)(ii)">
<p class="indent-3" data-title="600.80(g)(4)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> Manufacturer;</p>
</div>
<div id="p-600.80(g)(4)(iii)">
<p class="indent-3" data-title="600.80(g)(4)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> Lot number;</p>
</div>
<div id="p-600.80(g)(4)(iv)">
<p class="indent-3" data-title="600.80(g)(4)(iv)"><span class="paragraph-hierarchy"><span class="paren">(</span>iv<span class="paren">)</span></span> Route or site of administration;</p>
</div>
<div id="p-600.80(g)(4)(v)">
<p class="indent-3" data-title="600.80(g)(4)(v)"><span class="paragraph-hierarchy"><span class="paren">(</span>v<span class="paren">)</span></span> Date given; and</p>
</div>
<div id="p-600.80(g)(4)(vi)">
<p class="indent-3" data-title="600.80(g)(4)(vi)"><span class="paragraph-hierarchy"><span class="paren">(</span>vi<span class="paren">)</span></span> Number of previous doses.</p>
</div>
</div>
<div id="p-600.80(g)(5)">
<p class="indent-2" data-title="600.80(g)(5)"><span class="paragraph-hierarchy"><span class="paren">(</span>5<span class="paren">)</span></span> <em class="paragraph-heading">Initial reporter information.</em> </p>
<div id="p-600.80(g)(5)(i)">
<p class="indent-3" data-title="600.80(g)(5)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> Name, address, and telephone number;</p>
</div>
<div id="p-600.80(g)(5)(ii)">
<p class="indent-3" data-title="600.80(g)(5)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> Whether the initial reporter is a health care professional; and</p>
</div>
<div id="p-600.80(g)(5)(iii)">
<p class="indent-3" data-title="600.80(g)(5)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> Occupation, if a health care professional.</p>
</div>
</div>
<div id="p-600.80(g)(6)">
<p class="indent-2" data-title="600.80(g)(6)"><span class="paragraph-hierarchy"><span class="paren">(</span>6<span class="paren">)</span></span> <em class="paragraph-heading">Facility and personnel where vaccine was administered.</em> </p>
<div id="p-600.80(g)(6)(i)">
<p class="indent-3" data-title="600.80(g)(6)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> Name of person who administered vaccine;</p>
</div>
<div id="p-600.80(g)(6)(ii)">
<p class="indent-3" data-title="600.80(g)(6)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> Name of responsible physician at facility where vaccine was administered; and</p>
</div>
<div id="p-600.80(g)(6)(iii)">
<p class="indent-3" data-title="600.80(g)(6)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> Name, address (including city, county, and state), and telephone number of facility where vaccine was administered.</p>
</div>
</div>
<div id="p-600.80(g)(7)">
<p class="indent-2" data-title="600.80(g)(7)"><span class="paragraph-hierarchy"><span class="paren">(</span>7<span class="paren">)</span></span> <em class="paragraph-heading">Applicant information.</em> </p>
<div id="p-600.80(g)(7)(i)">
<p class="indent-3" data-title="600.80(g)(7)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> Applicant name and contact office address;</p>
</div>
<div id="p-600.80(g)(7)(ii)">
<p class="indent-3" data-title="600.80(g)(7)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> Telephone number;</p>
</div>
<div id="p-600.80(g)(7)(iii)">
<p class="indent-3" data-title="600.80(g)(7)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> Report source, such as spontaneous, literature, or study;</p>
</div>
<div id="p-600.80(g)(7)(iv)">
<p class="indent-3" data-title="600.80(g)(7)(iv)"><span class="paragraph-hierarchy"><span class="paren">(</span>iv<span class="paren">)</span></span> Date received by applicant;</p>
</div>
<div id="p-600.80(g)(7)(v)">
<p class="indent-3" data-title="600.80(g)(7)(v)"><span class="paragraph-hierarchy"><span class="paren">(</span>v<span class="paren">)</span></span> Application number and type;</p>
</div>
<div id="p-600.80(g)(7)(vi)">
<p class="indent-3" data-title="600.80(g)(7)(vi)"><span class="paragraph-hierarchy"><span class="paren">(</span>vi<span class="paren">)</span></span> Whether the ICSR is a 15-day “Alert report”;</p>
</div>
<div id="p-600.80(g)(7)(vii)">
<p class="indent-3" data-title="600.80(g)(7)(vii)"><span class="paragraph-hierarchy"><span class="paren">(</span>vii<span class="paren">)</span></span> Whether the ICSR is an initial report or followup report; and</p>
</div>
<div id="p-600.80(g)(7)(viii)">
<p class="indent-3" data-title="600.80(g)(7)(viii)"><span class="paragraph-hierarchy"><span class="paren">(</span>viii<span class="paren">)</span></span> Unique case identification number, which must be the same in the initial report and any subsequent followup report(s).</p>
</div>
</div>
</div>
<div id="p-600.80(h)">
<p class="indent-1" data-title="600.80(h)"><span class="paragraph-hierarchy"><span class="paren">(</span>h<span class="paren">)</span></span> <em class="paragraph-heading">Electronic format for submissions.</em> </p>
<div id="p-600.80(h)(1)">
<p class="indent-2" data-title="600.80(h)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> Safety report submissions, including ICSRs, ICSR attachments, and the descriptive information in periodic reports, must be in an electronic format that FDA can process, review, and archive. FDA will issue guidance on how to provide the electronic submission (e.g., method of transmission, media, file formats, preparation and organization of files).</p>
</div>
<div id="p-600.80(h)(2)">
<p class="indent-2" data-title="600.80(h)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> Persons subject to the requirements of <a href="/current/title-21/section-600.80#p-600.80(c)" class="cfr external">paragraph (c)</a> of this section may request, in writing, a temporary waiver of the requirements in <a href="/current/title-21/section-600.80#p-600.80(h)(1)" class="cfr external">paragraph (h)(1)</a> of this section. These waivers will be granted on a limited basis for good cause shown. FDA will issue guidance on requesting a waiver of the requirements in <a href="/current/title-21/section-600.80#p-600.80(h)(1)" class="cfr external">paragraph (h)(1)</a> of this section. Requests for waivers must be submitted in accordance with <a href="/current/title-21/section-600.90" class="cfr external">§ 600.90</a>.</p>
</div>
</div>
<div id="p-600.80(i)">
<p class="indent-1" data-title="600.80(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> <em class="paragraph-heading">Multiple reports.</em>  An applicant should not include in reports under this section any adverse experience that occurred in clinical trials if they were previously submitted as part of the biologics license application. If a report refers to more than one biological product marketed by an applicant, the applicant should submit the report to the biologics license application for the product listed first in the report.</p>
</div>
<div id="p-600.80(j)">
<p class="indent-1" data-title="600.80(j)"><span class="paragraph-hierarchy"><span class="paren">(</span>j<span class="paren">)</span></span> <em class="paragraph-heading">Patient privacy.</em>  For nonvaccine biological products, an applicant should not include in reports under this section the names and addresses of individual patients; instead, the applicant should assign a unique code for identification of the patient. The applicant should include the name of the reporter from whom the information was received as part of the initial reporter information, even when the reporter is the patient. The names of patients, health care professionals, hospitals, and geographical identifiers in adverse experience reports are not releasable to the public under FDA's public information regulations in <a href="/current/title-21/part-20" class="cfr external">part 20 of this chapter</a>. For vaccine adverse experience reports, these data will become part of the CDC Privacy Act System 09-20-0136, “Epidemiologic Studies and Surveillance of Disease Problems.” Information identifying the person who received the vaccine or that person's legal representative will not be made available to the public, but may be available to the vaccinee or legal representative.</p>
</div>
<div id="p-600.80(k)">
<p class="indent-1" data-title="600.80(k)"><span class="paragraph-hierarchy"><span class="paren">(</span>k<span class="paren">)</span></span> <em class="paragraph-heading">Recordkeeping.</em>  The applicant must maintain for a period of 10 years records of all adverse experiences known to the applicant, including raw data and any correspondence relating to the adverse experiences.</p>
</div>
<div id="p-600.80(l)">
<p class="indent-1" data-title="600.80(l)"><span class="paragraph-hierarchy"><span class="paren">(</span>l<span class="paren">)</span></span> <em class="paragraph-heading">Revocation of biologics license.</em>  If an applicant fails to establish and maintain records and make reports required under this section with respect to a licensed biological product, FDA may revoke the biologics license for such a product in accordance with the procedures of <a href="/current/title-21/section-601.5" class="cfr external">§ 601.5 of this chapter</a>.</p>
</div>
<div id="p-600.80(m)">
<p class="indent-1" data-title="600.80(m)"><span class="paragraph-hierarchy"><span class="paren">(</span>m<span class="paren">)</span></span> <em class="paragraph-heading">Exemptions.</em>  Manufacturers of the following listed products are not required to submit adverse experience reports under this section:</p>
<div id="p-600.80(m)(1)">
<p class="indent-2" data-title="600.80(m)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> Whole blood or components of whole blood.</p>
</div>
<div id="p-600.80(m)(2)">
<p class="indent-2" data-title="600.80(m)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> In vitro diagnostic products, including assay systems for the detection of antibodies or antigens to retroviruses. These products are subject to the reporting requirements for devices.</p>
</div>
</div>
<div id="p-600.80(n)"><p class="indent-1" data-title="600.80(n)"><span class="paragraph-hierarchy"><span class="paren">(</span>n<span class="paren">)</span></span> <em class="paragraph-heading">Disclaimer.</em>  A report or information submitted by an applicant under this section (and any release by FDA of that report or information) does not necessarily reflect a conclusion by the applicant or FDA that the report or information constitutes an admission that the biological product caused or contributed to an adverse effect. An applicant need not admit, and may deny, that the report or information submitted under this section constitutes an admission that the biological product caused or contributed to an adverse effect. For purposes of this provision, this paragraph also includes any person reporting under <a href="/current/title-21/section-600.80#p-600.80(c)(1)(iii)" class="cfr external">paragraph (c)(1)(iii)</a> of this section.</p></div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/59-FR-54042" class="fr-reference" data-reference="59 FR 54042">59 FR 54042</a>, Oct. 27, 1994, as amended at <a href="https://www.federalregister.gov/citation/62-FR-34168" class="fr-reference" data-reference="62 FR 34168">62 FR 34168</a>, June 25, 1997; <a href="https://www.federalregister.gov/citation/62-FR-52252" class="fr-reference" data-reference="62 FR 52252">62 FR 52252</a>, Oct. 7, 1997; <a href="https://www.federalregister.gov/citation/63-FR-14612" class="fr-reference" data-reference="63 FR 14612">63 FR 14612</a>, Mar. 26, 1998; <a href="https://www.federalregister.gov/citation/64-FR-56449" class="fr-reference" data-reference="64 FR 56449">64 FR 56449</a>, Oct. 20, 1999; <a href="https://www.federalregister.gov/citation/70-FR-14982" class="fr-reference" data-reference="70 FR 14982">70 FR 14982</a>, Mar. 24, 2005; <a href="https://www.federalregister.gov/citation/79-FR-33090" class="fr-reference" data-reference="79 FR 33090">79 FR 33090</a>, June 10, 2014]
</p>
</div>

<div class="section" id="600.81">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-600.81","citation":"21 CFR 600.81"}'>§ 600.81 Distribution reports.</h4>
<div id="p-600.81(a)">
<p class="indent-1" data-title="600.81(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> <em class="paragraph-heading">Reporting requirements.</em>  The applicant must submit to the Center for Biologics Evaluation and Research or the Center for Drug Evaluation and Research, information about the quantity of the product distributed under the biologics license, including the quantity distributed to distributors. The interval between distribution reports must be 6 months. Upon written notice, FDA may require that the applicant submit distribution reports under this section at times other than every 6 months. The distribution report must consist of the bulk lot number (from which the final container was filled), the fill lot numbers for the total number of dosage units of each strength or potency distributed (e.g., fifty thousand per 10-milliliter vials), the label lot number (if different from fill lot number), labeled date of expiration, number of doses in fill lot/label lot, date of release of fill lot/label lot for distribution at that time. If any significant amount of a fill lot/label lot is returned, include this information. Disclosure of financial or pricing data is not required. As needed, FDA may require submission of more detailed product distribution information. Upon written notice, FDA may require that the applicant submit reports under this section at times other than those stated. Requests by an applicant to submit reports at times other than those stated should be made as a request for a waiver under <a href="/current/title-21/section-600.90" class="cfr external">§ 600.90</a>.</p>
</div>
<div id="p-600.81(b)">
<p class="indent-1" data-title="600.81(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> </p>
<div id="p-600.81(b)(1)">
<p class="indent-2" data-title="600.81(b)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> <em class="paragraph-heading">Electronic format.</em>  Except as provided for in <a href="/current/title-21/section-600.81#p-600.81(b)(2)" class="cfr external">paragraph (b)(2)</a> of this section, the distribution reports required under <a href="/current/title-21/section-600.81#p-600.81(a)" class="cfr external">paragraph (a)</a> of this section must be submitted to the Agency in an electronic format that FDA can process, review, and archive. FDA will issue guidance on how to provide the electronic submission (e.g., method of transmission, media, file formats, preparation and organization of files).</p>
</div>
<div id="p-600.81(b)(2)"><p class="indent-2" data-title="600.81(b)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> <em class="paragraph-heading">Waivers.</em>  An applicant may request, in writing, a temporary waiver of the requirements in <a href="/current/title-21/section-600.81#p-600.81(b)(1)" class="cfr external">paragraph (b)(1)</a> of this section. These waivers will be granted on a limited basis for good cause shown. FDA will issue guidance on requesting a waiver of the requirements in <a href="/current/title-21/section-600.81#p-600.81(b)(1)" class="cfr external">paragraph (b)(1)</a> of this section. Requests for waivers must be submitted in accordance with <a href="/current/title-21/section-600.90" class="cfr external">§ 600.90</a>.</p></div>
</div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/59-FR-54042" class="fr-reference" data-reference="59 FR 54042">59 FR 54042</a>, Oct. 27, 1994, as amended at <a href="https://www.federalregister.gov/citation/64-FR-56449" class="fr-reference" data-reference="64 FR 56449">64 FR 56449</a>, Oct. 20, 1999; <a href="https://www.federalregister.gov/citation/70-FR-14983" class="fr-reference" data-reference="70 FR 14983">70 FR 14983</a>, Mar. 24, 2005; <a href="https://www.federalregister.gov/citation/79-FR-33091" class="fr-reference" data-reference="79 FR 33091">79 FR 33091</a>, June 10, 2014]
</p>
</div>

<div class="section" id="600.82">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-600.82","citation":"21 CFR 600.82"}'>§ 600.82 Notification of a permanent discontinuance or an interruption in manufacturing.</h4>
<div id="p-600.82(a)">
<p class="indent-1" data-title="600.82(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> <em class="paragraph-heading">Notification of a permanent discontinuance or an interruption in manufacturing.</em> </p>
<div id="p-600.82(a)(1)">
<p class="indent-2" data-title="600.82(a)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> An applicant of a biological product, other than blood or blood components for transfusion, which is licensed under section 351 of the Public Health Service Act, and which may be dispensed only under prescription under section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act (<a href="https://www.govinfo.gov/link/uscode/21/353" class="usc external" target="_blank" rel="noopener noreferrer">21 U.S.C. 353(b)(1)</a>), must notify FDA in writing of a permanent discontinuance of manufacture of the biological product or an interruption in manufacturing of the biological product that is likely to lead to a meaningful disruption in supply of that biological product in the United States if:</p>
<div id="p-600.82(a)(1)(i)">
<p class="indent-3" data-title="600.82(a)(1)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> The biological product is life supporting, life sustaining, or intended for use in the prevention or treatment of a debilitating disease or condition, including any such biological product used in emergency medical care or during surgery; and</p>
</div>
<div id="p-600.82(a)(1)(ii)">
<p class="indent-3" data-title="600.82(a)(1)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> The biological product is not a radiopharmaceutical biological product.</p>
</div>
</div>
<div id="p-600.82(a)(2)">
<p class="indent-2" data-title="600.82(a)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> An applicant of blood or blood components for transfusion, which is licensed under section 351 of the Public Health Service Act, and which may be dispensed only under prescription under section 503(b) of the Federal Food, Drug, and Cosmetic Act, must notify FDA in writing of a permanent discontinuance of manufacture of any product listed in its license or an interruption in manufacturing of any such product that is likely to lead to a significant disruption in supply of that product in the United States if:</p>
<div id="p-600.82(a)(2)(i)">
<p class="indent-3" data-title="600.82(a)(2)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> The product is life supporting, life sustaining, or intended for use in the prevention or treatment of a debilitating disease or condition, including any such product used in emergency medical care or during surgery; and</p>
</div>
<div id="p-600.82(a)(2)(ii)">
<p class="indent-3" data-title="600.82(a)(2)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> The applicant is a manufacturer of a significant percentage of the U.S. blood supply.</p>
</div>
</div>
</div>
<div id="p-600.82(b)">
<p class="indent-1" data-title="600.82(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> <em class="paragraph-heading">Submission and timing of notification.</em>  Notifications required by <a href="/current/title-21/section-600.82#p-600.82(a)" class="cfr external">paragraph (a)</a> of this section must be submitted to FDA electronically in a format that FDA can process, review, and archive:</p>
<div id="p-600.82(b)(1)">
<p class="indent-2" data-title="600.82(b)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> At least 6 months prior to the date of the permanent discontinuance or interruption in manufacturing; or</p>
</div>
<div id="p-600.82(b)(2)">
<p class="indent-2" data-title="600.82(b)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> If 6 months' advance notice is not possible because the permanent discontinuance or interruption in manufacturing was not reasonably anticipated 6 months in advance, as soon as practicable thereafter, but in no case later than 5 business days after such a permanent discontinuance or interruption in manufacturing occurs.</p>
</div>
</div>
<div id="p-600.82(c)">
<p class="indent-1" data-title="600.82(c)"><span class="paragraph-hierarchy"><span class="paren">(</span>c<span class="paren">)</span></span> <em class="paragraph-heading">Information included in notification.</em>  Notifications required by <a href="/current/title-21/section-600.82#p-600.82(a)" class="cfr external">paragraph (a)</a> of this section must include the following information:</p>
<div id="p-600.82(c)(1)">
<p class="indent-2" data-title="600.82(c)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> The name of the biological product subject to the notification, including the National Drug Code for such biological product, or an alternative standard for identification and labeling that has been recognized as acceptable by the Center Director;</p>
</div>
<div id="p-600.82(c)(2)">
<p class="indent-2" data-title="600.82(c)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> The name of the applicant of the biological product;</p>
</div>
<div id="p-600.82(c)(3)">
<p class="indent-2" data-title="600.82(c)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> Whether the notification relates to a permanent discontinuance of the biological product or an interruption in manufacturing of the biological product;</p>
</div>
<div id="p-600.82(c)(4)">
<p class="indent-2" data-title="600.82(c)(4)"><span class="paragraph-hierarchy"><span class="paren">(</span>4<span class="paren">)</span></span> A description of the reason for the permanent discontinuance or interruption in manufacturing; and</p>
</div>
<div id="p-600.82(c)(5)">
<p class="indent-2" data-title="600.82(c)(5)"><span class="paragraph-hierarchy"><span class="paren">(</span>5<span class="paren">)</span></span> The estimated duration of the interruption in manufacturing.</p>
</div>
</div>
<div id="p-600.82(d)">
<p class="indent-1" data-title="600.82(d)"><span class="paragraph-hierarchy"><span class="paren">(</span>d<span class="paren">)</span></span> </p>
<div id="p-600.82(d)(1)">
<p class="indent-2" data-title="600.82(d)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> <em class="paragraph-heading">Public list of biological product shortages.</em>  FDA will maintain a publicly available list of biological products that are determined by FDA to be in shortage. This biological product shortages list will include the following information:</p>
<div id="p-600.82(d)(1)(i)">
<p class="indent-3" data-title="600.82(d)(1)(i)"><span class="paragraph-hierarchy"><span class="paren">(</span>i<span class="paren">)</span></span> The names and National Drug Codes for such biological products, or the alternative standards for identification and labeling that have been recognized as acceptable by the Center Director;</p>
</div>
<div id="p-600.82(d)(1)(ii)">
<p class="indent-3" data-title="600.82(d)(1)(ii)"><span class="paragraph-hierarchy"><span class="paren">(</span>ii<span class="paren">)</span></span> The name of each applicant for such biological products;</p>
</div>
<div id="p-600.82(d)(1)(iii)">
<p class="indent-3" data-title="600.82(d)(1)(iii)"><span class="paragraph-hierarchy"><span class="paren">(</span>iii<span class="paren">)</span></span> The reason for the shortage, as determined by FDA, selecting from the following categories: Requirements related to complying with good manufacturing practices; regulatory delay; shortage of an active ingredient; shortage of an inactive ingredient component; discontinuation of the manufacture of the biological product; delay in shipping of the biological product; demand increase for the biological product; or other reason; and</p>
</div>
<div id="p-600.82(d)(1)(iv)">
<p class="indent-3" data-title="600.82(d)(1)(iv)"><span class="paragraph-hierarchy"><span class="paren">(</span>iv<span class="paren">)</span></span> The estimated duration of the shortage.</p>
</div>
</div>
<div id="p-600.82(d)(2)">
<p class="indent-2" data-title="600.82(d)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> <em class="paragraph-heading">Confidentiality.</em>  FDA may choose not to make information collected to implement this paragraph available on the biological product shortages list or available under section 506C(c) of the Federal Food, Drug, and Cosmetic Act (<a href="https://www.govinfo.gov/link/uscode/21/356c" class="usc external" target="_blank" rel="noopener noreferrer">21 U.S.C. 356c(c)</a>) if FDA determines that disclosure of such information would adversely affect the public health (such as by increasing the possibility of hoarding or other disruption of the availability of the biological product to patients). FDA will also not provide information on the public shortages list or under section 506C(c) of the Federal Food, Drug, and Cosmetic Act that is protected by <a href="https://www.govinfo.gov/link/uscode/18/1905" class="usc external" target="_blank" rel="noopener noreferrer">18 U.S.C. 1905</a> or <a href="https://www.govinfo.gov/link/uscode/5/552" class="usc external" target="_blank" rel="noopener noreferrer">5 U.S.C. 552(b)(4)</a>, including trade secrets and commercial or financial information that is considered confidential or privileged under <a href="/current/title-21/section-20.61" class="cfr external">§ 20.61 of this chapter</a>.</p>
</div>
</div>
<div id="p-600.82(e)">
<p class="indent-1" data-title="600.82(e)"><span class="paragraph-hierarchy"><span class="paren">(</span>e<span class="paren">)</span></span> <em class="paragraph-heading">Noncompliance letters.</em>  If an applicant fails to submit a notification as required under <a href="/current/title-21/section-600.82#p-600.82(a)" class="cfr external">paragraph (a)</a> of this section and in accordance with <a href="/current/title-21/section-600.82#p-600.82(b)" class="cfr external">paragraph (b)</a> of this section, FDA will issue a letter to the applicant informing it of such failure.</p>
<div id="p-600.82(e)(1)">
<p class="indent-2" data-title="600.82(e)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> Not later than 30 calendar days after the issuance of such a letter, the applicant must submit to FDA a written response setting forth the basis for noncompliance and providing the required notification under <a href="/current/title-21/section-600.82#p-600.82(a)" class="cfr external">paragraph (a)</a> of this section and including the information required under <a href="/current/title-21/section-600.82#p-600.82(c)" class="cfr external">paragraph (c)</a> of this section; and</p>
</div>
<div id="p-600.82(e)(2)">
<p class="indent-2" data-title="600.82(e)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> Not later than 45 calendar days after the issuance of a letter under this paragraph, FDA will make the letter and the applicant's response to the letter public, unless, after review of the applicant's response, FDA determines that the applicant had a reasonable basis for not notifying FDA as required under <a href="/current/title-21/section-600.82#p-600.82(a)" class="cfr external">paragraph (a)</a> of this section.</p>
</div>
</div>
<div id="p-600.82(f)">
<p class="indent-1" data-title="600.82(f)"><span class="paragraph-hierarchy"><span class="paren">(</span>f<span class="paren">)</span></span> <em class="paragraph-heading">Definitions.</em>  The following definitions of terms apply to this section:</p>
<div id="p-600.82(f)(Biological%20product%20shortage%20or%20shortage)">
<p class="indent-2" data-title="600.82(f) “Biological product shortage or shortage”" data-term="true"><span class="paragraph-hierarchy"><em>Biological product shortage</em> or <em>shortage</em></span>   means a period of time when the demand or projected demand for the biological product within the United States exceeds the supply of the biological product.</p>
</div>
<div id="p-600.82(f)(Intended%20for%20use%20in%20the%20prevention%20or%20treatment%20of%20a%20debilitating%20disease%20or%20condition)">
<p class="indent-2" data-title="600.82(f) “Intended for use in the prevention or treatment of a debilitating disease or condition”" data-term="true"><em class="paragraph-hierarchy">Intended for use in the prevention or treatment of a debilitating disease or condition</em>   means a biological product intended for use in the prevention or treatment of a disease or condition associated with mortality or morbidity that has a substantial impact on day-to-day functioning.</p>
</div>
<div id="p-600.82(f)(Life%20supporting%20or%20life%20sustaining)">
<p class="indent-2" data-title="600.82(f) “Life supporting or life sustaining”" data-term="true"><em class="paragraph-hierarchy">Life supporting or life sustaining</em>   means a biological product that is essential to, or that yields information that is essential to, the restoration or continuation of a bodily function important to the continuation of human life.</p>
</div>
<div id="p-600.82(f)(Meaningful%20disruption)">
<p class="indent-2" data-title="600.82(f) “Meaningful disruption”" data-term="true"><em class="paragraph-hierarchy">Meaningful disruption</em>   means a change in production that is reasonably likely to lead to a reduction in the supply of a biological product by a manufacturer that is more than negligible and affects the ability of the manufacturer to fill orders or meet expected demand for its product, and does not include interruptions in manufacturing due to matters such as routine maintenance or insignificant changes in manufacturing so long as the manufacturer expects to resume operations in a short period of time.</p>
</div>
<div id="p-600.82(f)(Significant%20disruption)"><p class="indent-2" data-title="600.82(f) “Significant disruption”" data-term="true"><em class="paragraph-hierarchy">Significant disruption</em>   means a change in production that is reasonably likely to lead to a reduction in the supply of blood or blood components by a manufacturer that substantially affects the ability of the manufacturer to fill orders or meet expected demand for its product, and does not include interruptions in manufacturing due to matters such as routine maintenance or insignificant changes in manufacturing so long as the manufacturer expects to resume operations in a short period of time.</p></div>
</div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/80-FR-38939" class="fr-reference" data-reference="80 FR 38939">80 FR 38939</a>, July 8, 2015]
</p>
</div>

<div class="section" id="600.90">
<h4 data-hierarchy-metadata='{"path":"/current/title-21/section-600.90","citation":"21 CFR 600.90"}'>§ 600.90 Waivers.</h4>
<div id="p-600.90(a)">
<p class="indent-1" data-title="600.90(a)"><span class="paragraph-hierarchy"><span class="paren">(</span>a<span class="paren">)</span></span> An applicant may ask the Food and Drug Administration to waive under this section any requirement that applies to the applicant under <a href="/current/title-21/section-600.80" class="cfr external">§§ 600.80</a> and <a href="/current/title-21/section-600.81" class="cfr external">600.81</a>. A waiver request under this section is required to be submitted with supporting documentation. The waiver request is required to contain one of the following:</p>
<div id="p-600.90(a)(1)">
<p class="indent-2" data-title="600.90(a)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> An explanation why the applicant's compliance with the requirement is unnecessary or cannot be achieved,</p>
</div>
<div id="p-600.90(a)(2)">
<p class="indent-2" data-title="600.90(a)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> A description of an alternative submission that satisfies the purpose of the requirement, or</p>
</div>
<div id="p-600.90(a)(3)">
<p class="indent-2" data-title="600.90(a)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> Other information justifying a waiver.</p>
</div>
</div>
<div id="p-600.90(b)">
<p class="indent-1" data-title="600.90(b)"><span class="paragraph-hierarchy"><span class="paren">(</span>b<span class="paren">)</span></span> FDA may grant a waiver if it finds one of the following:</p>
<div id="p-600.90(b)(1)">
<p class="indent-2" data-title="600.90(b)(1)"><span class="paragraph-hierarchy"><span class="paren">(</span>1<span class="paren">)</span></span> The applicant's compliance with the requirement is unnecessary or cannot be achieved,</p>
</div>
<div id="p-600.90(b)(2)">
<p class="indent-2" data-title="600.90(b)(2)"><span class="paragraph-hierarchy"><span class="paren">(</span>2<span class="paren">)</span></span> The applicant's alternative submission satisfies the requirement, or</p>
</div>
<div id="p-600.90(b)(3)"><p class="indent-2" data-title="600.90(b)(3)"><span class="paragraph-hierarchy"><span class="paren">(</span>3<span class="paren">)</span></span> The applicant's submission otherwise justifies a waiver.</p></div>
</div>
<p class="citation">[<a href="https://www.federalregister.gov/citation/59-FR-54042" class="fr-reference" data-reference="59 FR 54042">59 FR 54042</a>, Oct. 27, 1994, as amended at <a href="https://www.federalregister.gov/citation/79-FR-33092" class="fr-reference" data-reference="79 FR 33092">79 FR 33092</a>, June 10, 2014]
</p>
</div>

</div>
</div><script type="application/json" id="source-and-authority-data">{"origins":[{"level":"part","identifier":"600","label_level":"Part 600","hierarchy":{"title":"21","chapter":"I","subchapter":"F","part":"600"},"current":true,"authority":["\u003ca href=\"https://www.govinfo.gov/link/uscode/21/321\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e21 U.S.C. 321\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/351\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e351\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/352\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e352\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/353\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e353\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/355\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e355\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/356c\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e356c\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/356e\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e356e\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/360\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e360\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/360i\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e360i\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/371\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e371\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/374\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e374\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/21/379k\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e379k\u003c/a\u003e-l; \u003ca href=\"https://www.govinfo.gov/link/uscode/42/216\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e42 U.S.C. 216\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/42/262\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e262\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/42/263\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e263\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/42/263a\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e263a\u003c/a\u003e, \u003ca href=\"https://www.govinfo.gov/link/uscode/42/264\" class=\"usc external\" target=\"_blank\" rel=\"noopener noreferrer\"\u003e264\u003c/a\u003e.\n"],"source":[],"link":"/current/title-21/part-600","title":"Part 600"}]}</script>

</div><div class="seal-block seal-block-footer"><h6>eCFR Content</h6></div></div>      </div>
    </div>
  </div>
</div>

        </div>
      </div>
    </div>

    <div class="site-footer container-fluid" id="footer">
  <div class="container">
    <div class="col-xs-12 col-md-12">
      <div class="row">
        <div class="col-xs-3 col-md-3">
          <h2>Pages</h2>
          <ul class="list with-bullets">
            <li><a href="/">Home</a></li>
            <li><a href="/">Titles</a></li>
            <li><a href="/search">Search</a></li>
            <li><a href="/recent-changes">Recent Changes</a></li>
            <li><a href="/corrections">Corrections</a></li>
          </ul>
        </div>

        <div class="col-xs-3 col-md-3">
          <h2>Reader Aids</h2>
          <ul class="list with-bullets">
              <li>
                <a href="https://www.ecfr.gov/reader-aids/using-ecfr">Using the eCFR Point-in-Time System</a>
              </li>
              <li>
                <a href="https://www.ecfr.gov/reader-aids/understanding-the-ecfr">Understanding the eCFR</a>
              </li>
              <li>
                <a href="https://www.ecfr.gov/reader-aids/government-policy-and-ofr-procedures">Government Policy and OFR Procedures</a>
              </li>
              <li>
                <a href="https://www.ecfr.gov/reader-aids/ecfr-developer-resources">Developer Resources</a>
              </li>
          </ul>
        </div>
        <div class="col-xs-3 col-md-3">
          <h2>Information</h2>
          <ul class="list with-bullets">
            <li><a href="/reader-aids/government-policy-and-ofr-procedures/about-this-site">About This Site</a></li>
            <li><a href="/reader-aids/government-policy-and-ofr-procedures/about-this-site#legal-status">Legal Status</a></li>
            <li><a href="/reader-aids/government-policy-and-ofr-procedures/privacy">Privacy</a></li>
            <li><a href="/reader-aids/government-policy-and-ofr-procedures/accessibility">Accessibility</a></li>
            <li><a href="/reader-aids/government-policy-and-ofr-procedures/foia">FOIA</a></li>
            <li><a href="https://www.archives.gov/eeo/policy/no-fear-notice.html">No Fear Act</a></li>
            <li><a href="https://www.archives.gov/federal-register/contact.html#coop">Continuity Information</a></li>
          </ul>
        </div>

        <div class="col-xs-3 col-md-3">
          <h2>My eCFR</h2>
          <ul class="list with-bullets">
            <li>
              <a href="/my/subscriptions">My Subscriptions</a>
            </li>
            <li>
              <a data-turbo="false" href="https://www.ecfr.gov/auth/sign_in?jwt=eyJhbGciOiJIUzI1NiJ9.eyJub3RpZmljYXRpb25zIjp7ImluZm8iOiJZb3Ugd2lsbCBiZSByZWRpcmVjdGVkIGJhY2sgdG8gdGhlIGVDRlIgYWZ0ZXIgeW91IGhhdmUgc2lnbmVkIGluIG9yIGNyZWF0ZWQgYW4gYWNjb3VudC4ifX0.-sYkHWfC02yb0CpuUqmPkxxnF0yzlNHaS5520hYIUy8&amp;redirect_to=https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-600">Sign In / Sign Up</a>
            </li>
          </ul>
        </div>


      </div>
    </div>
  </div>
</div>

</body></html>
